Pathology In Depth

Library › Pancreas and ampulla pathology: pancreatitis, ductal adenocarcinoma and precursors, cystic, solid and neuroendocrine neoplasms, and pancreatic and ampullary cancer staging

Pancreas and ampulla pathology: pancreatitis, ductal adenocarcinoma and precursors, cystic, solid and neuroendocrine neoplasms, and pancreatic and ampullary cancer staging

Last reviewed 2026-11-17 by a board-certified pathologist. 135 references.

Non-Neoplastic Pancreas: Developmental Anomalies, Acute, Chronic, Hereditary and Autoimmune Pancreatitis, Pseudocysts and Non-Neoplastic Cysts, Allograft and Islet Pathology

Definition and classification. Non-neoplastic pancreatic disease comprises developmental anomalies, acute and chronic pancreatitis, the hereditary, autoimmune and paraduodenal forms of chronic pancreatitis, pseudocysts and non-neoplastic cysts, allograft rejection and diseases of the islets. Chronic, autoimmune and paraduodenal pancreatitis form masses that mimic pancreatic ductal adenocarcinoma (PDAC) (Adsay and Zamboni 2004; Okazaki et al. 2022). The WHO Classification of Digestive System Tumours, 6th edition (2026), regards acinar cystic transformation as a non-neoplastic cystic lesion and no longer includes it in the tumour classification (Arends et al. 2026). Previous rule (5th edition, 2019): the former acinar cell cystadenoma, shown to be non-neoplastic by clonality analysis, was listed among the 5th-edition pancreatic entities as acinar cystic transformation, the new name for acinar cell cystadenoma (Nagtegaal et al. 2020).

Related page: Pancreatitis, pseudocyst and lymphoepithelial cyst on cytology (acute and chronic pancreatitis, autoimmune pancreatitis, pseudocyst and lymphoepithelial cyst on EUS sampling) Related page: Normal pancreas, gastrointestinal contaminants and EUS-guided sampling (normal pancreatic cytology and intrapancreatic accessory spleen) Related page: Pancreatic cyst fluid chemistry and molecular testing (amylase, CEA and glucose in cyst fluid) Related page: Small Intestinal Mucosal Disease: Celiac Disease and Its Mimics, Infections, Drug Injury and Immune Enteropathies (pancreatic heterotopia and Meckel diverticulum) Related page: Cholestatic and Biliary Liver Disease: Primary Biliary Cholangitis, Primary and IgG4-Related Sclerosing Cholangitis, Pediatric Cholestasis, Ductal Plate Malformations and Hepatic Cysts (IgG4-related sclerosing cholangitis) Related page: Diagnostic Enzymes and Serum Tumor Markers (serum amylase and lipase) Related page: Liver, Kidney and Gastrointestinal Function Tests (pancreatic function tests) Related page: Bone Marrow Failure, Pure Red Cell Aplasia and the Laboratory Approach to Cytopenias and Leukocyte Disorders (Shwachman–Diamond syndrome: neutropenia, SBDS and marrow findings) Related page: Diabetes and Glycemic Markers: Glucose, HbA1c, Ketones and the Hypoglycemia Workup (hypoglycemia workup, insulin and C-peptide) Related page: Pancreatic Ductal Adenocarcinoma, Its Subtypes and Pancreatic Intraepithelial Neoplasia (chronic pancreatitis versus PDAC at frozen section) Related page: Cystic and Intraductal Neoplasms of the Pancreas: IPMN, IOPN, ITPN, Mucinous Cystic Neoplasm, Serous Neoplasms and Simple Mucinous Cyst (simple mucinous cyst and the classification of neoplastic cysts)

Normal pancreatic histology and developmental anomalies of the pancreas

  • Lobular architecture. Tightly packed lobules of acini are separated by paucicellular fibrous septa that contain ducts, veins, arteries and rare nerves. Normal parenchyma is free of inflammation (Drachenberg et al. 2025).
  • Centroacinar cells. MUC1 and MUC6 are markers of intercalated duct centroacinar cells (Park 2021).
  • Regional islet composition. Islets rich in pancreatic polypeptide are largely confined to the uncinate process of the pancreatic head. Some of these islets lack alpha and beta cells in non-diabetic donors, which is relevant when insulin-deficient islets are counted (van der Heide et al. 2026).
  • Embryology. Dorsal and ventral buds arise from the foregut in the 4th to 5th weeks. The ventral bud rotates with the bile duct posterior to the duodenum and fuses with the dorsal bud at about 7 weeks. The main pancreatic duct (Wirsung) forms from the ventral duct and the distal dorsal duct, and the accessory duct (Santorini) forms from the proximal dorsal duct (Sharma et al. 2024).
Anomaly Developmental basis Findings and associations Source
Pancreas divisum Ventral and dorsal ducts fail to fuse 4%–14% of autopsies. Type 1 (classic): dorsal duct drains through the minor papilla and ventral duct through the major papilla. Type 2: absent ventral duct. Type 3 (incomplete): small communicating branch. Associated with recurrent acute pancreatitis, mainly of the dorsal pancreas, and chronic abdominal pain Sharma et al. 2024
Annular pancreas Failed rotation of the ventral bud Pancreatic tissue encircles the second part of the duodenum completely or partially; 5–15 per 100,000 adults in cadaver studies Sharma et al. 2024
Dorsal pancreatic agenesis Nondevelopment of the dorsal anlage Partial: absent neck, body and tail. Complete: duct of Santorini also absent. Associated with HNF1B mutation and with diabetes, because most beta cells are in the dorsal pancreas Sharma et al. 2024
Pancreatic hypoplasia or agenesis Absent or hypoplastic gland One of three mechanistic groups of congenital exocrine pancreatic insufficiency; the other two are exocrine tissue injury and isolated enzyme deficiency Scheers and Berardis 2022
Heterotopic pancreas in the duodenal wall Pancreatic tissue outside the gland Cystic dystrophy of heterotopic pancreas is part of the spectrum of paraduodenal pancreatitis Adsay and Zamboni 2004

Acute pancreatitis: incidence, causes, necrosis and fat necrosis

Acute pancreatitis has an incidence of 33–74 cases per 100,000 person-years. About 20% of patients progress to severe disease (Carrara et al. 2026). The revised Atlanta classification (2012) defines an early and a late phase, and severe disease has persistent organ failure lasting more than 48 hours (Banks et al. 2013).

Cause Data Source
Gallstones (biliary) 40%–60% of cases worldwide; 50% in Europe, up to 78% in Latin America and less than 28% in India. Duct obstruction raises duct pressure and ductal permeability Carrara et al. 2026
Alcohol 21%–35% of cases worldwide and up to 44% in India. Only a minority of heavy drinkers develop pancreatitis Carrara et al. 2026
Hypertriglyceridemia 2%–5% of cases. The traditional threshold is >1000 mg/dL; risk rises from 177 mg/dL, with a hazard ratio of 8.7 at ≥443 mg/dL Carrara et al. 2026
Hypercalcemia Serum calcium ≥12.0 mg/dL indicates hypercalcemic pancreatitis. About 90% of hypercalcemia is due to primary hyperparathyroidism or malignancy. High cytoplasmic calcium activates trypsinogen prematurely Carrara et al. 2026
Drugs Fewer than 5% of cases. More than 500 drugs are reported; randomized-trial evidence exists only for didanosine, azathioprine and 6-mercaptopurine Carrara et al. 2026
Endoscopic retrograde cholangiopancreatography (ERCP) and trauma Post-ERCP pancreatitis results from transient duct obstruction Carrara et al. 2026
Genetic PRSS1, SPINK1 and CFTR; CFTR variants occur in up to 12% of patients with pancreatic disorders Carrara et al. 2026
Pancreas divisum Recurrent acute pancreatitis, mainly dorsal; supporting data are controversial Sharma et al. 2024; Carrara et al. 2026
Autoimmune pancreatitis Less than 1% of acute pancreatitis Carrara et al. 2026
Idiopathic About 20% of cases; the proportion rises with age Carrara et al. 2026
  • Interstitial edematous and necrotizing pancreatitis. Interstitial edematous pancreatitis enlarges the gland through inflammatory edema. Necrotizing pancreatitis develops in about 10% of patients and involves pancreatic parenchyma, peripancreatic tissue or both; peripancreatic necrosis alone is the most common form. Mortality of necrotizing pancreatitis is about 15% and rises to 30%–39% when the necrosis is infected (Carrara et al. 2026).
  • Enzymatic fat necrosis and saponification. Released enzymes digest pancreatic and extrapancreatic fat, and the hydrolysis of triglycerides releases free fatty acids. The fatty acids combine with serum calcium and precipitate as calcium soaps (saponification) (Mejia et al. 2026). Fatty acid release is associated with hypocalcemia (Khatua et al. 2020). Extrapancreatic saponification can mimic peritoneal carcinomatosis on imaging and at operation (Mejia et al. 2026).

Related page: Pancreatitis, pseudocyst and lymphoepithelial cyst on cytology (revised Atlanta severity grades and fluid collections)

  • Timing of intervention. Debridement of necrosis is delayed, optimally to about 4 weeks, to allow encapsulation (Carrara et al. 2026).
  • Long-term course. Of patients with severe acute pancreatitis, 20% develop recurrent episodes and 35% of these progress to chronic pancreatitis. About 35% develop exocrine pancreatic insufficiency and about 23% develop diabetes (Carrara et al. 2026).

Chronic pancreatitis and hereditary pancreatitis

  • Definition and epidemiology. Chronic pancreatitis is persistent inflammation with ductal abnormalities that leads to fibrosis and atrophy and compromises exocrine and endocrine function. In the United States the annual incidence is 5–8 and the prevalence 42–73 per 100,000 adults, with a male-to-female ratio of about 2:1. Alcohol, smoking, autoimmunity and hypercalcemia are the most common adult risk factors. Congenital malformations cause a significant share of pediatric cases, and about one-third of cases are idiopathic (Carnovale et al. 2026).
  • Acute recurrent pancreatitis. Acute recurrent pancreatitis requires at least two documented episodes separated by complete clinical resolution. It is reversible when the cause is removed, and most authors regard it as a precursor of chronic pancreatitis (Carnovale et al. 2026).
  • Diagnostic triad. Fibrosis, loss of acinar tissue and duct changes are the cardinal histologic features, and the presence of all three is the most important diagnostic criterion (Luchini et al. 2020). Fewer than 5% of heavy drinkers develop chronic pancreatitis, so cofactors such as smoking, obesity and genetic background are required (Luchini et al. 2020).
Category Gross findings Microscopic findings Source
Alcoholic Accentuated lobules early; later a small atrophic gland with dilated, distorted ducts, calcium carbonate calculi and pseudocysts in up to half Early perilobular and interlobular fibrosis of spindled fibroblasts in thin wavy collagen; later intralobular fibrosis, squamous metaplasia of dilated ducts and loss of exocrine and endocrine tissue Luchini et al. 2020
Obstructive Disease confined to the gland distal to the obstruction, with ductal dilatation and multiple retention cysts; pseudocysts very rare Perilobular and interlobular fibrosis distal to the obstruction Luchini et al. 2020
Hereditary PRSS1- and CFTR-related disease: progressive lipomatous atrophy; SPINK1-associated disease: progressive fibrosis Patterns described below for PRSS1 Luchini et al. 2020; Singhi et al. 2014
  • Islet aggregates versus microadenoma. Aggregated residual islets in early alcoholic chronic pancreatitis enter the differential diagnosis of neuroendocrine microadenoma. Immunostains for insulin and glucagon show the normal distribution of islet hormones (Luchini et al. 2020).
  • Histologic sequence (PRSS1 series). In 10 total pancreatectomies from PRSS1 carriers, children showed patchy loss of acini and ducts with loosely packed perilobular and interlobular fibrosis, ductal dilatation, squamous metaplasia and intraductal calcifications. Young adults showed further acinar loss with fibrosis and intermingled adipocytes. Older adults had soft, shrunken pancreata almost entirely replaced by mature fat (lipomatous atrophy), with periductal fibrosis around the main and larger interlobular ducts, dilated ducts and intraductal calculi (Singhi et al. 2014).
  • Islets in chronic pancreatitis. Islets of Langerhans are preserved and aggregate, which gives them a "hyperplastic" appearance. They persist with nerves in the fat of end-stage glands, and islet amyloid was present in 2 of 4 older adults (Singhi et al. 2014).
  • Fibrosis pattern by cause. Fibrosis in PRSS1 pancreatitis is thin and loosely packed compared with chronic pancreatitis due to alcohol or obstruction. Fat necrosis and saponification were absent in the older adults (Singhi et al. 2014).
  • Imaging in PRSS1 pancreatitis. Computed tomography showed diffuse atrophy in 80%, a dilated main pancreatic duct in 60% and numerous intraductal calcifications in 40%. A 2.5-cm head mass suspicious for carcinoma proved to be fatty replacement (Singhi et al. 2014).
  • Cystic fibrosis. Exocrine insufficiency affects about 85% of people with cystic fibrosis. Loss of CFTR function concentrates protein in ductal secretions, plugs the ducts and destroys acini, while islets remain relatively intact (Malik et al. 2023).
Gene Protein and mechanism Inheritance and phenotype Cancer risk and surveillance Source
PRSS1 Cationic trypsinogen; R122H causes autoactivation and resists autodegradation of trypsin (dual gain of function) Autosomal dominant, about 80% penetrance. R122H (52.4%) and N29I (17.3%) are the most frequent variants. Onset before age 18 in more than 70%; diabetes in 14%–26% of adults High relative and absolute risk of PDAC, increased by smoking, diabetes and age. Surveillance for hereditary pancreatitis starts at age 40 or 20 years after the first attack Singhi et al. 2014; Wu et al. 2026; Goggins et al. 2020
SPINK1 Protease inhibitor that inactivates intrapancreatic trypsin Disease modifier that lowers the threshold for, or worsens, pancreatitis from other causes Covered by the same hereditary pancreatitis surveillance, which does not depend on gene status Singhi et al. 2014; Goggins et al. 2020
CFTR Anion channel. Some variants impair bicarbonate permeability and cause pancreatitis without cystic fibrosis Two variants without residual function cause viscous secretions and exocrine insufficiency, and the absent exocrine tissue prevents pancreatitis. A variant with residual function preserves exocrine tissue but predisposes to acute recurrent or chronic pancreatitis Hereditary pancreatitis surveillance applies irrespective of gene Carnovale et al. 2026; Goggins et al. 2020
CTRC Chymotrypsin C Pancreatitis susceptibility gene with a significantly increased risk of pancreatitis Hereditary pancreatitis surveillance applies irrespective of gene Goggins et al. 2020
CPA1 Carboxypeptidase A1, which regulates proenzyme maturation and secretion Pathogenic variants are strongly related to early-onset chronic pancreatitis CPA1 and CPB1 variants associated with cancer risk do not always progress through clinical pancreatitis Carnovale et al. 2026; Goggins et al. 2020
  • Definition of hereditary pancreatitis. Hereditary pancreatitis is defined by pedigree: two or more first-degree relatives, or three or more second-degree relatives, with unexplained recurrent acute or chronic pancreatitis in two or more generations (Singhi et al. 2014).

Autoimmune pancreatitis type 1 and type 2

Type 1 autoimmune pancreatitis (AIP) is lymphoplasmacytic sclerosing pancreatitis (LPSP), the pancreatic manifestation of IgG4-related disease. Its histologic hallmarks are a dense lymphoplasmacytic infiltrate rich in IgG4-positive plasma cells, storiform fibrosis and obliterative phlebitis (Okazaki et al. 2022). Type 2 AIP is idiopathic duct-centric chronic pancreatitis (IDCP), defined by the granulocytic epithelial lesion (GEL) (Maruyama et al. 2013; Zen 2022). The two types are distinct diseases without overlap (Zen 2022).

Feature Type 1 AIP (LPSP) Type 2 AIP (IDCP) Source
Mean age 60 years, typically older than 40 30 years, including children Zen 2022
Male sex 80% 50% Zen 2022
Serum IgG4 elevation 80%–90% 10% Zen 2022
Other organ involvement 50% None Zen 2022
Inflammatory bowel disease Less than 5% 40% (75% ulcerative colitis, 15% Crohn disease) Zen 2022
Presentation Painless jaundice in 80% Pain or acute pancreatitis in 60% Zen 2022
Pattern of inflammation Lobule-centric Duct-centric Zen 2022
Storiform fibrosis and obliterative phlebitis Prominent Present, less prominent Zen 2022
Neutrophils No GEL and no granulocytic acinar injury GEL (neutrophils within duct epithelium), intraluminal neutrophil clusters resembling crypt abscesses, granulocytic acinar injury Zen 2022
IgG4-positive plasma cells Abundant and diffuse Typically fewer than 10 per high-power field (HPF) in biopsies and fewer than 50 per HPF in resections; IgG4/IgG ratio not above 40% Zen 2022
Steroid response About 100% About 100% Zen 2022
Relapse 30%–50% Less than 10% Zen 2022
  • International Consensus Diagnostic Criteria (ICDC, 2011). Each of the five ICDC cardinal features (listed in Pancreatitis, pseudocyst and lymphoepithelial cyst on cytology) is graded as a level 1 or level 2 finding. AIP is diagnosed as definitive or probable type 1 or type 2, or as AIP not otherwise specified when the type cannot be determined (Shimosegawa et al. 2011).
  • ICDC serology. Serum IgG4 >2× the upper limit of normal is a level 1 finding and 1–2× the upper limit a level 2 finding (Nista et al. 2022). With an upper limit of 140 mg/dL, these are >280 and >140 mg/dL (Chang et al. 2014). Serum IgG4 above 300 mg/dL, or more than twice the upper reference limit, is highly suggestive of type 1 AIP, and an IgG4/IgG ratio above 10% supports type 1 AIP when the elevation is mild (Zen 2022).
  • Histology in type 2 AIP. The ICDC diagnosis of type 2 AIP rests on histologic IDCP with GEL. Without histology, type 2 AIP cannot be diagnosed in a patient without inflammatory bowel disease (Maruyama et al. 2013; Zen 2022).
  • Histologic definitions. In type 1 AIP, inflammation centers on medium-sized and large interlobular ducts. Venulitis involves the venous wall and in late-stage disease evolves into obliterative phlebitis with fibrosis of the lumen, and the fibrosis becomes whorled or storiform. Lymphoid aggregates are present in most cases (Luchini et al. 2020).
ICDC histology and supporting criteria Level 1 Level 2 Source
Type 1 AIP (LPSP) histology At least 3 of: periductal lymphoplasmacytic infiltrate without granulocytic infiltration; obliterative phlebitis; storiform fibrosis; abundant (>10 cells/HPF) IgG4-positive cells Any 2 of the same four features Nista et al. 2022
Type 2 AIP (IDCP) histology Granulocytic infiltration of the duct wall (GEL) with or without granulocytic acinar inflammation, and absent or scant (0–10 cells/HPF) IgG4-positive cells Granulocytic and lymphoplasmacytic acinar infiltrate, and absent or scant (0–10 cells/HPF) IgG4-positive cells Nista et al. 2022
Type 2 AIP other organ involvement None defined Clinically diagnosed inflammatory bowel disease Nista et al. 2022
Response to steroids (both types) Rapid (<2 weeks) radiologic resolution or marked improvement of pancreatic or extrapancreatic manifestations Same as level 1 Nista et al. 2022

Related page: Pancreatitis, pseudocyst and lymphoepithelial cyst on cytology (EUS sampling yield for ICDC histologic criteria)

  • PD-L1 in type 2 AIP. Aberrant PD-L1 expression in duct epithelium was found in 70% of type 2 AIP and was almost absent in type 1 AIP, other pancreatitis and pancreas adjacent to carcinoma (99% specificity) (Zen 2022).
  • Steroid trial. Prednisolone 0.6–1.0 mg/kg with reassessment of imaging and CA 19-9 after 2 weeks forms part of the diagnostic process (Zen 2022). Glucocorticoid therapy induces remission in 98% of patients with AIP (Carrara et al. 2026).
  • IgG4-related disease classification. The 2019 ACR/EULAR criteria require involvement of at least one of 11 organs, exclusion by any of 32 clinical, serologic, radiologic or pathologic items, and a weighted score from eight inclusion domains. A threshold of 20 points gave specificities of 99.2% and 97.8% and sensitivities of 85.5% and 82.0% in two validation cohorts (Wallace et al. 2020).

Related page: Plasma Proteins, Protein Electrophoresis, Free Light Chains and CSF Oligoclonal Bands (serum IgG4 measurement and the prozone effect)

Paraduodenal (groove) pancreatitis

  • Definition. Paraduodenal pancreatitis is chronic pancreatitis centered in and around the duodenal wall near the minor papilla. It unifies cystic dystrophy of heterotopic pancreas, para-duodenal wall cyst, pancreatic hamartoma of the duodenum, myoadenomatosis and groove pancreatitis (Adsay and Zamboni 2004).
  • Histology. The duodenal wall contains dilated ducts with inspissated secretions and pseudocystic change, surrounded by hypercellular granulation tissue, foreign-body giant cells engulfing mucoprotein and myofibroblastic proliferation. Brunner gland hyperplasia is typical. Dense myoid stromal proliferation with intervening rounded lobules of acinar tissue resembles myoadenomatosis, a hamartoma or a leiomyoma. Fibrosis extends into the adjacent pancreas and the groove between the pancreas, common bile duct and duodenum (Adsay and Zamboni 2004).
  • Patients. In a systematic review of 1404 patients, the mean age was 49 years, 86% were men and 79% had excessive alcohol use (Ukegjini et al. 2023). Compared with patients with PDAC, patients with groove pancreatitis were younger (50.4 versus 62.3 years) and more often smokers (82.7% versus 39.8%) (Ukegjini et al. 2023).
  • Carcinoma mimicry. Marked scarring and ill-defined borders make the lesion mimic pancreatic or periampullary carcinoma (Adsay and Zamboni 2004). Surgery, performed for pain, suspected malignancy, jaundice or duodenal obstruction, had a success rate above 90% (Ukegjini et al. 2023).
  • Solid and cystic variants. The solid variant expands the groove with marginal involvement of the pancreas and common bile duct. The cystic variant shows cysts in the duodenal wall near the minor papilla, with pancreatitis in the adjacent parenchyma; the minor papilla may be absent or obstructed by calcified proteinaceous material. The cysts lie in the submucosa and muscularis propria or extend into the groove, are lined by duct-type epithelium that may be replaced by granulation tissue and contain small calculi (Luchini et al. 2020).
  • Gross examination. The accessory ampulla lies about 2 cm proximal and slightly anterior to the major papilla. Mucosal nodularity or puckering at this site without significant ulceration raises the possibility of paraduodenal pancreatitis and directs sampling to this region and the adjacent pancreas (Adsay et al. 2014).

Pseudocyst and non-neoplastic pancreatic cysts

Lesion Patients and setting Lining and wall Immunohistochemistry and fluid Source
Pseudocyst Encapsulated collection after interstitial edematous pancreatitis, usually beyond 4 weeks No epithelial lining by definition; wall of fibrous and granulation tissue, forming a well-defined inflammatory wall Fluid rich in amylase; fluid analysis in Pancreatic cyst fluid chemistry and molecular testing Banks et al. 2013; Karoumpalis and Christodoulou 2016; Pitman et al. 2014
Walled-off necrosis Necrotizing pancreatitis Encapsulated necrotic pancreatic or peripancreatic tissue Sterile or infected Carrara et al. 2026; Banks et al. 2013
Lymphoepithelial cyst Men (9:1), median age 48.5 years; exophytic, without connection to the main pancreatic duct True cyst lined by non-dysplastic squamous epithelium surrounded by mature lymphoid tissue Imaging is mixed cystic-solid in 80%, with a subsolid component or mural nodules Khristenko et al. 2023
Squamoid cyst of pancreatic ducts Incidental or symptomatic unilocular cyst; 33 cases reported by 2021 Cystic dilatation of a duct lined by attenuated, transitional or stratified squamous epithelium without keratinization or a granular layer; no lymphoid tissue; no surrounding pancreatitis MUC1 and MUC6 (centroacinar phenotype), p63, CK7 and CK19 positive; cyst fluid CEA elevated in some (565 and 127 ng/mL) Park 2021
Retention cyst Cyst behind an obstructed pancreatic duct Flat mucinous lining, interpreted as partial low-grade PanIN lining Gastric phenotype (MUC5AC positive, MUC1 and MUC2 negative) when mucinous Basturk et al. 2015
Acinar cystic transformation Mean age 43.5 years; 65.3% women; also reported in children Single layer of cuboidal to columnar cells with acinar differentiation and apical eosinophilic granules; no atypia or mitoses Trypsin and CK19 positive Zhong et al. 2025
  • Flat mucinous cysts without obstruction. Lesions formerly called mucinous non-neoplastic cyst or cystic mucinous duct lesion are now termed simple mucinous cyst, which the WHO 6th edition classifies as a neoplastic cystic lesion (Basturk et al. 2015; Arends et al. 2026).

Related page: Cystic and Intraductal Neoplasms of the Pancreas: IPMN, IOPN, ITPN, Mucinous Cystic Neoplasm, Serous Neoplasms and Simple Mucinous Cyst (simple mucinous cyst)

Pancreas allograft pathology: Banff rejection schema

  • Adequacy. An adequate biopsy contains three lobular areas with their septal connective tissue (Drachenberg et al. 2025).
  • T cell-mediated rejection (TCMR). TCMR begins in the septal connective tissue with venulitis and ductitis and then spreads to periseptal acinar tissue. Venulitis is circumferential cuffing of septal veins with subendothelial inflammatory cells and endothelial damage or lifting. Activity is indicated by interstitial edema, proliferative connective tissue, activated lymphocytes, eosinophils, acinar inflammation and acinar cell necrosis (Drachenberg et al. 2025).
  • Banff grades and stages. Inflammation confined mainly to the septa corresponds to grade I, and prominent CD3-positive acinar infiltrates require separation of grade I from higher grades (Drachenberg et al. 2025). The table gives the Banff 2011 schema (Drachenberg et al. 2008; Drachenberg et al. 2011), as reproduced by Redfield et al. 2015.
Category Histologic criteria Source
TCMR grade I (mild) Active septal inflammation (activated blastic lymphocytes with or without eosinophils) with venulitis and/or ductitis, and/or focal acinar inflammation of no more than two foci per lobule with absent or minimal acinar injury Redfield et al. 2015
TCMR grade II (moderate) Multifocal nonconfluent acinar inflammation (≥3 foci per lobule) with spotty acinar cell injury and dropout, and/or mild intimal arteritis (<25% luminal compromise) Redfield et al. 2015
TCMR grade III (severe) Diffuse acinar inflammation with focal or diffuse confluent acinar necrosis, and/or moderate or severe intimal arteritis (>25% luminal compromise), and/or transmural necrotizing arteritis Redfield et al. 2015
AMR components Donor-specific antibody; tissue injury (interacinar inflammation or capillaritis, acinar cell damage, vasculitis, thrombosis); C4d in interacinar capillaries in ≥5% of the acinar lobular surface Redfield et al. 2015
AMR grade I Preserved architecture, mild monocytic-macrophagic or mixed infiltrates, rare acinar cell damage Redfield et al. 2015
AMR grade II Capillaritis, capillary dilatation, congestion, multicellular acinar dropout and red-cell extravasation with overall preserved architecture Redfield et al. 2015
AMR grade III Architectural disarray, interstitial hemorrhage, confluent parenchymal necrosis, arterial and venous wall necrosis and thrombosis Redfield et al. 2015
Chronic rejection (graft fibrosis) stage I Fibrosis <30% of the core, with eroded lobular contours and normal central lobules Redfield et al. 2015
Chronic rejection stage II Fibrosis 30%–60% of the core, with atrophy at the periphery and center of most lobules Redfield et al. 2015
Chronic rejection stage III Fibrosis >60% of the core, with only isolated residual acini and/or islets Redfield et al. 2015
  • Antibody-mediated rejection (AMR). AMR rests on three elements: circulating donor-specific antibody (DSA), morphologic evidence of microvascular injury and C4d staining of interacinar capillaries. Three elements establish acute AMR, two give a diagnosis of suspicious for AMR, and one element alone is insufficient. AMR and T cell-mediated rejection can coexist and are graded independently (Drachenberg et al. 2011). TCMR combines septal and acinar CD3-positive infiltrates, whereas AMR is centered on the microvasculature with early macrophage (CD68) and neutrophil influx (Drachenberg et al. 2025).
  • Indeterminate category. Septal, mainly mononuclear infiltrates that cuff veins or ducts without venulitis or ductitis are classified as indeterminate. Indeterminate findings occurred in about 16% of biopsies for graft dysfunction and in about 8% of surveillance biopsies at 1, 4 and 12 months (Drachenberg et al. 2025).
  • Rejection mimics. Early ischemic pancreatitis and peripancreatitis cause inflammation confined to the septa with preserved lobules, spotty acinar drop-out and neutrophils. Fat necrosis from surgical manipulation attracts mainly macrophages. Impaired exocrine drainage causes ductal dilatation, stasis, squamous metaplasia and ductular proliferation that CK7 separates from septal inflammation (Drachenberg et al. 2025).
  • Banff 2022 update. The 2022 report refines the terminology of T cell-mediated and antibody-mediated rejection in active and chronic forms. It adds, for the first time, a clinicopathologic approach to islet pathology in the early and late post-transplant periods, guidance on endoscopic biopsies of the donor duodenal cuff and recommendations on donor-derived cell-free DNA (Drachenberg et al. 2024). Previous rules: the 2008 schema graded acute cell-mediated rejection (ACMR) and treated AMR only tentatively (Drachenberg et al. 2008). The 2011 update set the three-element AMR criteria (Drachenberg et al. 2011).

Related page: HLA Typing, HLA Antibody Testing, Crossmatch and Platelet and Neutrophil Antibody Testing (donor-specific antibody methods) Related page: Renal Vascular Disease, Thrombotic Microangiopathy and Kidney Transplant Pathology (Banff kidney criteria for the kidney of a simultaneous pancreas-kidney transplant)

Islet pathology in diabetes and adult nesidioblastosis

Condition Islet findings Source
Type 1 diabetes Autoimmune beta-cell destruction. Insulitis is defined as at least 15 CD45-positive cells associated with at least 3 islets. Insulin-deficient islets accumulate, relative pancreas weight falls, and median islet size rises in autoantibody-positive stage 1 or 2 disease before declining van der Heide et al. 2026
Type 2 diabetes Islet amyloid composed of islet amyloid polypeptide (IAPP), apolipoprotein E and perlecan; IAPP is unique to islet amyloid. Congo red gives green birefringence and fibrils measure 7–10 nm. Aggregated IAPP is toxic to beta cells Li and Zhang 2025
Cystic fibrosis Islets relatively intact with altered proportions of endocrine cell types; modest beta-cell loss in cystic fibrosis-related diabetes, similar in fatty and fibrotic exocrine patterns Malik et al. 2023
Adult nesidioblastosis (noninsulinoma pancreatogenous hypoglycemia) Beta cells with enlarged hyperchromatic nuclei and abundant clear cytoplasm; ductuloinsular complexes Doi et al. 2022
  • Criteria for diffuse adult nesidioblastosis. The four major criteria are exclusion of insulinoma, multiple beta cells with enlarged hyperchromatic nuclei and abundant clear cytoplasm, islets with a normal spatial distribution of cell types, and no proliferative activity of endocrine cells. Ductuloinsular complexes, islet cells budding from duct epithelium, are conclusive evidence (Doi et al. 2022).
  • Setting and treatment. Adult nesidioblastosis has been reported after gastric bypass and Roux-en-Y anastomosis, and glucagon-like peptide-1 has been proposed as a mechanism. Resection is the definitive treatment. Diazoxide is more effective for nesidioblastosis after gastric bypass than for idiopathic disease (Doi et al. 2022).

Congenital hyperinsulinism

  • Frequency. Congenital hyperinsulinism (CHI) affects 1 in 28,000 to 1 in 40,000 infants (Larsen et al. 2025) and is the leading cause of persistent hypoglycemia in infancy and childhood (Contractor et al. 2026).
  • KATP-channel disease. Defects of ABCC8 (SUR1) and KCNJ11 (Kir6.2) account for nearly half of genetically confirmed CHI and most severe diazoxide-unresponsive disease (Contractor et al. 2026).
Feature Diffuse CHI Focal CHI Source
Genetics Biallelic recessive ABCC8 or KCNJ11 variants Paternally inherited recessive ABCC8 or KCNJ11 variant plus somatic loss of the maternal 11p15 region (paternal uniparental disomy) Larsen et al. 2025
Mechanism All beta cells affected Loss of heterozygosity of the KATP channel and imbalance of the imprinted genes H19, IGF2 and CDKN1C Larsen et al. 2025
Histology Disease throughout the pancreas; islet cells with giant nuclei larger than three times an acinar nucleus (nuclear enlargement in 4.9% of islets in one ABCC8 case) Focal adenomatosis with confluent hyperplastic islets Larsen et al. 2025
Share of operated patients 39%–58% 42%–51% Larsen et al. 2025
Localization and surgery Near-total pancreatectomy, with persistent hypoglycemia or diabetes as risks 18F-DOPA PET/CT localization and limited resection, which often cures without recurrence Contractor et al. 2026
  • Intraoperative frozen section. Frozen section and final histology confirm the lesion during and after resection. In one patient with a paternal KCNJ11 variant and focal 18F-DOPA uptake, no lesion was found at surgery, frozen section and final histology were inconclusive, and the cure was incomplete (Larsen et al. 2025).
  • Diazoxide response. Diazoxide binds SUR1 and holds the KATP channel open, so complete loss-of-function KATP variants are diazoxide unresponsive. CHI due to GLUD1 (with hyperammonemia), GCK, HADH and SLC16A1 variants preserves channel function and usually responds (Contractor et al. 2026).
  • Atypical histology. Atypical CHI, 7.1% of operated cases in one series, shows larger islets in some lobules with smaller islets elsewhere (morphological mosaicism) or localized islet nuclear enlargement, and some cases carry mosaic HK1, GCK, GLUD1 or ABCC8 variants (Larsen et al. 2025).

Shwachman–Diamond syndrome and congenital exocrine pancreatic insufficiency

  • Genetics. Shwachman–Diamond syndrome is an autosomal recessive ribosomal disorder with exocrine pancreatic insufficiency, hematopoietic dysfunction, skeletal abnormalities and a predisposition to marrow failure and myelodysplasia (Zhou et al. 2026). About 90% of patients carry biallelic SBDS variants (type 1); EFL1 (type 2), DNAJC21 and EIF6 variants account for others. Prevalence is about 1 in 76,000 (Scheers and Berardis 2022).
  • Pancreatic pathology. Autopsy pancreata show acinar hypoplasia with extensive fatty infiltration without fibrosis or inflammation, and ducts and islets are preserved. Enzyme secretion is severely reduced while fluid and anion outputs remain normal (Scheers and Berardis 2022).
  • Frequency and screening. Shwachman–Diamond syndrome is the second most frequent cause of congenital exocrine insufficiency after cystic fibrosis. Newborn screening for cystic fibrosis detects high serum trypsinogen (Scheers and Berardis 2022).

Pancreatic Ductal Adenocarcinoma, Its Subtypes and Pancreatic Intraepithelial Neoplasia

Definition and classification. Pancreatic ductal adenocarcinoma (PDAC) is an invasive gland-forming epithelial neoplasm with ductal differentiation and accounts for about 90% of pancreatic neoplasms (Haeberle and Esposito 2019). Its microscopic precursor is pancreatic intraepithelial neoplasia (PanIN), and its macroscopic precursors are intraductal papillary mucinous neoplasm (IPMN), mucinous cystic neoplasm (MCN) and intraductal tubulopapillary neoplasm (ITPN) (Haeberle and Esposito 2019). The WHO Classification of Digestive System Tumours, 6th edition (2026), grades all pancreatic precursors in two tiers and redefines undifferentiated carcinoma to include carcinoma with mesenchymal differentiation and SWI/SNF-deficient undifferentiated carcinoma (Arends et al. 2026). Two-tier grading of PanIN, IPMN and MCN already applied in the 5th edition (2019), so it is unchanged for pancreatic precursors (Nagtegaal et al. 2020). The open 6th-edition summary does not list the other PDAC subtypes, and their definitions follow the 5th edition (Haeberle and Esposito 2019). Resections are reported with the CAP Pancreas (Exocrine) protocol (CAP 2025).

Related page: Pancreatic ductal adenocarcinoma and its variants on cytology (PDAC cytology, molecular pathogenesis table, cell-block immunocytochemistry and PDAC variants on FNA) Related page: The WHO Reporting System for Pancreaticobiliary Cytopathology (WHO Reporting System categories and risk of malignancy) Related page: Pancreatoduodenectomy Specimens and the Staging and Reporting of Pancreatic and Ampullary Carcinoma (pancreatoduodenectomy grossing, margins, AJCC 8th edition staging, CAP elements and treatment response) Related page: Cystic and Intraductal Neoplasms of the Pancreas: IPMN, IOPN, ITPN, Mucinous Cystic Neoplasm, Serous Neoplasms and Simple Mucinous Cyst (IPMN, MCN, IOPN, ITPN and simple mucinous cyst) Related page: Non-Neoplastic Pancreas: Developmental Anomalies, Acute, Chronic, Hereditary and Autoimmune Pancreatitis, Pseudocysts and Non-Neoplastic Cysts, Allograft and Islet Pathology (chronic, autoimmune and paraduodenal pancreatitis) Related page: Solid Cellular Neoplasms of the Pancreas: Solid Pseudopapillary Neoplasm, Acinar Cell Carcinoma, Pancreatoblastoma and Metastases to the Pancreas (acinar cell carcinoma, solid pseudopapillary neoplasm and metastases to the pancreas) Related page: Gallbladder and Extrahepatic Bile Duct Pathology: Cholecystitis, Gallstones, Precursor Neoplasms, Gallbladder Carcinoma and Extrahepatic Cholangiocarcinoma (distal cholangiocarcinoma) Related page: Gastric Dysplasia, Gastric Carcinoma, Gastroesophageal Biomarkers and Small Intestinal Adenocarcinoma (ampullary-ductal adenocarcinoma and the other ampullary carcinoma types) Related page: Diagnostic Enzymes and Serum Tumor Markers (serum CA 19-9 and CEA)

Pancreatic intraepithelial neoplasia (PanIN)

  • Definition. PanINs are microscopic (usually <0.5 cm) mucinous papillary or flat intraepithelial neoplasms with a ductal phenotype (Haeberle and Esposito 2019; Basturk et al. 2015). IPMNs are usually ≥1.0 cm (Basturk et al. 2015).
  • Frequency. PanIN was found in 16% of normal pancreata and in 82% of pancreata with PDAC (Haeberle and Esposito 2019).
  • Two-tier grading (Baltimore consensus, 2015). PanIN is graded as low grade or high grade by the highest degree of architectural and cytologic atypia anywhere in the lesion (Basturk et al. 2015). Previous rule (2004 classification and WHO 2010): three tiers: PanIN-1 (1A and 1B), PanIN-2 and PanIN-3 (Basturk et al. 2015).
Grade (2015) Former grade Histology Source
Low-grade PanIN PanIN-1A, PanIN-1B and PanIN-2 Flat or papillary mucinous epithelium without dysplasia, or with mild-to-moderate nuclear irregularity, hyperchromasia and loss of polarity CAP 2025; Basturk et al. 2015
High-grade PanIN PanIN-3 (carcinoma in situ in some regions) Flat or papillary mucinous epithelium with marked nuclear irregularity, hyperchromasia and loss of polarity, often with cribriforming and intraluminal blebbing of noncohesive cells CAP 2025; Basturk et al. 2015
  • Reporting. Low-grade PanIN is common, of no proven clinical significance and need not be reported. High-grade PanIN is reported, particularly when no invasive carcinoma is present, and is a surrogate marker of invasion elsewhere in the gland (Basturk et al. 2015). High-grade PanIN is staged as pTis (CAP 2025).
  • PanIN at margins. PanIN of any grade at the margin does not affect survival after resection of invasive carcinoma. High-grade PanIN at a margin without invasive carcinoma may justify further surgery (Basturk et al. 2015). High-grade PanIN at the margin of an otherwise completely resected carcinoma is noted in the report (CAP 2025).
  • Intraductal spread of invasive carcinoma. Invasive carcinoma extends back along ducts ("cancerization of the ducts") in up to 70% of resections and can be impossible to separate from high-grade PanIN, especially at a frozen-section margin. The consensus term is intraductal spread of invasive carcinoma (Basturk et al. 2015).
  • PanIN versus IPMN. Almost all PanINs show gastric-foveolar differentiation (Basturk et al. 2015). Lesions of 0.5–1.0 cm and the criteria for incipient IPMN are given in Cystic and Intraductal Neoplasms of the Pancreas: IPMN, IOPN, ITPN, Mucinous Cystic Neoplasm, Serous Neoplasms and Simple Mucinous Cyst.
  • Molecular progression. KRAS mutations are frequent in low-grade and high-grade PanIN, whereas CDKN2A, TP53 and SMAD4 mutations are usually confined to high-grade PanIN and are less frequent than in PDAC (Haeberle and Esposito 2019).
  • Acinar-ductal metaplasia and atypical flat lesion. Acinar-ductal metaplasia replaces acini by ductular structures, which may contain mucin and resemble low-grade PanIN, and it can harbor KRAS mutations. Atypical flat lesions are mostly non-mucinous intralobular aggregates of small ducts, usually <0.5 cm, lined by cuboidal cells with cytologic atypia in a cellular stroma with whorls of spindle cells in a myxomatous matrix. They were first described in mouse models, occur in areas of lobulocentric atrophy in people with an inherited predisposition, often harbor KRAS mutations and need not be reported routinely (Basturk et al. 2015).

Pancreatic ductal adenocarcinoma: epidemiology, risk factors and hereditary syndromes

  • Burden. Pancreatic cancer was the twelfth most common malignancy and the sixth leading cause of cancer death worldwide in 2022, with 511,000 new cases and 476,000 deaths. Five-year overall survival is 3%–15%, and resection is feasible in fewer than 20% of patients (Krupa et al. 2025).
  • Risk factors. Established risk factors are tobacco smoking, high body mass index, elevated fasting plasma glucose and Helicobacter pylori infection (Krupa et al. 2025). Hereditary pancreatitis carries a high risk of PDAC (Singhi et al. 2014). New-onset diabetes can precede the diagnosis by months or years (Krupa et al. 2025).
  • Chronic pancreatitis as a risk factor. Chronic pancreatitis and diabetes mellitus increase the risk of PDAC, as does a previously resected PDAC (Luchini et al. 2020a). After a diagnosis of chronic pancreatitis, the cumulative risk of PDAC is 1.8% at 10 years and 4.0% at 20 years (Pateras et al. 2024).
  • Paraneoplastic and presenting features. Painless jaundice results from bile duct obstruction by head tumors (Haeberle and Esposito 2019). Trousseau syndrome, panniculitis with polyarthritis, dermatomyositis and polymyositis are reported paraneoplastic manifestations (Krupa et al. 2025).
  • Hereditary basis. About 10% of PDAC has a hereditary basis (Krupa et al. 2025). Deleterious germline variants occur in about 5%–10% of apparently sporadic PDAC and explain about 10%–20% of familial clustering (Goggins et al. 2020). Familial pancreatic cancer is defined by two affected first-degree relatives (Stoffel et al. 2019).
  • Germline testing. ASCO recommends assessment of hereditary risk, including a comprehensive family history, in every patient with pancreatic adenocarcinoma, and germline testing may be discussed even when the family history is unremarkable (Stoffel et al. 2019). The NCCN recommends offering germline testing to all patients with newly diagnosed PDAC (Goggins et al. 2020).
Gene Syndrome Criteria for pancreatic surveillance (CAPS 2020) Source
STK11 Peutz–Jeghers syndrome All carriers, regardless of family history Goggins et al. 2020
CDKN2A Familial atypical multiple mole melanoma (FAMMM) All carriers Goggins et al. 2020
BRCA2 Hereditary breast and ovarian cancer At least one affected first-degree relative, or at least two affected relatives of any degree Goggins et al. 2020
PALB2, ATM Hereditary breast and ovarian cancer (PALB2); ATM added in 2020 At least one affected first-degree relative Goggins et al. 2020
BRCA1 Hereditary breast and ovarian cancer At least one affected first-degree relative (69.6% agreement; consensus not reached) Goggins et al. 2020
MLH1, MSH2, MSH6 Lynch syndrome At least one affected first-degree relative Goggins et al. 2020
PRSS1 and other pancreatitis genes Hereditary pancreatitis From age 40, or 20 years after the first attack, irrespective of gene Goggins et al. 2020
TP53 Li–Fraumeni syndrome Increased PDAC risk, with odds estimated from case-control analysis Krupa et al. 2025; Goggins et al. 2020
No identified gene Familial pancreatic cancer kindred First-degree relative of an affected person who has an affected first-degree relative; surveillance from age 50 or 55, or 10 years before the youngest affected relative Goggins et al. 2020
  • Lifetime risk. The average lifetime risk of pancreatic cancer in the United States is about 1 in 64, and an individual with two affected first-degree relatives has a lifetime risk of about 8% (Goggins et al. 2020).

Pancreatic ductal adenocarcinoma: gross features, histology and grade

  • Gross features. PDAC most often arises in the proximal pancreas and measures 2–4 cm at diagnosis, larger in the distal pancreas. It is a firm, poorly defined white-yellow mass that usually already infiltrates peripancreatic fat, duodenum, stomach or portal vein, and regional nodal metastases are common at diagnosis (Haeberle and Esposito 2019).
  • Site. In 159,548 SEER cases, conventional PDAC arose in the head in 51.5%, the body or tail in 26.1% and an unspecified or overlapping site in 22.4%; two-thirds of tumors with a recorded site were in the head (Bengtsson et al. 2024).
  • Infiltrating glands and desmoplasia. PDAC consists of atypical tubular glands resembling medium-sized or small ducts in a desmoplastic stroma of stromal cells, inflammatory cells and extracellular matrix. Clear cell, cribriform and gyriform components occur, and desmoplasia is less developed in poorly differentiated tumors (Haeberle and Esposito 2019).
  • Diagnostic hallmarks of invasion. Neoplastic glands are often ruptured or incomplete with areas of epithelial denudation, whereas normal ducts have a continuous lining. Well-differentiated PDAC nuclei can be four times larger than the nuclei of entrapped non-neoplastic ducts. Infiltrating glands lie in abnormal locations, for example immediately adjacent to muscular blood vessels, a criterion that remains usable when atypia is mild, as after neoadjuvant therapy (Luchini et al. 2020a).
  • Glands in fat. "Naked" glands in peripancreatic fat are a hallmark of PDAC. Fat can also result from adipose involution of the pancreas, and residual islets in the fat identify this pattern (Luchini et al. 2020a; Luchini et al. 2020b).
  • Prognostic invasion. Venous and lymphatic invasion and perineural invasion are adverse prognostic factors (CAP 2025).
  • Grade (CAP). Grade is based on glandular differentiation: G1 >95% glands, G2 50%–95% glands and G3 ≤49% glands. High grade is an unfavorable prognostic factor. Signet-ring cell carcinoma is grade 3 by convention, and acinar cell carcinoma, acinar cell cystadenocarcinoma, serous cystadenocarcinoma, solid pseudopapillary neoplasm and neuroendocrine carcinoma are not graded with this scheme. The Klöppel scheme, which combines glandular differentiation, mucin, mitoses and nuclear pleomorphism, has no greater predictive value than glandular differentiation alone (CAP 2025).
WHO grading criterion G1 G2 G3 Source
Architecture Tubular, middle-sized duct-like structures, papillary projections Middle-sized and small duct-like structures, cribriform structures Solid areas, budding, single-cell infiltration Haeberle and Esposito 2019
Cells Columnar, mucin retained Cuboidal, partial loss of mucin Polygonal, pleomorphic or spindle, mucin lost Haeberle and Esposito 2019
Nuclei Slightly polymorphous Moderately polymorphous Very polymorphous Haeberle and Esposito 2019
Mitoses 1–5 per 10 HPF 6–10 per 10 HPF >10 per 10 HPF Haeberle and Esposito 2019

Immunohistochemistry of pancreatic ductal adenocarcinoma

No single marker establishes PDAC, and the diagnosis rests on histology (Haeberle and Esposito 2019).

Marker Result in PDAC Use Source
CK7, CK19 and CK18 Positive; CK20 sometimes positive Ductal phenotype, distinction from other primaries in metastases Haeberle and Esposito 2019
CEA and MUC1 Apical and cytoplasmic in tumor glands; reactive glands show no or only apical staining Neoplastic versus reactive glands Haeberle and Esposito 2019
CA 19-9, CA125, MUC4 and MUC5AC Usually positive Supporting markers Haeberle and Esposito 2019
SMAD4 (DPC4) Lost: complete absence of staining in carcinoma cells Lost in 55% of 1,146 resected PDACs; loss predicted shorter disease-free survival (HR 1.24) and overall survival (HR 1.27). Immunostaining mirrors gene status: 17 of 18 carcinomas with wild-type SMAD4 retained the protein, and 21 of 23 with inactivated SMAD4 lost it Masugi et al. 2023; Wilentz et al. 2000
p53 Aberrant: diffuse strong nuclear staining or complete loss of staining; heterogeneous nuclear staining is the wild-type pattern Aberrant in 49% of 1,146 resected PDACs; predicted TP53 mutation with 95% specificity and 61% sensitivity Masugi et al. 2023
p16 (CDKN2A) and MTAP Loss of expression p16 lost in 85% of resected PDACs. MTAP loss, a surrogate for CDKN2A homozygous deletion (about 40% of PDAC), was found in 25% of FNA-diagnosed PDACs with 100% specificity and 31.5% sensitivity Masugi et al. 2023; Lucà et al. 2025
S100P Nuclear and cytoplasmic staining Positive in 71% of FNA-diagnosed PDACs; a panel of MTAP and S100P raised sensitivity to 75% at the same specificity in 27 EUS-guided biopsies Lucà et al. 2025
Acinar, neuroendocrine and intestinal markers Trypsin, chymotrypsin, lipase, BCL10, chromogranin A and synaptophysin negative; CK20 and MUC2 usually negative, with expression in carcinomas arising from intestinal-type IPMN Separation from acinar cell carcinoma, neuroendocrine tumors and intestinal carcinoma Luchini et al. 2020a
Mismatch repair proteins Loss in mismatch repair-deficient tumors Lynch syndrome and immune checkpoint inhibitor eligibility CAP 2025

Molecular pathology of pancreatic ductal adenocarcinoma

  • Core drivers. KRAS, TP53, SMAD4 and CDKN2A are the four classic cancer genes of PDAC (Haeberle and Esposito 2019). Deep sequencing of 150 PDACs found KRAS mutations in 93%, and recurrent mutations in TP53, CDKN2A, SMAD4, RNF43, ARID1A, TGFBR2, GNAS, RREB1 and PBRM1 (Cancer Genome Atlas Research Network 2017). By droplet digital PCR, KRAS was mutant in 98% of 1,146 resected PDACs (Masugi et al. 2023).
  • Copy number changes. Frequent arm-level losses involved 18q (71%), 17p (64%), 6q (51%) and 9p (48%) (Cancer Genome Atlas Research Network 2017).
  • SMAD4. SMAD4 is inactivated by allelic loss in about 55% of PDACs (Wilentz et al. 2000).
  • DNA damage repair. Germline or somatic mutations in ATM, BRCA1, BRCA2 or PALB2 were present in 10% of tumors, a potential predictor of platinum or PARP inhibitor sensitivity (Cancer Genome Atlas Research Network 2017; Krupa et al. 2025).
  • KRAS wild-type PDAC. About 5%–10% of PDACs lack KRAS mutation and are enriched for other RAS pathway and oncogenic alterations, including GNAS, CTNNB1 and BRAF mutations and ERBB2 amplification (Cancer Genome Atlas Research Network 2017; Krupa et al. 2025). Fusions involve ALK, ROS1, NTRK, RET, FGFR and NRG1. Fusions occur in 1.2% of PDAC, mostly KRAS wild type; NTRK fusions in 0.3% and NRG1 fusions in less than 1%. Zenocutuzumab received accelerated FDA approval for NRG1 fusion-positive PDAC (Krupa et al. 2025).
  • Microsatellite instability. MSI or mismatch repair deficiency occurs in about 1%–2% of PDAC (1.1% by sequencing). It is strongly associated with medullary and mucinous (colloid) histology and with KRAS and TP53 wild-type tumors, and 78% arise in the head. Tumors with medullary or colloid histology are tested by immunohistochemistry, followed by MSI-PCR when results are doubtful (Luchini et al. 2021). Mismatch repair testing identifies Lynch syndrome and eligibility for immune checkpoint inhibitors, and NCCN suggests considering it for pancreatic adenocarcinoma (CAP 2025).
  • HER2. HER2 testing of advanced gastrointestinal cancers is increasing without standardized criteria for non-gastric sites, and the report states which criteria were applied (CAP 2025).
  • Transcriptomic subtypes. The classical subtype, with epithelial and adhesion genes, has the best prognosis and the quasi-mesenchymal subtype the worst. The exocrine-like subtype may reflect contamination by normal acini (Haeberle and Esposito 2019).

Subtypes of pancreatic ductal adenocarcinoma

PDAC subtypes with the molecular pathogenesis of conventional PDAC are adenosquamous carcinoma, undifferentiated (anaplastic) carcinoma, undifferentiated carcinoma with osteoclast-like giant cells, micropapillary carcinoma, signet-ring cell carcinoma and large-duct type carcinoma. Colloid carcinoma, medullary carcinoma and hepatoid carcinoma have a distinct molecular pathogenesis (Haeberle and Esposito 2019).

Subtype Defining features Molecular and immunohistochemical features Prognosis or associations SEER frequency Source
Conventional PDAC Duct-like glands in desmoplastic stroma KRAS, CDKN2A, TP53 and SMAD4 5-year survival 5.1% 95.9% Bengtsson et al. 2024
Colloid (mucinous) carcinoma (5th edition) ≥80% of the neoplastic epithelium floats in extracellular mucin pools; arises with intestinal-type IPMN GNAS with frequent KRAS mutations; associated with MSI 5-year survival 10.6% in SEER (multivariable HR 0.78) and about 50% in institutional series 2.6% Bengtsson et al. 2024; Haeberle and Esposito 2019; Luchini et al. 2021
Adenosquamous carcinoma (5th edition) Squamous component ≥30% of the tumor; the glandular component can be minimal p40 in the squamous component Worse than conventional PDAC (multivariable HR 1.16); 5-year survival after resection 15.7% versus 19.1% 0.8% Bengtsson et al. 2024; Haeberle and Esposito 2019
Signet-ring cell carcinoma (5th edition) Individual poorly cohesive cells, usually with intracellular mucin vacuoles and displaced nuclei, forming ≥80% of the tumor; earlier authors required ≥50% Molecular pathogenesis of conventional PDAC Worse than conventional PDAC; grade 3 by convention 0.5% Bengtsson et al. 2024; Haeberle and Esposito 2019; CAP 2025
Undifferentiated (anaplastic) carcinoma Solid or dispersed large pleomorphic cells with multinucleated tumor giant cells Pan-keratin and vimentin co-expression, E-cadherin loss Worse than conventional PDAC 0.1% Bengtsson et al. 2024; Haeberle and Esposito 2019
Undifferentiated carcinoma with osteoclast-like giant cells (5th edition) Pleomorphic mononuclear neoplastic cells with non-neoplastic osteoclast-like giant cells Giant cells are CD68 positive 5-year survival 28.4% in SEER (multivariable HR 0.68) and about 60% in institutional series 0.1% Bengtsson et al. 2024; Haeberle and Esposito 2019
Hepatoid carcinoma (5th edition) ≥50% hepatocellular differentiation: large polygonal cells with eosinophilic granular cytoplasm, sometimes with a ductal component Immunoprofile mimics hepatocellular carcinoma Exceedingly rare 0.01% Bengtsson et al. 2024; Haeberle and Esposito 2019
Medullary carcinoma (5th edition) Poor differentiation, syncytial growth, pushing border, necrosis and lymphocytic reaction Associated with MSI and with KRAS and TP53 wild-type status 5-year survival 33.3% (n = 9); MSI tumors respond well to immunotherapy 0.006% Bengtsson et al. 2024; Luchini et al. 2021
Large cell carcinoma with rhabdoid phenotype Pleomorphic neoplastic giant cells with abundant eosinophilic cytoplasm and rhabdoid inclusions SMARCB1 alterations with wild-type KRAS Worst subtype: median survival 2 months, 5-year survival 0% (n = 5) 0.003% Bengtsson et al. 2024; Haeberle and Esposito 2019
  • Additional subtype features (5th edition). p63 and p40 highlight the squamous component of adenosquamous carcinoma, which carries KRAS, TP53 and UPF1 mutations. Colloid carcinoma expresses MUC2, CK20 and CDX2 and carries GNAS mutations in up to 60%. Medullary carcinoma can also arise in a hypermutated POLE-mutant setting without MSI. Undifferentiated carcinoma with osteoclast-like giant cells contains three cell types: neoplastic spindle or pleomorphic cells, mononuclear histiocytes and non-neoplastic giant cells with over 20 nuclei; without an associated conventional PDAC component its prognosis can be favorable (Luchini et al. 2020a).
  • Cystic presentation of PDAC. Rarely PDAC appears cystic; the cyst may reflect intraductal colonization of a retention cyst or a congenital cyst (Luchini et al. 2020a). The cystic forms are listed in Cystic and Intraductal Neoplasms of the Pancreas: IPMN, IOPN, ITPN, Mucinous Cystic Neoplasm, Serous Neoplasms and Simple Mucinous Cyst.
  • Other 5th-edition subtypes. Invasive micropapillary carcinoma consists of densely packed micropapillary clusters within clefts, with "inside-out" MUC1 staining of the stroma-facing surface and cytoplasmic E-cadherin and galectin-3. Large-duct type carcinoma forms large, sometimes dilated ducts that mimic a non-invasive cystic tumor, with survival similar to conventional PDAC (Haeberle and Esposito 2019).
  • Undifferentiated carcinoma in the 6th edition. "Carcinoma with mesenchymal differentiation" replaces the 5th-edition term "carcinoma with sarcomatoid components", and the undifferentiated carcinoma category is expanded to include SWI/SNF-deficient carcinoma, defined by somatic alterations in ARID1A, SMARCA2 (BRM), SMARCA4 (BRG1) or SMARCB1 (INI1). Undifferentiated carcinomas lack definite squamous, glandular or neuroendocrine differentiation (Arends et al. 2026). Previous rule (5th edition): carcinoma with sarcomatoid components within undifferentiated carcinoma (Arends et al. 2026).
  • CAP histologic types. The CAP exocrine protocol lists ductal adenocarcinoma NOS, colloid carcinoma, poorly cohesive carcinoma, signet-ring carcinoma, carcinomas associated with IPMN, intraductal oncocytic papillary neoplasm, ITPN and MCN, medullary carcinoma, adenosquamous carcinoma, hepatoid carcinoma, large cell carcinoma with rhabdoid phenotype, undifferentiated carcinoma NOS and undifferentiated carcinoma with osteoclast-like giant cells among its histologic types (CAP 2025).

Frozen section of pancreatic margins: carcinoma versus chronic pancreatitis

The frozen section has little value for the uncinate, vascular groove and free-surface margins except in intraductal neoplasms (Adsay et al. 2014).

Finding Category Interpretation Source
Nuclear size variation of 4:1 or more between ductal cells Major criterion Favors carcinoma Hyland et al. 1981
Incomplete ductal lumens Major criterion Favors carcinoma Hyland et al. 1981
Disorganized duct distribution Major criterion Favors carcinoma Hyland et al. 1981
Huge irregular nucleoli Minor criterion Favors carcinoma Hyland et al. 1981
Necrotic glandular debris Minor criterion Favors carcinoma Hyland et al. 1981
Glandular mitoses Minor criterion Favors carcinoma Hyland et al. 1981
Glands without connective tissue stroma within smooth muscle bundles (periampullary biopsies) Minor criterion Favors carcinoma Hyland et al. 1981
Perineural invasion Minor criterion Favors carcinoma Hyland et al. 1981
Gland immediately adjacent to a muscular blood vessel Topographic hallmark Favors carcinoma, including when atypia is mild Luchini et al. 2020a
Naked glands in peripancreatic fat Topographic hallmark Favors carcinoma; islets in the fat indicate fatty involution of the gland Luchini et al. 2020a; Luchini et al. 2020b
Preserved, aggregated islets among fibrosis Chronic pancreatitis Islets persist while acini are lost Singhi et al. 2014
  • Combining criteria. Major and minor criteria applied together are especially helpful when chronic pancreatitis complicates the frozen section (Hyland et al. 1981).
  • Accuracy. In a series of 68 pancreatic resections reviewed by Bonaroti et al., frozen section was 97% accurate for final margin status and 83% accurate for the histologic diagnosis. Reported false-positive rates are 0%–3% (Bonaroti et al. 2016).

Related page: Cystic and Intraductal Neoplasms of the Pancreas: IPMN, IOPN, ITPN, Mucinous Cystic Neoplasm, Serous Neoplasms and Simple Mucinous Cyst (frozen section and margin reporting in IPMN)

Differential diagnosis of pancreatic ductal adenocarcinoma

Up to 5% of pancreatectomies performed for presumed carcinoma prove non-neoplastic, most often because of chronic inflammatory lesions such as autoimmune and paraduodenal pancreatitis (Adsay et al. 2004).

Entity Features that separate it from PDAC Source
Chronic pancreatitis Lobular atrophy with fibrosis, preserved and aggregated islets, dilated ducts with calculi; no major frozen-section criteria of carcinoma Singhi et al. 2014; Hyland et al. 1981
Type 1 autoimmune pancreatitis Lobule-centric lymphoplasmacytic infiltrate with IgG4-positive plasma cells, storiform fibrosis and obliterative phlebitis Okazaki et al. 2022
Paraduodenal pancreatitis Duodenal wall cysts near the minor papilla, Brunner gland hyperplasia and myoid stroma Adsay and Zamboni 2004
Distal cholangiocarcinoma Bulk of the tumor encircles the common bile duct; criteria for bile duct origin in Pancreatoduodenectomy Specimens and the Staging and Reporting of Pancreatic and Ampullary Carcinoma CAP Ampulla 2025
Ampullary carcinoma More than 75% of the tumor is located in the ampulla CAP Ampulla 2025
Lipomatous atrophy presenting as a mass Fat replacement of the pancreatic head that mimics a neoplasm on imaging Singhi et al. 2014
Metastasis to the pancreas Covered in Solid Cellular Neoplasms of the Pancreas: Solid Pseudopapillary Neoplasm, Acinar Cell Carcinoma, Pancreatoblastoma and Metastases to the Pancreas Haeberle and Esposito 2019

Related page: Pancreatoduodenectomy Specimens and the Staging and Reporting of Pancreatic and Ampullary Carcinoma (assignment of the site of origin in pancreatoduodenectomy specimens)

Pancreatoduodenectomy Specimens and the Staging and Reporting of Pancreatic and Ampullary Carcinoma

Definition and scope. Carcinomas of the exocrine pancreas and the ampulla of Vater are staged with the AJCC Cancer Staging Manual, 8th edition, which remains current for both sites (CAP 2025a; CAP 2025b). They are reported with the CAP Pancreas (Exocrine) protocol, version 4.3.0.0 (June 2025), and the CAP Ampulla of Vater protocol, version 4.3.0.0 (June 2025). The exocrine protocol covers pancreaticoduodenectomy (Whipple resection) and partial or total pancreatectomy for invasive carcinoma, including small cell and large cell neuroendocrine carcinoma. It excludes well-differentiated neuroendocrine tumors, ampullary tumors, lymphoma and sarcoma, and it is not required for intraductal neoplasms or mucinous cystic neoplasms without invasive carcinoma (CAP 2025a). The ampulla protocol covers ampullectomy and pancreaticoduodenectomy for intra-ampullary, peri-ampullary duodenal and mixed carcinomas, and it excludes well-differentiated neuroendocrine tumors (CAP 2025b).

Related page: Gastric Dysplasia, Gastric Carcinoma, Gastroesophageal Biomarkers and Small Intestinal Adenocarcinoma (ampullary-duodenal adenoma, intra-ampullary papillary-tubular neoplasm and the four ampullary adenocarcinoma types of the WHO 6th edition) Related page: Neuroendocrine, Mesenchymal and Lymphoid Tumors of the Esophagus, Stomach and Small Intestine (ampullary neuroendocrine tumors and AJCC Version 9 duodenal and ampullary NET staging) Related page: Gallbladder and Extrahepatic Bile Duct Pathology: Cholecystitis, Gallstones, Precursor Neoplasms, Gallbladder Carcinoma and Extrahepatic Cholangiocarcinoma (distal cholangiocarcinoma, its AJCC 8th edition chapter and the CAP Distal Extrahepatic Bile Ducts protocol) Related page: Pancreatic Neuroendocrine Neoplasms: Neuroendocrine Tumors, Functioning Syndromes, Neuroendocrine Carcinoma, Hereditary Syndromes and Staging (AJCC Version 9 staging of pancreatic neuroendocrine tumors and the CAP Pancreas (Endocrine) protocol) Related page: Pancreatic Ductal Adenocarcinoma, Its Subtypes and Pancreatic Intraepithelial Neoplasia (PDAC histology, subtypes, PanIN and frozen section) Related page: Cystic and Intraductal Neoplasms of the Pancreas: IPMN, IOPN, ITPN, Mucinous Cystic Neoplasm, Serous Neoplasms and Simple Mucinous Cyst (IPMN, MCN, IOPN and ITPN with associated invasive carcinoma) Related page: Pancreatic ductal adenocarcinoma and its variants on cytology (PDAC on EUS-guided sampling)

Orientation and dissection of pancreatoduodenectomy specimens

  • The "trapezoid". With the duodenum laid flat and the pancreas held above it, the posteromedial pancreatic head shows the vascular bed (the concave groove of the superior mesenteric and portal veins) at the center, the pancreatic neck margin at the left edge and the uncinate margin at the right edge. The common bile duct margin lies at the upper right plateau (Adsay et al. 2014).
  • Recognizing the margins. The pancreatic neck margin is flat, often cauterized and finely granular, with the duct orifice usually in the upper outer quadrant. The uncinate margin is elongated, soft and irregularly nodular. The vascular bed is smooth, firm and concave (Adsay et al. 2014).
  • Inking. The uncinate margin is inked, and sections through the tumor at its closest approach to it are submitted. The vascular groove is inked and sampled the same way (CAP 2025a).
  • Intraductal tumors. For an intraductal tumor, the pancreatic neck margin and the common bile duct margin are the most critical, and complete en face sections of both are taken (CAP 2025a).
  • Portal vein segment. Perpendicular sections document invasion of the vein wall, and the superior and inferior edges of the vein are also resection margins (Adsay et al. 2014). Portal vein invasion does not change the T category but is an independent prognostic factor (CAP 2025a).
  • Lymph node harvest. Lymph nodes lie in the surfaces and creases of the specimen and are retrieved before the head is sectioned. In the "orange-peeling" method all free surfaces are shaved into seven regions (Adsay et al. 2014).
  • Ampullary tumors. The ampulla is not covered by pancreas at the pancreaticoduodenal groove, so ampullary carcinomas can invade periduodenal soft tissue and duodenal serosa without passing through the pancreas. The serosa at the groove is inked and sampled perpendicularly (Adsay et al. 2014).
  • Distal pancreatectomy. The anterior and posterior surfaces are inked and the specimen is sliced perpendicular to the long axis of the pancreas (Haeberle and Esposito 2019).
  • Landmarks of distal pancreatectomy. The spleen and the transection margin orient the specimen from left to right, and the splenic artery and vein in the posterosuperior groove orient it from cranial to caudal. Slices parallel to the transection margin show the distance from tumor to margin, fat infiltration and splenic vessel invasion. The most important nodal sampling site runs along the splenic vessels (Luchini et al. 2020).
  • Resections after neoadjuvant therapy. The tumor bed is often fibrotic with blurred borders. It is sampled extensively, and a small or unidentifiable tumor bed is submitted entirely (Luchini et al. 2020). Grading is not applied after neoadjuvant therapy because therapy-induced atypia makes it unreliable (Luchini et al. 2020).
  • Margin nomenclature. The superior mesenteric vessel margin is also called the uncinate margin. The posterior aspect of the pancreatic head can be read either as a margin behind the transection line or as a surface toward the duodenum, and a "positive" margin can mean tumor at the margin or tumor within 1 mm of it, so the report states which definition is applied (Luchini et al. 2020).
Sectioning method Technique Strengths Limitations Source
Axial slicing (Verbeke) Serial slices perpendicular to the long axis of the descending duodenum along its whole craniocaudal length; anterior, posterior and medial surfaces inked in different colors Same protocol for every specimen; circumferential margins assessable; correlation with CT and MRI; favored by the Royal College of Pathologists; detects more R1 resections The ampullary region can fall between slices; main-duct and branch-duct IPMN cannot be separated Soer et al. 2018; Haeberle and Esposito 2019
Bivalving along probes (Adsay) Probes in the pancreatic duct and common bile duct; the head is cut in the plane of both ducts and the ampulla, then the halves are sliced Ampullary compartments and tumor origin are seen in one plane; supports the four-type ampullary classification and the duct relationships of cystic tumors Technically more difficult; the pancreatic duct is hard to probe distally in about a third of cases Adsay et al. 2014; Soer et al. 2018

Margins of pancreatoduodenectomy and pancreatectomy specimens

Margin or surface Location and synonyms CAP 4.3 status Source
Pancreatic neck (parenchymal) Transection of the pancreatic neck Margin; en face section for intraductal tumors CAP 2025a; Adsay et al. 2014
Proximal and distal pancreatic parenchymal Transection margins of partial pancreatectomies Margin CAP 2025a
Uncinate Nonperitonealized posteroinferior surface of the uncinate process; also called retroperitoneal or superior mesenteric artery margin Margin; the most common site of local recurrence CAP 2025a; CAP 2025b
Common bile duct Transected bile duct at the upper right of the trapezoid Margin; en face section CAP 2025a; Adsay et al. 2014
Proximal enteric Gastric or duodenal Margin CAP 2025a
Distal enteric Duodenal or jejunal Margin CAP 2025a
Vascular groove (bed) Groove of the superior mesenteric and portal veins Listed with the margins; classification as surface or margin remains debated, and involvement is always documented CAP 2025a
Anterior and posterior surfaces Free surfaces of the pancreatic head Listed with the margins; reported as pancreatic surface involvement, and involvement is always documented CAP 2025a
Deep (radial), duodenal mucosal and pancreatic duct Margins of ampullectomy and ampullary resections Margins in the ampulla protocol CAP 2025b
  • Previous rule (CAP Pancreas (Exocrine) 4.2.0.2, 2021): the vascular groove, anterior surface and non-uncinate posterior surface were not considered resection margins, and reporting of anterior and posterior surface involvement was recommended but not required (CAP 2021).
  • 1 mm rule. Tumor at or within 1 mm of a resection margin constitutes a positive margin. Margin status is reported as R0 (no residual disease), R1 (microscopic residual disease) or R2 (macroscopic residual disease) (CAP 2025a).
  • Variation in the R1 definition. Europe and Japan have defined R1 as tumor within 1 mm of the margin, whereas resections in the United States were classified as incomplete only when tumor reached the margin. R0 carries prognostic value only when defined as ≥1 mm clearance, and studies using ≥1.5 mm or ≥2 mm clearance found stronger prediction (Soer et al. 2018). Patients with "R0 wide" margins (no tumor within 1 mm) survive longer than those with tumor within 1 mm ("R1 1 mm" or "R0 narrow") or at the margin (R1) (Haeberle and Esposito 2019).
  • Indirect spread near a margin. Tumor within 1 mm of a margin only through lymphovascular or perineural invasion or a lymph node is R1 for the Royal College of Pathologists and R0 for the UICC unless the vessel wall is invaded within 1 mm. The Royal College excludes the anterior free surface from the 1-mm rule (Soer et al. 2018).
  • Effect of dissection on R1 rates. Published R1 rates range from 18%–85% for pancreatic, 0%–27% for ampullary and 0%–72% for distal bile duct carcinoma, mainly because of differences in pathologic assessment (Verbeke and Gladhaug 2012).
  • Margin status in ampullary carcinoma. The uncinate margin is the most common site of local recurrence, and microscopically positive (R1) margins worsen prognosis (CAP 2025b).
  • High-grade intraepithelial neoplasia at margins. Both protocols report margin status for high-grade dysplasia or high-grade intraepithelial neoplasia separately from invasive carcinoma (CAP 2025a; CAP 2025b).

Regional lymph nodes of the pancreas and ampulla

  • Pancreatic head. Regional nodes lie along the common bile duct, common hepatic artery, portal vein, pylorus, anterior and posterior pancreaticoduodenal arcades, superior mesenteric vein and right lateral wall of the superior mesenteric artery (CAP 2025a).
  • Pancreatic body and tail. Regional nodes lie along the common hepatic artery, celiac axis, splenic artery and splenic hilum (CAP 2025a).
  • Ampulla. Regional nodes are peripancreatic nodes and nodes along the hepatic artery and portal vein (CAP 2025b).
  • Distant nodes. Involvement of any other nodal group is distant metastasis (CAP 2025a; CAP 2025b).
  • Number examined. Microscopic examination of at least 12 lymph nodes is recommended for Whipple resections of pancreatic and ampullary carcinoma (CAP 2025a; CAP 2025b; Luchini et al. 2020). Routine levels or immunohistochemistry for micrometastases are not recommended for ampullary carcinoma (CAP 2025b).
  • Prognosis. Lymph node metastasis is an independent adverse prognostic factor, and outcome data support the division of node-positive tumors into N1 and N2 (CAP 2025a).

AJCC 8th edition staging of exocrine pancreatic carcinoma

The T1–T3 categories are defined by size because size stratifies prognosis better than extension into peripancreatic tissue. Only the invasive component is measured, and gross size is corroborated microscopically (CAP 2025a).

pT (AJCC 8th edition) Definition Previous rule (AJCC 7th edition) Source
pTis Carcinoma in situ, including high-grade PanIN (PanIN-3), IPMN, intraductal oncocytic papillary neoplasm, ITPN and MCN with high-grade dysplasia Carcinoma in situ CAP 2025a
pT1 Tumor ≤2 cm in greatest dimension T1: confined to the pancreas, ≤2 cm CAP 2025a; Colino-Gallardo et al. 2025
pT1a Tumor ≤0.5 cm No subcategory CAP 2025a; Colino-Gallardo et al. 2025
pT1b Tumor >0.5 cm and <1 cm No subcategory CAP 2025a; Colino-Gallardo et al. 2025
pT1c Tumor 1–2 cm No subcategory CAP 2025a; Colino-Gallardo et al. 2025
pT2 Tumor >2 cm and ≤4 cm T2: confined to the pancreas, >2 cm CAP 2025a; Colino-Gallardo et al. 2025
pT3 Tumor >4 cm T3: extends beyond the pancreas without involvement of the celiac axis or superior mesenteric artery CAP 2025a; Colino-Gallardo et al. 2025
pT4 Tumor involves the celiac axis, superior mesenteric artery and/or common hepatic artery, regardless of size T4: involves the celiac axis or superior mesenteric artery (unresectable) CAP 2025a; Colino-Gallardo et al. 2025
pN (AJCC 8th edition) Definition Previous rule (AJCC 7th edition) Source
pN0 No regional lymph node metastasis Same CAP 2025a; Colino-Gallardo et al. 2025
pN1 Metastasis in 1–3 regional lymph nodes N1: any regional lymph node metastasis CAP 2025a; Colino-Gallardo et al. 2025
pN2 Metastasis in ≥4 regional lymph nodes No N2 category CAP 2025a; Colino-Gallardo et al. 2025
Stage group AJCC 8th edition AJCC 7th edition Source
IA T1 N0 M0 T1 N0 M0 Colino-Gallardo et al. 2025
IB T2 N0 M0 T2 N0 M0 Colino-Gallardo et al. 2025
IIA T3 N0 M0 T3 N0 M0 Colino-Gallardo et al. 2025
IIB T1–T3 N1 M0 T1–T3 N1 M0 Colino-Gallardo et al. 2025
III Any T N2 M0, or T4 any N M0 T4 any N M0 Colino-Gallardo et al. 2025
IV Any T any N M1 Any T any N M1 Colino-Gallardo et al. 2025
  • Extension that does not change pT. Invasion of peripancreatic soft tissue, peritoneum, extrapancreatic bile duct or duodenum (including the ampulla) by head tumors, or of stomach, spleen, left adrenal gland or peritoneum by body and tail tumors, does not affect the T category and is recorded in the report (CAP 2025a).
  • pT4 in practice. Tumors involving the superior mesenteric artery, celiac axis or common hepatic artery are usually unresectable, so T4 is usually assigned radiologically (CAP 2025a).
  • Distant metastasis. Peritoneal seeding or positive peritoneal cytology is M1 (CAP 2025a).
  • Multiple tumors. When more than one grossly recognizable synchronous carcinoma is present, the highest T is assigned with the suffix (m) or the number of tumors, for example pT3(m) or pT3(2). This does not apply to a single tumor with separate microscopic foci (CAP 2025a).
  • Invasive carcinoma in intraductal and mucinous cystic neoplasms. Only the invasive component determines T. For multifocal invasion, the report gives the size of the largest focus and the aggregate size of all foci or the percentage of invasive tumor, and the largest focus is used for staging (CAP 2025a).
  • Vessel invasion. Lymphatic or venous invasion does not change the T category (CAP 2025a).
  • Descriptors. The prefix y marks classification after neoadjuvant therapy, r marks recurrence after a disease-free interval and a marks autopsy staging; m and y do not change the stage group (CAP 2025a).
  • Size after neoadjuvant therapy. The ypT category uses only the extent or size of viable tumor, estimated by adding the sizes of all viable tumor foci within the mass on combined gross and microscopic assessment. Acellular mucin pools after chemoradiation are not residual tumor (CAP 2025a).

CAP Pancreas (Exocrine) protocol: reporting elements and the June 2025 revision

Element Responses and rules Source
Procedure Excisional biopsy (enucleation); pancreaticoduodenectomy; total pancreatectomy; partial pancreatectomy of the body or tail CAP 2025a
Tumor site Head, uncinate process, body or tail. Head tumors lie right of the left border of the superior mesenteric vein, and the uncinate process is part of the head. Body tumors lie between the left borders of the superior mesenteric vein and the aorta, and tail tumors between the left border of the aorta and the splenic hilum CAP 2025a
Histologic type WHO types, including carcinomas associated with IPMN, intraductal oncocytic papillary neoplasm, ITPN and MCN, acinar cell carcinoma, pancreatoblastoma, solid pseudopapillary neoplasm, neuroendocrine carcinoma and MiNEN CAP 2025a
Histologic grade G1–G3 by percentage of gland formation, as defined in Pancreatic Ductal Adenocarcinoma, Its Subtypes and Pancreatic Intraepithelial Neoplasia; required only for ductal carcinoma CAP 2025a
Tumor size Unifocal: greatest dimension. Multifocal invasion with an intraductal neoplasm or MCN: largest focus, aggregate size and percentage invasive CAP 2025a
Direct extension From confined to pancreas through ampulla, duodenal wall, peripancreatic tissue, bile duct, stomach, veins and arteries CAP 2025a
Pancreatic surface involvement Posterior or anterior surface, reported when applicable CAP 2025a
Lymphatic and/or vascular invasion; perineural invasion Required; both are adverse prognostic factors CAP 2025a
Treatment effect Modified Ryan score 0–3 CAP 2025a
Margins Invasive carcinoma and high-grade dysplasia or intraepithelial neoplasia reported separately; closest margin and distance optional CAP 2025a
Regional lymph nodes Number with tumor and number examined CAP 2025a
pTNM AJCC 8th edition pT, pN and pathologically confirmed pM, with y, r and (m) descriptors CAP 2025a
Additional findings (optional) PanIN with highest grade, chronic pancreatitis, acute pancreatitis; gastritis, duodenitis and ampullitis in the attached organs CAP 2025a
Ancillary studies (optional) Mismatch repair immunohistochemistry or MSI testing; HER2 with the scoring criteria stated CAP 2025a
  • Changes in version 4.3.0.0 (June 2025). The revision modified the histologic type and tumor size questions and the margins and special studies sections, added a conditionally reported pancreatic surface involvement question and renamed lymphovascular invasion as lymphatic and/or vascular invasion (CAP 2025a; CAP 2025c). Use of version 4.3.0.0 is required for accreditation from March 2026 (CAP 2025a).
  • Previous rule (version 4.2.0.2). Tumor size had a single greatest-dimension response, and pancreatic surface involvement was an optional element (CAP 2021). The histologic type list included mixed acinar-neuroendocrine carcinoma, mixed ductal-neuroendocrine carcinoma and mixed acinar-endocrine-ductal carcinoma, and the 2025 list omits these three and asks for the components of a MiNEN to be specified (CAP 2021; CAP 2025a).

Treatment response in pancreatic and ampullary carcinoma after neoadjuvant therapy

Modified Ryan score Description Source
0 No viable cancer cells (complete response) CAP 2025a; CAP 2025b
1 Single cells or rare small groups of cancer cells (near complete response) CAP 2025a; CAP 2025b
2 Residual cancer with evident tumor regression, but more than single cells or rare small groups (partial response) CAP 2025a; CAP 2025b
3 Extensive residual cancer with no evident tumor regression (poor or no response) CAP 2025a; CAP 2025b
  • Three-tier alternative. A three-tier modification correlates better with outcome: grade 0, no residual carcinoma; grade 1, single cells or small groups amounting to <5% residual carcinoma; grade 2, ≥5% residual carcinoma (CAP 2025a).
Other regression system Grades Source
Evans I, little (<10%) or no tumor cell destruction; IIa, destruction of 10%–50%; IIb, destruction of 51%–90%; III, few (<10%) viable-appearing tumor cells (IIIM with sizable mucin pools); IV, no viable tumor cells (IVM with acellular mucin pools) Matsuda et al. 2020
MD Anderson 0, no viable tumor; 1, <5% viable tumor cells; 2, ≥5% viable tumor cells Matsuda et al. 2020
Japan Pancreas Society 1a, residual tumor ≥90%; 1b, 50% to <90%; 2, 10% to <50%; 3, <10%; 4, no viable cancer cells Matsuda et al. 2020
  • Reproducibility. In 97 resections after neoadjuvant therapy, interobserver κ was 0.34 for Evans, 0.50 for CAP, 0.65 for MD Anderson and 0.33 for the Japan Pancreas Society system. The CAP and Evans systems are the most commonly used worldwide (Matsuda et al. 2020).
  • Difficulties in grading regression. Pre-treatment tumor size is unknown, therapy-naive PDAC already has prominent desmoplasia, and regression is patchy. Necrosis, inflammation, mucin pools, cytoplasmic eosinophilia and vacuolization and high-grade nuclear atypia after therapy also occur in untreated PDAC (Haeberle and Esposito 2019).
  • Specimens without residual cancer. A primary resection with no residual cancer after neoadjuvant therapy does not require the synoptic protocol for accreditation (CAP 2025a; CAP 2025b).

Ampullary carcinoma: anatomy, definition and site categories

  • Anatomy. The distal common bile duct and main pancreatic duct (Wirsung) converge in the ampulla, which opens into the duodenum at the papilla of Vater. The ducts form a common channel in about two-thirds of people, merge at the orifice in 30% and open separately within the ampulla in 2%. The intra-ampullary surface is lined by pancreatobiliary-type ductal epithelium, the duodenal surface of the papilla by small intestinal epithelium, and the sphincter of Oddi encircles the distal merged ducts (CAP 2025b).
  • Definition. A carcinoma is ampullary when the bulk of the tumor (>75%) lies in the ampulla (CAP 2025b). Carcinomas centered on the ampulla, circumferentially surrounding it or replacing it are ampullary carcinomas, and precursor lesions at the ampulla support the assignment in large tumors (Soer et al. 2018).
  • Site categories. CAP 4.3.0.0 records the tumor site as intra-ampullary (IAPN-associated or ampullary ductal origin), (peri-)ampullary-duodenal, mixed intra-ampullary and ampullary-duodenal, or other. This anatomic classification is made grossly, radiologically or endoscopically and verified microscopically, and it is separate from histologic typing (CAP 2025b).
  • Gross appearance by site. Ampullary-duodenal tumors form a visible lesion on the duodenal surface of the papilla, often from a surface adenoma. IAPN-associated tumors produce an elevated ampulla covered by stretched normal mucosa with a patulous orifice. Ampullary-ductal tumors are subtle sclerotic lesions that constrict the duct walls with minimal puckering of the surface (CAP 2025b).
  • Site and histologic type. Ampullary-duodenal carcinomas are more often intestinal type, and ampullary-ductal carcinomas are much more often pancreatobiliary type (CAP 2025b).
  • IAPN with invasion. The sizes of the preinvasive and invasive components are reported separately, and T category, grade and histologic type are based only on the invasive component (CAP 2025b). Prognosis of the four ampullary carcinoma types is covered in Gastric Dysplasia, Gastric Carcinoma, Gastroesophageal Biomarkers and Small Intestinal Adenocarcinoma.
  • Hereditary settings. Patients with familial adenomatous polyposis have an estimated lifetime incidence of ampullary carcinoma of about 12%, and ampullary adenocarcinoma also occurs in Lynch syndrome (CAP 2025b).

Intestinal and pancreatobiliary immunophenotypes of ampullary carcinoma

Ampullary carcinoma is typed on its invasive component as pancreatobiliary, intestinal or mixed. CK20, CDX2, MUC2 and MUC1 aid the distinction, many cases remain ambiguous, and the prognostic significance of the distinction is unresolved (CAP 2025b).

Immunophenotype (Ang 2014 schema) Definition Source
Intestinal CK20, CDX2 or MUC2 positive with MUC1 negative; or CK20, CDX2 and MUC2 all positive irrespective of MUC1 Ang et al. 2014
Pancreatobiliary MUC1 positive with CDX2 and MUC2 negative, irrespective of CK20 Ang et al. 2014
Ambiguous Any pattern that fits neither definition Ang et al. 2014
CK7 Positive in ≥70% of both intestinal and pancreatobiliary carcinomas; not informative Ang et al. 2014
  • Performance of the schema. In 105 consecutive ampullary carcinomas, hematoxylin and eosin consensus was reached in 77%. Interobserver agreement was good for intestinal (κ 0.57) and pancreatobiliary (κ 0.48) types and poor for the mixed type (κ 0.09). Adding the immunohistochemical schema classified 92% of cases as intestinal or pancreatobiliary, including 75% of poorly differentiated and 69% of histologically mixed carcinomas, and 88% of mucinous adenocarcinomas were intestinal (Ang et al. 2014).
  • Reproducibility of histologic typing. In 232 resected ampullary carcinomas, overall interobserver agreement was fair (κ 0.39), and 40% were classified as mixed by consensus. Pancreatobiliary-type carcinomas had shorter median survival (41 versus 80 months) and 5-year survival (38% versus 57%) than intestinal-type carcinomas, but the difference was not independent of established prognostic factors. Pancreatobiliary-type ampullary carcinoma still had better survival than PDAC (41 versus 16 months), even when matched for size and node status (Reid et al. 2016).
  • Prognostic markers. In 136 ampullary carcinomas with more than 5 mm of invasion, MUC1, CDX2, MUC2 and CK20 showed no prognostic correlation, and the Ang ambiguous group was 29%. MUC5AC was a strong prognosticator (5-year survival 68% versus 31% at a 20% cutoff) (Xue et al. 2017).
  • Population data on subtype. In 726 ampullary adenocarcinomas in SEER (2004–2021), 53.0% were intestinal type and 47.0% pancreatobiliary or mixed type. Pancreatobiliary or mixed tumors had worse cancer-specific survival (median 39 versus 168 months; adjusted HR 1.60) and more often were T3 (57.5% versus 34.5%), node positive (62.8% versus 51.4%) and poorly differentiated (35.8% versus 19.2%) (Zhang et al. 2026).
  • Non-TNM prognostic factors. Patient age, perineural and vascular invasion, margin status and tumor budding are independent prognostic factors. Size of invasive carcinoma, histologic type and grade appear to play a lesser role (CAP 2025b).

AJCC 8th edition staging of ampullary carcinoma

pT (AJCC 8th edition) Definition Source
pTis Carcinoma in situ; includes noninvasive IAPN CAP 2025b
pT1a Tumor limited to ampulla of Vater or sphincter of Oddi CAP 2025b
pT1b Tumor invades beyond the sphincter of Oddi (perisphincteric invasion) and/or into the duodenal submucosa CAP 2025b
pT2 Tumor invades into the muscularis propria of the duodenum CAP 2025b
pT3a Tumor directly invades pancreas (up to 0.5 cm) CAP 2025b
pT3b Tumor extends more than 0.5 cm into the pancreas, or extends into peripancreatic tissue or periduodenal tissue or duodenal serosa without involvement of the celiac axis or superior mesenteric artery CAP 2025b
pT4 Tumor involves the celiac axis, superior mesenteric artery and/or common hepatic artery, irrespective of size CAP 2025b
pN1 Metastasis to one to three regional lymph nodes CAP 2025b
pN2 Metastasis to four or more regional lymph nodes CAP 2025b
  • N category. The 8th edition revised the ampullary T categories and subdivided the N category into N1 (1–3 nodes) and N2 (≥4 nodes) (Shin 2023).
  • Previous rule (AJCC 7th edition, ampulla). N was assigned only by the presence (N1) or absence (N0) of regional nodal metastasis (Park et al. 2024; Na and Seo 2026).
  • Value of the N1/N2 split. In 86 resected ampullary adenocarcinomas treated with adjuvant therapy, two or more metastatic nodes predicted outcome better than the pN category in multivariable analysis (Park et al. 2024). In 147 periampullary adenocarcinomas, the N1/N2 subdivision added little prognostic information beyond nodal positivity, whereas the lymph node ratio added information mainly when few nodes were examined (Na and Seo 2026).
  • UICC 9th edition. The 9th edition of the UICC TNM classification made no changes to the ampulla of Vater, pancreas or well-differentiated gastrointestinal neuroendocrine tumor classifications (Brierley et al. 2026).
Stage group (AJCC 8th edition, ampulla of Vater) T N M Source
IA T1a N0 M0 Shin 2023
IB T1b or T2 N0 M0 Shin 2023
IIA T3a N0 M0 Shin 2023
IIB T3b N0 M0 Shin 2023
IIIA T1–T3 N1 M0 Shin 2023
IIIB T4 Any N M0 Shin 2023
IIIB Any T N2 M0 Shin 2023
IV Any T Any N M1 Shin 2023
  • Invasive carcinoma with IAPN. Only the invasive component determines T, and when invasion is multifocal the deepest focus of invasion is used (CAP 2025b).
  • Grade. G1 >95% glands, G2 50%–95% and G3 ≤49%; signet-ring cell carcinoma is grade 3 by convention, and the scheme does not apply to neuroendocrine carcinoma (CAP 2025b).

CAP Ampulla of Vater protocol: reporting elements and the June 2025 revision

Element Responses and rules Source
Procedure Ampullectomy; pancreaticoduodenectomy CAP 2025b
Tumor site Intra-ampullary (IAPN-associated or ampullary ductal origin); (peri-)ampullary-duodenal; mixed CAP 2025b
Histologic type Adenocarcinoma of pancreatobiliary, intestinal or mixed type; adenocarcinoma NOS; adenocarcinoma arising in IAPN; mucinous adenocarcinoma; poorly cohesive and signet-ring cell carcinoma; medullary and adenosquamous carcinoma; large cell and small cell neuroendocrine carcinoma; undifferentiated carcinoma; MiNEN CAP 2025b
Tumor size Unifocal: greatest dimension. Multifocal invasion with IAPN: largest focus, aggregate size and percentage invasive CAP 2025b
Tumor extent Ampulla or sphincter of Oddi, perisphincteric tissue, duodenal submucosa, muscularis propria, pancreas ≤0.5 cm or >0.5 cm, peripancreatic and periduodenal tissue, serosa, adjacent organs and arteries CAP 2025b
Lymphatic and/or vascular invasion; perineural invasion; treatment effect Required CAP 2025b
Margins Deep (radial), duodenal mucosal, pancreatic duct, bile duct, pancreatic neck, uncinate, proximal and distal enteric; high-grade dysplasia reported separately CAP 2025b
Regional lymph nodes and pTNM Number with tumor and number examined; AJCC 8th edition pT, pN and pM CAP 2025b
Ancillary studies (optional) Mismatch repair immunohistochemistry or MSI testing CAP 2025b
  • Changes in version 4.3.0.0 (June 2025). The revision modified the tumor site, histologic type, tumor size, tumor extent and margin status for dysplasia questions, renamed lymphovascular invasion as lymphatic and/or vascular invasion, made perineural invasion required and added a required treatment effect question (CAP 2025b; CAP 2025c).
  • Previous rule (version 4.2.0.1). Perineural invasion was optional, no treatment effect question existed and tumor size had a single greatest-dimension response. The histologic type list included invasive papillary adenocarcinoma, tubular adenocarcinoma with mixed features and mixed adenoneuroendocrine carcinoma, and the pT categories were the same (CAP Ampulla 2021).

Assigning the site of origin of a carcinoma in a pancreatoduodenectomy

Primary site Criteria Source
Ampulla of Vater Bulk (>75%) of the tumor in the ampulla; centered on, encircling or replacing the ampulla; ampullary precursor lesion CAP 2025b; Soer et al. 2018
Distal common bile duct Bulk of the tumor encircles the common bile duct grossly, confirmed microscopically; dysplasia in the bile duct, circumferential duct involvement, intraglandular neutrophil-rich debris and small tubules favor bile duct origin CAP 2025b; Soer et al. 2018
Nonampullary duodenum Epicenter in the duodenum, wedge-shaped growth with its base on the duodenal mucosa and an uninvolved ampulla Adsay et al. 2014
Pancreas Epicenter in the pancreatic parenchyma without the ampullary or bile duct criteria CAP 2025b; Soer et al. 2018
  • Accuracy of assignment. Tumor origin is often reclassified on slide review, and the published proportions of pancreatic (33%–89%), ampullary (5%–42%) and distal bile duct (5%–38%) carcinomas among pancreatoduodenectomies vary widely, indicating that the distinction is less accurate than generally believed (Verbeke and Gladhaug 2012). In Western series about 5% of pancreatoduodenectomies contain primary bile duct carcinoma (Adsay et al. 2014).
  • Staging consequence. Distal bile duct, ampullary and pancreatic carcinomas have separate AJCC 8th edition chapters and CAP protocols, so the site assignment determines the pT definitions used (CAP 2025a; CAP 2025b).

Cystic and Intraductal Neoplasms of the Pancreas: IPMN, IOPN, ITPN, Mucinous Cystic Neoplasm, Serous Neoplasms and Simple Mucinous Cyst

Definition and classification. Pancreatic cystic neoplasms comprise intraductal neoplasms that communicate with the ductal tree, mucinous cysts that do not communicate with it, serous neoplasms, and solid neoplasms with cystic change. The intraductal neoplasms are intraductal papillary mucinous neoplasm (IPMN), intraductal oncocytic papillary neoplasm (IOPN) and intraductal tubulopapillary neoplasm (ITPN). Mucinous cystic neoplasm (MCN) lacks duct communication and papillae and has ovarian-type subepithelial stroma (Pea et al. 2025). The WHO Classification of Digestive System Tumours, 6th edition (2026), adds the simple mucinous cyst as a neoplastic cystic lesion and removes acinar cystic transformation from the tumour classification as non-neoplastic (Arends et al. 2026). The 6th edition grades all precursor lesions as low grade or high grade, with former intermediate grade merged into low grade (Arends et al. 2026). For PanIN, IPMN and MCN this two-tier system was already in force in the 5th edition, based on the highest grade present (Nagtegaal et al. 2020; Basturk et al. 2015). The 5th edition separated IOPN and ITPN from the IPMN subtypes because of their distinct genomic and morphologic features (Nagtegaal et al. 2020). The 6th-edition summary does not restate the criteria for IPMN subtypes, IOPN, ITPN, MCN and serous neoplasms; these criteria follow the 5th edition.

Related page: Non-Neoplastic Pancreas: Developmental Anomalies, Acute, Chronic, Hereditary and Autoimmune Pancreatitis, Pseudocysts and Non-Neoplastic Cysts, Allograft and Islet Pathology (pseudocyst, lymphoepithelial cyst, retention cyst and acinar cystic transformation) Related page: Pancreatic Ductal Adenocarcinoma, Its Subtypes and Pancreatic Intraepithelial Neoplasia (pancreatic intraepithelial neoplasia and colloid carcinoma as a ductal adenocarcinoma subtype) Related page: Pancreatoduodenectomy Specimens and the Staging and Reporting of Pancreatic and Ampullary Carcinoma (AJCC 8th edition pT and pN tables, margins and the CAP exocrine pancreas protocol) Related page: Solid Cellular Neoplasms of the Pancreas: Solid Pseudopapillary Neoplasm, Acinar Cell Carcinoma, Pancreatoblastoma and Metastases to the Pancreas (solid pseudopapillary neoplasm, acinar cell cystadenocarcinoma and metastatic renal cell carcinoma) Related page: Pancreatic Neuroendocrine Neoplasms: Neuroendocrine Tumors, Functioning Syndromes, Neuroendocrine Carcinoma, Hereditary Syndromes and Staging (cystic pancreatic neuroendocrine tumor and von Hippel–Lindau disease) Related page: Pancreatic cyst fluid chemistry and molecular testing (CEA, amylase and glucose thresholds and GNAS, KRAS, RNF43, VHL and CTNNB1 testing in cyst fluid) Related page: Pancreatic cystic neoplasms on cytology (IPMN, MCN, serous, IOPN and ITPN on EUS-FNA and atypia grading in cyst fluid) Related page: The WHO Reporting System for Pancreaticobiliary Cytopathology (WHO reporting system categories for pancreatic cyst cytology) Related page: Gallbladder and Extrahepatic Bile Duct Pathology: Cholecystitis, Gallstones, Precursor Neoplasms, Gallbladder Carcinoma and Extrahepatic Cholangiocarcinoma (IPNB, ITPN and IOPN of the bile ducts)

Pathologic classification of pancreatic cystic lesions

Category Entities Source
Non-neoplastic cysts Acinar cystic transformation, removed from the tumour classification in the 6th edition (Non-Neoplastic Pancreas: Developmental Anomalies, Acute, Chronic, Hereditary and Autoimmune Pancreatitis, Pseudocysts and Non-Neoplastic Cysts, Allograft and Islet Pathology) Nagtegaal et al. 2020; Arends et al. 2026
Intraductal neoplasms (duct communication) IPMN (main duct, branch duct, mixed type); IOPN; ITPN Nagtegaal et al. 2020; Danti et al. 2026
Mucinous cysts without duct communication MCN (ovarian-type stroma); simple mucinous cyst (no ovarian-type stroma, 6th edition) Arends et al. 2026; Pea et al. 2025
Serous neoplasms Serous cystadenoma (microcystic, macrocystic, solid, von Hippel–Lindau syndrome-associated and mixed serous-neuroendocrine types); serous cystadenocarcinoma Lu et al. 2025; Tan et al. 2026
Solid neoplasms with cystic change Solid pseudopapillary neoplasm with central cystic and hemorrhagic degeneration; cystic pancreatic neuroendocrine tumor without duct communication; acinar cell cystadenocarcinoma Danti et al. 2026; CAP 2025
Ductal adenocarcinoma with cystic change Neoplastic: large-duct type cysts (small intratumoral cysts with a honeycomb pattern that mimic serous cystadenoma or branch-duct IPMN), neoplastic mucin cysts, colloid carcinoma and degenerative cystic change from necrosis and hemorrhage. Non-neoplastic: retention cysts from duct obstruction and pseudocysts from tumor-associated pancreatitis Zou et al. 2024; Luchini et al. 2020

Comparison of the main pancreatic cystic neoplasms

Feature IPMN MCN Serous cystadenoma Simple mucinous cyst (6th edition)
Patients Slight male predominance; sixth to seventh decades (Urgesi et al. 2026) Women in 95%; patients with invasive carcinoma older than those without (55 vs 44 years) (Crippa et al. 2008) Women in 74%; median age 58 years (Jais et al. 2016) Female sex less frequent than in MCN in a cohort with associated carcinoma (Pea et al. 2025)
Site and size Head in 55.6% of 448 resected branch-duct or mixed-type IPMNs; mean cyst size 32 mm (Kang et al. 2019) Distal pancreas in 97%; all cancers were ≥40 mm or had nodules (Crippa et al. 2008) Body and tail more often (Danti et al. 2026); median size 40 mm at early resection (Jais et al. 2016) Larger than 1 cm by definition (Arends et al. 2026)
Duct communication Main duct, branch ducts or both (Danti et al. 2026) None (Crippa et al. 2008) None (Danti et al. 2026) None (Pea et al. 2025)
Lining Papillary mucin-producing columnar epithelium of gastric, intestinal or pancreatobiliary type (Basturk et al. 2015) Mucinous columnar epithelium without papillary projections (Pea et al. 2025) Small uniform cuboidal glycogen-rich cells (Chi et al. 2023) Gastric-type epithelium without papillae (Arends et al. 2026)
Stroma Fibrous duct wall Ovarian-type stroma with ER, PR and α-inhibin expression (Lam et al. 2008) Fibrous septa; central scar common in microcystic tumors (Lu et al. 2025) No ovarian-type stroma (Arends et al. 2026)
Genes GNAS, KRAS, RNF43 (Wu et al. 2011a, 2011b) KRAS, RNF43; KRAS and TP53 most common with carcinoma (Wu et al. 2011b; Pea et al. 2025) VHL (Wu et al. 2011b) KRAS, BRAF, TP53, SMAD4 (Arends et al. 2026)
Malignant potential Main-duct and mixed type 40%–90% malignancy (Urgesi et al. 2026) Cancer in 17.5%; 5-year disease-specific survival 100% noninvasive and 57% invasive (Crippa et al. 2008) Three serous cystadenocarcinomas and 0.1% disease-related mortality among 2622 patients (Jais et al. 2016) Precursor of ductal adenocarcinoma (Arends et al. 2026; Pea et al. 2025)

Intraductal papillary mucinous neoplasm: definition and duct type

IPMN is a grossly visible, predominantly papillary or rarely flat, noninvasive mucin-producing epithelial neoplasm arising in the main pancreatic duct or branch ducts (Basturk et al. 2015). Pancreatic intraepithelial neoplasia (PanIN) usually measures less than 0.5 cm, and IPMN usually measures 1.0 cm or more (Basturk et al. 2015). Lesions of 0.5 to 1.0 cm with long finger-like papillae, intestinal or oncocytic differentiation, or a GNAS mutation are termed incipient IPMN. Small gastric-type cysts without these features are reported descriptively (Basturk et al. 2015). IPMNs account for about 8%–20% of pancreatectomy specimens at referral centers (Mino-Kenudson et al. 2011).

  • Duct type. Main-duct IPMN dilates the main pancreatic duct (MPD) alone, branch-duct IPMN dilates branch ducts alone, and mixed-type IPMN involves both (Danti et al. 2026). In a validation of the 2017 guidelines, branch-duct IPMN was a cyst larger than 5 mm communicating with a nondilated MPD, and mixed type was a branch-duct IPMN with MPD dilatation larger than 5 mm without obstruction (Kang et al. 2019).
  • Duct type and epithelium. Main-duct IPMNs often have intestinal-type epithelium and branch-duct IPMNs usually gastric-type epithelium (Mino-Kenudson et al. 2011).
  • Multifocality and follow-up. IPMNs can be multifocal. Patients with resected IPMNs remain at risk of metachronous IPMN or invasive carcinoma in the remnant, so follow-up is warranted for any grade and any margin status (Basturk et al. 2015).

IPMN epithelial subtypes and mucin profiles

The consensus subtypes are gastric, intestinal, pancreatobiliary and oncocytic (Furukawa et al. 2005).

Subtype (5th edition) Mucin and transcription factor profile Associated invasive carcinoma and outcome Source
Gastric MUC5AC positive; MUC1 and MUC2 negative Tubular adenocarcinoma, which arose mainly in gastric-type branch-duct IPMN; outcome of invasive carcinoma from gastric-type IPMN worse than from other types Basturk et al. 2015; Mino-Kenudson et al. 2011
Intestinal MUC2 and CDX2 positive; MUC5AC positive Colloid carcinoma; all colloid carcinomas arose in intestinal-type IPMN, mostly main duct Basturk et al. 2017; Mino-Kenudson et al. 2011
Pancreatobiliary MUC1 positive; MUC6 and MUC5AC positive Highest risk of progression, with the intestinal type Basturk et al. 2017 (MUC1 in pancreatobiliary-type IPMN); Sperti and Belluzzi 2025
Oncocytic (now IOPN) MUC5AC and MUC6 positive Oncocytic carcinoma; median survival 132 months Paolino et al. 2024; Mino-Kenudson et al. 2011
  • Kyoto 2024 pathology statement. The gastric type has the more favorable prognosis and is mostly low-grade branch-duct IPMN. The intestinal and pancreatobiliary types carry the highest risk of progression. Molecular studies indicate that the gastric type may give rise to the other subtypes and therefore carries a risk of progression (Sperti and Belluzzi 2025).

IPMN grade, associated invasive carcinoma and concomitant carcinoma

  • Grade. IPMNs are graded as low grade or high grade on histology alone, by the highest grade present. Former intermediate-grade dysplasia is low grade. "Invasive IPMN", "malignant IPMN" and "mucinous cystadenocarcinoma" are discouraged terms (Basturk et al. 2015). The Kyoto guidelines likewise report high-grade dysplasia and invasive carcinoma as separate categories and discard the term malignancy (Sperti and Belluzzi 2025).
  • Associated invasive carcinoma. The diagnosis is "IPMN, ___ grade, with an associated invasive carcinoma". "Invasive carcinoma with an associated IPMN" may be used when the invasive component is substantial. The report documents the precursor and the invasive component separately: type, grade, size and stage (Basturk et al. 2015).
  • Histologic types of the invasive component. Of 61 invasive IPMNs, 62% were tubular, 26% colloid and 12% oncocytic. Colloid carcinoma has extensive (>80%) stromal mucin pools. Median survival was 35 months for tubular, 95 months for colloid and 132 months for oncocytic carcinoma. Tubular adenocarcinoma had survival not significantly different from conventional ductal adenocarcinoma (Mino-Kenudson et al. 2011).
  • KRAS in invasive IPMN. KRAS mutations were present in about 80% of tubular and colloid carcinomas and in 20% of oncocytic carcinomas (Mino-Kenudson et al. 2011).
  • Concomitant carcinoma. A ductal adenocarcinoma separate from the IPMN is concomitant. A clear transition from in situ to invasive carcinoma supports an associated carcinoma, and intervening uninvolved pancreas supports a concomitant one. The distance between the IPMN and the carcinoma is measured, and the intervening tissue is sampled extensively or completely (Basturk et al. 2015).
  • Staging of the invasive component. Only the invasive component determines the pT category, and IPMN with high-grade dysplasia is pTis (CAP 2025). Multifocal invasion is measured and staged as set out in Pancreatoduodenectomy Specimens and the Staging and Reporting of Pancreatic and Ampullary Carcinoma.

Kyoto 2024 high-risk stigmata and worrisome features, with the revised Fukuoka 2017 rules

The International Evidence-Based Kyoto Guidelines (2024) revised the 2017 international (Fukuoka) guidelines on high-risk stigmata (HRS), worrisome features (WF), surveillance, pathology and cyst fluid markers (Ohtsuka et al. 2024). Kyoto incorporates endoscopic ultrasound (EUS) findings and EUS-guided fine needle aspiration cytology into the HRS and WF assessment. The 2017 guidelines gave EUS a limited diagnostic role (Ohtsuka et al. 2024; Sperti and Belluzzi 2025).

Criterion Kyoto 2024 Fukuoka 2017 (previous rule) Source
Obstructive jaundice with a cyst of the pancreatic head HRS HRS Borges et al. 2025; Kang et al. 2019
Enhancing mural nodule ≥5 mm or solid component HRS HRS (enhancing mural nodule ≥5 mm) Borges et al. 2025; Kang et al. 2019
MPD ≥10 mm HRS HRS Borges et al. 2025; Kang et al. 2019
Suspicious or positive cytology for high-grade dysplasia or adenocarcinoma HRS Not an HRS. The HRS were obstructive jaundice with a head cyst, enhancing mural nodule ≥5 mm and MPD ≥10 mm Borges et al. 2025; Kang et al. 2019
MPD 5–9 mm WF WF Borges et al. 2025; Kang et al. 2019
Cyst ≥30 mm WF WF (≥3 cm) Borges et al. 2025; Kang et al. 2019
Enhancing mural nodule <5 mm WF WF Borges et al. 2025; Kang et al. 2019
Thickened or enhancing cyst wall WF WF Borges et al. 2025; Kang et al. 2019
Abrupt change in MPD caliber with distal pancreatic atrophy WF WF Borges et al. 2025; Kang et al. 2019
Increased serum CA 19-9 (Borges and Kang used >37 U/mL) WF WF, added in 2017 Borges et al. 2025; Kang et al. 2019
Cyst growth WF at ≥2.5 mm/year WF at >5 mm over 2 years Borges et al. 2025; Kang et al. 2019; Sperti and Belluzzi 2025
New-onset or recently exacerbated diabetes mellitus WF, new in Kyoto Not a WF Sperti and Belluzzi 2025
Acute pancreatitis; lymphadenopathy WF WF (Kyoto kept the remaining WF unchanged) Borges et al. 2025; Sperti and Belluzzi 2025
  • Surveillance change. For a small branch-duct IPMN unchanged after 5 years of surveillance, Kyoto offers two options: stopping surveillance, or continuing it for possible concomitant ductal adenocarcinoma (Ohtsuka et al. 2024). The 2015 American Gastroenterological Association guideline had earlier proposed stopping after five stable years (Tanaka et al. 2017).
  • Performance. In 88 patients meeting Kyoto criteria for surgery, 22.8% had high-grade dysplasia or invasive carcinoma and 77.2% had benign lesions (Borges et al. 2025).
  • Pathologic correlation of HRS and WF. The diagnosis rests on the grade and invasion found in the resection (Basturk et al. 2015).

Frozen section and resection margins in IPMN

  • Indication. Frozen sections may assess margin status. Their value for the main lesion is limited unless an intraoperative decision depends on the result (Basturk et al. 2015).
  • Further resection. Further resection is recommended when high-grade dysplasia is present at a margin at frozen section, although the evidence is not strong (Basturk et al. 2015).
  • Reporting the margin. Because PanIN and IPMN can be indistinguishable at a margin, the margin diagnosis may be "intraductal mucinous epithelium with low-grade (or high-grade) dysplasia (PanIN or IPMN)" (Basturk et al. 2015).
  • Margins in branch-duct IPMN. Margin evaluation may be inconsequential for branch-duct IPMN without main duct dilatation because a positive result is unlikely (Basturk et al. 2015).

Related page: Pancreatic Ductal Adenocarcinoma, Its Subtypes and Pancreatic Intraepithelial Neoplasia (intraductal spread of invasive carcinoma mimicking PanIN or IPMN) Related page: Pancreatoduodenectomy Specimens and the Staging and Reporting of Pancreatic and Ampullary Carcinoma (en face neck and bile duct margins for intraductal tumors, margin distances and the 1 mm rule)

Intraductal oncocytic papillary neoplasm (5th edition)

  • Definition. IOPN is an intraductal neoplasm of oncocytic cells, which contain numerous large mitochondria (Singhi et al. 2020).
  • Histology. Complex arborizing papillae are lined by multiple layers of cells with abundant granular eosinophilic cytoplasm and single prominent nucleoli. Intraepithelial lumina are common and can produce a cribriform pattern, and mucin is much less than in IPMN. Growth along adjacent ducts and tangential sectioning mimic invasion (Wang et al. 2019).
  • Clinical features. In a systematic review of 414 IOPNs, the male-to-female ratio was 1.5:1, the head was involved in 55.3%, and diffuse involvement of more than one segment occurred in about one in five. Mean size was 45.5 mm (Paolino et al. 2024). In a single-institution series of 24, the female-to-male ratio was 1.7 and mean age 59 years (Wang et al. 2019).
  • Invasion and outcome. An associated invasive carcinoma was present in 50%, mostly pT1 or pT2 and pN0, and more than 90% of patients were alive after resection (Paolino et al. 2024). In 24 IOPNs, growth along adjacent ducts mimicked invasion. Unequivocal invasion occurred in 29%, mostly as microscopic foci of small tubules or single oncocytic cells, and 10-year overall survival was 94% (Wang et al. 2019).
  • Immunohistochemistry. MUC5AC was expressed in 98.2% and MUC6 in 92.8% (Paolino et al. 2024).
  • Molecular pathology. All IOPNs tested carried ATP1B1::PRKACB, DNAJB1::PRKACA or ATP1B1::PRKACA fusions. The fusions were also present in matched invasive carcinomas and cyst fluid and were absent from 126 control pancreatobiliary lesions (Singhi et al. 2020). PRKACA or PRKACB fusions were found in all 68 IOPNs examined, PRKACB::ATP1B1 in 39.7%. KRAS, TP53, CDKN2A, SMAD4 and GNAS were altered less often than in ductal adenocarcinoma and IPMN (Paolino et al. 2024). The 5th-edition summary states that IOPN and ITPN lack KRAS mutation (Nagtegaal et al. 2020).

Intraductal tubulopapillary neoplasm (5th edition)

  • Clinical features. In 33 ITPNs, 17 patients were female and 14 male, mean age was 55 years and median size 4.5 cm. Tumors involved the head in 45%, the body or tail in 32% and the gland diffusely in 23% (Basturk et al. 2017).
  • Histology. Intraductal nodules of back-to-back small tubular glands form large cribriform structures. Papillae are focal (36% of cases). Cuboidal cells have no or minimal intracellular mucin, and necrosis within nodules, sometimes comedo-like, is common (Basturk et al. 2017).
  • Immunohistochemistry. Almost all labeled for CAM5.2, CK7 and CK19, and most for CA19-9, MUC1 and MUC6. CDX2, MUC2, MUC5AC, trypsin, chymotrypsin, chromogranin and synaptophysin were negative. SMAD4 was retained in all (Basturk et al. 2017).
  • Invasion and outcome. Invasion was present in 71%. Five-year survival was 71% with an invasive component and 100% without (Basturk et al. 2017).
  • Molecular pathology. ITPN lacks KRAS and BRAF mutations, which separates it from IPMN and ductal adenocarcinoma (Basturk et al. 2017). ITPNs more often carry mutations in KMT2 family genes and PI3K pathway genes (PIK3CA, PTEN), and a subset harbors FGFR2 fusions (Luchini et al. 2020).
  • ITPN versus acinar cell carcinoma. The acinar-like pattern of ITPN resembles acinar cell carcinoma. Absent trypsin and chymotrypsin separate them (Basturk et al. 2017).
  • Grade. The two-tier scheme applies to ITPN as it does to IPMN and MCN (CAP 2025).

Mucinous cystic neoplasm (5th edition)

  • Definition. MCN is a cyst-forming mucinous neoplasm with ovarian-type subepithelial stroma, without papillary projections and without communication with the pancreatic ducts (Crippa et al. 2008; Pea et al. 2025).
  • Patients and site. In 163 resected MCNs, 95% were in women and 97% in the distal pancreas, and 25% were incidental (Crippa et al. 2008).
  • Ovarian-type stroma. The stroma expresses estrogen receptor, progesterone receptor and α-inhibin. Its density in pancreatic MCN is more variable than in hepatobiliary MCN (Lam et al. 2008). ER, PR and α-inhibin staining can identify regressed ovarian-type stroma (Pea et al. 2025).
  • Grade and invasion. Of the 163 MCNs, 72% were adenomas, 10.5% borderline tumors, 5.5% in situ carcinomas and 12% invasive carcinomas under the earlier three-tier terms. Nodules and diameter ≥60 mm were associated with malignancy, and every MCN with cancer was ≥40 mm or had nodules (Crippa et al. 2008).
  • Outcome. Only patients with invasive carcinoma had recurrence. Five-year disease-specific survival was 100% for noninvasive MCN and 57% with invasive carcinoma (Crippa et al. 2008). Invasive carcinoma develops in up to 35% of MCNs in published series (Pea et al. 2025).
  • Molecular pathology. RNF43 mutations occurred in three of eight MCNs (Wu et al. 2011b). In 19 MCNs with invasive carcinoma, KRAS and TP53 were the most commonly altered genes, and CDKN2A alterations were largely restricted to the invasive component (Pea et al. 2025).

Simple mucinous cyst (new in the 6th edition)

  • 6th-edition rule. A simple mucinous cyst is a cavity-forming neoplastic lesion larger than 1 cm, lined by gastric-type epithelium without papillary architecture and without ovarian-type stroma. KRAS, BRAF, TP53 and SMAD4 alterations have been identified, and it likely represents a precursor of ductal adenocarcinoma (Arends et al. 2026).
  • Previous rule. The Baltimore consensus recommended the term "simple mucinous cyst" for flat mucinous cysts larger than 1 cm with gastric phenotype (MUC1 and MUC2 negative, MUC5AC positive), at most minimal atypia and no ovarian-type stroma. It regarded them as benign, with no potential for progression (Basturk et al. 2015). The 5th-edition summary lists no simple mucinous cyst entity (Nagtegaal et al. 2020).
  • Evidence for precursor status. In four simple mucinous cysts with co-occurring invasive carcinoma, cyst and carcinoma shared specific genomic alterations. Carcinomas arising from simple mucinous cysts appeared more aggressive than those arising from MCN (Pea et al. 2025).

Serous neoplasms (5th edition)

  • Histology. Serous cystadenoma consists of small uniform cuboidal glycogen-rich cells with uniform round nuclei and clear cytoplasm (Chi et al. 2023; Lu et al. 2025). In a locally invasive solid serous neoplasm, tumor cells contained PAS-positive, diastase-sensitive glycogen and were partially GLUT1 positive (Tan et al. 2026).
  • Patterns. The types are microcystic, macrocystic, solid, von Hippel–Lindau syndrome-associated and mixed serous-neuroendocrine (Lu et al. 2025). On imaging, microcystic "honeycomb" lesions account for about 45%, macrocystic or oligocystic forms 32%, mixed forms 18% and solid-appearing forms 5% (Danti et al. 2026). A honeycomb pattern, central scar and calcification are more frequent in the microcystic type (Lu et al. 2025). Macrocystic serous cystadenoma can be difficult to separate from pseudocyst or MCN (Danti et al. 2026).
  • Immunohistochemistry. α-Inhibin was positive in 18 of 23 resected serous cystadenomas, and PAX8 was absent or present in 1%–2% of tumor cells. Islet and lymphoid cells beside the tumor expressed PAX8 (Chi et al. 2023). The comparison with metastatic clear cell renal cell carcinoma is in Solid Cellular Neoplasms of the Pancreas: Solid Pseudopapillary Neoplasm, Acinar Cell Carcinoma, Pancreatoblastoma and Metastases to the Pancreas.
  • Natural history. Among 2622 patients, size increased in 37% of those followed beyond 1 year (growth 4 mm/year), and serous-cystic-neoplasm-related mortality was 0.1% (Jais et al. 2016).
  • Molecular pathology and syndrome. VHL mutations were present in four of eight serous cystadenomas (Wu et al. 2011b). Serous cystadenoma is part of the von Hippel–Lindau tumor spectrum (Geurts 2020).
  • Serous cystadenocarcinoma. The 5th edition restricts serous cystadenocarcinoma to tumors with documented distant metastasis (Tan et al. 2026). In 25 locally invasive serous neoplasms without metastasis at presentation, infiltrative growth was nearly universal, 40% invaded adjacent organs and 28% later developed distant metastases. Ki-67 hot spots of 5% and 10% contrasted with less than 2% in conventional serous cystadenoma (Tan et al. 2026). Serous cystadenocarcinoma is not assigned a histologic grade in the CAP protocol (CAP 2025).

Differential diagnosis of mucinous cysts in the resection specimen

Finding IPMN MCN Simple mucinous cyst (6th edition) Source
Duct communication Present Absent Absent Danti et al. 2026; Pea et al. 2025
Papillae Predominantly papillary, rarely flat Absent Absent Basturk et al. 2015; Pea et al. 2025; Arends et al. 2026
Ovarian-type stroma Absent Present (ER, PR, α-inhibin) Absent Lam et al. 2008; Arends et al. 2026
Lining Gastric, intestinal or pancreatobiliary type Mucinous columnar epithelium Gastric-type epithelium Furukawa et al. 2005; Pea et al. 2025; Arends et al. 2026
Genes GNAS in 66%, KRAS, RNF43 KRAS, RNF43; GNAS absent KRAS, BRAF, TP53, SMAD4 Wu et al. 2011a, 2011b; Arends et al. 2026
Behavior without carcinoma Risk related to grade and duct type 5-year disease-specific survival 100% when noninvasive Good outcome in the absence of dysplasia or carcinoma Urgesi et al. 2026; Crippa et al. 2008; Arends et al. 2026
  • Retention cyst. A flat mucinous cyst behind an obstruction of the pancreatic duct has been interpreted as a retention cyst with partial PanIN-type lining (Basturk et al. 2015).
  • Mucinous non-neoplastic cyst. Cysts without a visible obstruction, surrounded by paucicellular fibrous bands, were earlier termed mucinous non-neoplastic cyst or cystic mucinous duct lesion. The Baltimore consensus placed them under the term simple mucinous cyst (Basturk et al. 2015).

Gross examination, sampling and reporting of cystic neoplasms

  • Complete sampling. Ovarian-type stroma separates MCN from simple mucinous cyst, and neoplastic papillae separate IPMN from it. Both can be focal, so cysts are entirely sampled for histology (Pea et al. 2025).
  • Collapsed cysts. Thin-walled cysts may collapse during resection or examination. Radiographic size may be integrated to determine the size of small cysts (Basturk et al. 2015).
  • Report content. Entity, grade, epithelial type, duct involvement and size are reported, with the type, grade, size and stage of any associated invasive carcinoma recorded separately (Basturk et al. 2015).
  • CAP protocol scope. IPMN, IOPN, ITPN and MCN without associated invasive carcinoma do not require the CAP synoptic protocol for accreditation. With associated invasive carcinoma, they are reported with the exocrine pancreas protocol as specific histologic types (CAP 2025).

Solid Cellular Neoplasms of the Pancreas: Solid Pseudopapillary Neoplasm, Acinar Cell Carcinoma, Pancreatoblastoma and Metastases to the Pancreas

Definition and classification. The solid cellular neoplasms of the pancreas are solid pseudopapillary neoplasm (SPN), acinar cell carcinoma (ACC) and pancreatoblastoma. They are genetically distinct from ductal adenocarcinoma and share alterations of the APC/β-catenin pathway in varying proportions (Abraham et al. 2002a; Abraham et al. 2002b; Abraham et al. 2001). The CAP exocrine pancreas protocol lists acinar cell carcinoma, acinar cell cystadenocarcinoma, mixed acinar-ductal carcinoma, pancreatoblastoma, solid-pseudopapillary neoplasm and solid-pseudopapillary neoplasm with high-grade carcinoma as histologic types. ACC, acinar cell cystadenocarcinoma and SPN are not assigned a histologic grade (CAP 2025). The WHO Classification of Digestive System Tumours, 6th edition (2026), introduces amphicrine-like carcinoma, which includes an amphicrine-like subtype of ACC (Arends et al. 2026). The 6th-edition summary does not restate the criteria for SPN, ACC and pancreatoblastoma; these criteria follow the 5th edition and the primary literature.

Related page: Solid cellular neoplasms of the pancreas on cytology (PanNET, SPN, ACC and pancreatoblastoma on EUS-FNA and the cell-block panel) Related page: Metastases and lymphoma in pancreatic cytology (metastases and primary pancreatic lymphoma on cytology) Related page: Pancreatic Neuroendocrine Neoplasms: Neuroendocrine Tumors, Functioning Syndromes, Neuroendocrine Carcinoma, Hereditary Syndromes and Staging (PanNET, neuroendocrine carcinoma, MiNEN and amphicrine-like carcinoma in the pancreas) Related page: Cystic and Intraductal Neoplasms of the Pancreas: IPMN, IOPN, ITPN, Mucinous Cystic Neoplasm, Serous Neoplasms and Simple Mucinous Cyst (intraductal tubulopapillary neoplasm as an acinar cell carcinoma mimic and serous cystadenoma versus renal cell carcinoma) Related page: Pancreatic Ductal Adenocarcinoma, Its Subtypes and Pancreatic Intraepithelial Neoplasia (ductal adenocarcinoma and its subtypes) Related page: Pancreatoduodenectomy Specimens and the Staging and Reporting of Pancreatic and Ampullary Carcinoma (AJCC 8th edition exocrine pancreas staging, which applies to ACC, SPN and pancreatoblastoma reported with the exocrine protocol) Related page: Non-Neoplastic Pancreas: Developmental Anomalies, Acute, Chronic, Hereditary and Autoimmune Pancreatitis, Pseudocysts and Non-Neoplastic Cysts, Allograft and Islet Pathology (acinar cystic transformation) Related page: Renal Cell Carcinoma and Oncocytic Renal Tumors (clear cell renal cell carcinoma and von Hippel–Lindau disease) Related page: Diagnostic Enzymes and Serum Tumor Markers (serum lipase and other pancreatic enzymes)

Solid pseudopapillary neoplasm: clinical and gross features

  • Frequency and patients. SPN accounts for about 1%–3% of pancreatic neoplasms and predominantly affects young women. Association with familial adenomatous polyposis is rarely reported (Danti et al. 2026). In 62 patients, ages ranged from 8 to 71 years, 87.1% were female and mean tumor size was 7.2 cm (Comut et al. 2026).
  • Gross. SPNs are often grossly sharply circumscribed and cystic, although their microscopic margins may be indistinct (Abraham et al. 2002a). On imaging, they are large heterogeneous masses with mixed solid and cystic areas and hemorrhagic degeneration (Danti et al. 2026).
  • Age and sex. SPN accounts for 30% of pancreatic neoplasms in patients younger than 40 years. About 90% occur in adolescent girls and young women (mean age 28 years); tumors in men occur 5–10 years later and behave more aggressively. Hemoperitoneum is a presenting feature in a small proportion, and there is no known genetic or paraneoplastic syndrome (Luchini et al. 2020).
  • Extrapancreatic SPN. SPN also arises outside the pancreas, in the omentum, mesentery, retroperitoneum, ovary, stomach or duodenum. Within the pancreas it is more frequent in the tail (Danti et al. 2026).

Solid pseudopapillary neoplasm: histology, immunohistochemistry and genetics

  • Histology. Uniform, polygonal, discohesive cells grow in solid sheets with a rich microvasculature in smaller tumors. Degeneration in larger tumors leaves residual cells around vessels as perivascular rosettes, which produces the pseudopapillary pattern. Foamy histiocytes are present in degenerated areas (Abraham et al. 2002a). Grossly, SPNs are round solitary masses with a fibrous pseudocapsule, 0.5–25 cm (mean 10 cm). Diastase-resistant PAS-positive eosinophilic hyaline globules correspond to α1-antitrypsin granules. Most tumors contain foamy histiocytes, cholesterol clefts and foreign-body giant cells, and nuclei show grooves and indentations (Omiyale 2021a).
  • β-catenin and LEF1. Nuclear β-catenin accumulation was present in 95% and activating exon 3 CTNNB1 mutations in 90% of 20 SPNs (Abraham et al. 2002a). In a later series, nuclear β-catenin was present in all 61 evaluable SPNs, and targeted sequencing of 5 metastatic or locally invasive SPNs found CTNNB1 exon 3 mutation in each (Comut et al. 2026). Strong diffuse nuclear LEF1 labeling was present in all 35 SPN specimens and absent from PanNETs, ductal adenocarcinomas and ACCs (Singhi et al. 2014).
  • E-cadherin. With an antibody to the cytoplasmic domain, all 20 SPNs showed nuclear E-cadherin. With an antibody to the extracellular domain, all were negative (Chetty and Serra 2008). Membranous E-cadherin was absent in all SPNs and present in 96.4% of PanNETs (Kim et al. 2008).
  • CD99. All 55 SPNs showed paranuclear dot-like CD99 labeling. Positive PanNETs showed membranous or membranous and cytoplasmic labeling, and no ACC was reactive (Guo et al. 2011).
  • CD10, hormone receptors, neuroendocrine markers and keratin in SPN. CD10 was positive in 95%, progesterone receptor in 84.7% and androgen receptor in 82.5%. Synaptophysin (46.8%) and chromogranin (11.3%) were generally only focally positive (Comut et al. 2026). In another series, keratin was positive in 5.6% and chromogranin in none (Kim et al. 2008). SPNs also express vimentin, α1-antitrypsin, α1-antichymotrypsin, cyclin D1, claudin 5 and claudin 7, and are negative for trypsin, chymotrypsin, lipase and BCL10 (Omiyale 2021a). Cyclin D1 was overexpressed in 74% (Abraham et al. 2002a).
  • Degenerative and invasive features. Multinucleated atypical giant cells and nuclear pleomorphism, mainly in older patients, are degenerative changes. Pools of red cells ("blood lakes") at the periphery are distinguished from vascular invasion. Infiltrative borders without desmoplasia and capsular invasion are associated with local recurrence (Luchini et al. 2020).
  • Additional immunohistochemistry and genetics. CD117 is expressed in up to 50% of SPNs without KIT mutation, and CD56, neuron-specific enolase and CD99 are frequently positive. Fewer than 5% carry TP53 mutations, and SPNs with malignant behavior more often carry inactivating mutations of KDM6A, TET1 and BAP1 (Luchini et al. 2020).
  • KRAS, SMAD4 and p53 in SPN. No KRAS mutation was found in 20 SPNs, SMAD4 (DPC4) expression was intact, and p53 was overexpressed in 15.8% (Abraham et al. 2002a). SPNs carried the fewest somatic mutations of the cyst types sequenced (Wu et al. 2011).

Solid pseudopapillary neoplasm: behavior and high-grade transformation

  • Metastasis. Metastases develop in 10%–15%, most often to the liver or peritoneum, and lymph node involvement is rare (Comut et al. 2026). Even with disseminated disease the course is usually protracted, and reported 5-year survival is 97% (Tang et al. 2005). In a 62-patient series followed for a mean of 97.2 months, distant metastasis occurred in 6.5% and locally invasive disease in 6.5%, and overall survival was 95% (Comut et al. 2026). Five of 34 conventional SPNs developed liver metastases, and these patients survived a mean of 106 months (Tang et al. 2005).
  • Features of aggressive tumors. Metastatic or locally invasive SPNs more often had higher Ki-67 (median 5%, range 1%–15%), increased mitotic activity and capsular or parenchymal invasion. No single pathologic or molecular feature defined aggressive behavior (Comut et al. 2026). BAP1 loss was present in 22.8% (Comut et al. 2026).
  • High-grade transformation. Two rapidly fatal SPNs showed diffuse growth, extensive necrosis, significant nuclear atypia, 35–70 mitoses per 50 high-power fields and, in one, sarcomatoid carcinoma, beside areas of conventional SPN. They were proposed as high-grade malignant transformation of SPN (Tang et al. 2005). CAP lists "solid-pseudopapillary neoplasm with high grade carcinoma" as a histologic type (CAP 2025).

Acinar cell carcinoma: clinical features and lipase hypersecretion syndrome

  • Frequency. ACC accounts for about 1%–2% of pancreatic neoplasms (Wang et al. 2018).
  • Age, site and survival. Median age at diagnosis is 60 years, and children are rarely affected. ACC arises mostly in the pancreatic head, yet jaundice is rare. Five-year survival is 25% (Luchini et al. 2020). Grossly the tumor is soft and fleshy with hemorrhage and necrosis and lacks the desmoplasia of PDAC (Farhoud et al. 2026).
  • Patients and gross. ACC occurs in patients in their sixties. The mass is often large, round and demarcated and resembles pancreatic neuroendocrine tumor (PanNET) and SPN (Taskin and Adsay 2019).
  • Lipase hypersecretion syndrome. Circulating lipase, trypsin and chymotrypsin released by the carcinoma cause subcutaneous fat necrosis at the pressure points of the legs, often mistaken for erythema nodosum or rheumatic nodules. Bone and joint involvement, including polyarthralgia, and eosinophilia occur (Taskin and Adsay 2019; Abraham et al. 2002b). Most patients with the syndrome have liver metastases. The syndrome is specific to ACC (Taskin and Adsay 2019).
  • Prognosis. In 62 ACCs, surgery correlated with better prognosis. Size >6.5 cm, lymph node and distant metastases and UICC stage correlated with poor outcome, and stage was the only independent prognostic factor (La Rosa et al. 2012). Mean survival was 18 months, and occasional patients survived long term (Abraham et al. 2002b).

Acinar cell carcinoma: histology and immunohistochemistry

  • Histology. ACC recapitulates the growth pattern and secretory products of acini (Abraham et al. 2002b). The tumors are more atypical and proliferative than PanNET and SPN and commonly show single prominent nucleoli and distinctive chromophilia (Taskin and Adsay 2019).
  • Architectural patterns. Acinar and solid patterns are the most common, each predominant in about 30%–50% of tumors, and the rest show a mixture. Glandular, trabecular, gyriform, cystic and intraductal growth are less frequent; spindle cell and oncocytic variants are rare (Farhoud et al. 2026). The intraductal growth pattern is associated with a better prognosis (Luchini et al. 2020).
  • Cytoplasm and special stains. Moderate amounts of eosinophilic granular cytoplasm reflect zymogen granules, and nuclei are round to oval with a single prominent nucleolus (Farhoud et al. 2026). Periodic acid–Schiff staining after diastase digestion shows diastase-resistant cytoplasmic granules in more than 90% of tumors. Histochemical staining for lipase (butyrate esterase) is positive in about 70%–75% but is not routine (Farhoud et al. 2026).
  • Trypsin and other markers. Trypsin is positive in about 95%–100% of ACCs; chymotrypsin is often positive, lipase less consistently and amylase has low sensitivity (Farhoud et al. 2026). CK7, CK19, HepPar-1, glypican 3 and α-fetoprotein may be expressed (Luchini et al. 2020).
  • Acinar markers. BCL10 and trypsin were the most reliable markers in 62 ACCs, and amylase and lipase were unreliable (La Rosa et al. 2012). The C-terminal BCL10 antibody shows the same distribution as carboxyl ester hydrolase, is restricted to acinar cells of normal and ectopic pancreas, pancreatic metaplasia and ACC, and is more sensitive than antibodies to other pancreatic enzymes (La Rosa et al. 2009).
  • Neuroendocrine differentiation. Neuroendocrine differentiation is common in ACC (Taskin and Adsay 2019). Twelve of 62 tumors with more than 30% endocrine cells were reclassified as mixed acinar-neuroendocrine carcinoma, and survival after resection did not differ from pure ACC (La Rosa et al. 2012).
  • β-catenin. Negativity for nuclear β-catenin helps separate ACC from SPN (Taskin and Adsay 2019).

Acinar cell carcinoma: molecular pathology

  • Chromosome 11p and APC/β-catenin. Allelic loss on 11p was the most common alteration (50% of informative cases). APC/β-catenin pathway alterations occurred in 23.5%: one activating CTNNB1 mutation and three truncating APC mutations (Abraham et al. 2002b).
  • SMAD4, p53 and microsatellite instability in ACC. No SMAD4 loss or p53 accumulation was detected. One MSI-high ACC had medullary features (Abraham et al. 2002b).
  • BRAF rearrangements. BRAF fusions were found by FISH in 24% of 49 acinar-type neoplasms, including pure ACC and mixed carcinomas with acinar differentiation. SND1 was the most frequent partner (50%), followed by HERPUD1 (18%) (Wang et al. 2018).
  • RAF1 and other kinase fusions. BRAF and RAF1 fusions occur in about 20%–30% of ACCs, are enriched in KRAS wild-type tumors and need RNA-based sequencing for detection; SND1::BRAF is the most frequent. Tumors with these fusions have shown sensitivity to MEK inhibition. Rare RET (CCDC6::RET), NTRK, ALK and ROS1 fusions also occur (Farhoud et al. 2026). Microsatellite instability is found in about 10% of ACCs (Luchini et al. 2020).
  • Homologous recombination deficiency. HRD-associated alterations in BRCA1/BRCA2, ATM and FANCD2 were present in 7 of 8 ACCs (87.5%) and 29% of amphicrine-like ACCs, which suggests potential for PARP-inhibitor therapy (Kim et al. 2026).

Mixed acinar neoplasms and amphicrine-like acinar cell carcinoma

  • 6th-edition rule. Amphicrine-like carcinoma (ALC) has neuroendocrine and non-neuroendocrine cells intimately intermixed, or both lines of differentiation in single cells. Mixed neuroendocrine–non-neuroendocrine neoplasm (MiNEN) has morphologically distinct zones or nodules (Arends et al. 2026). ACCs with an intimately admixed neuroendocrine component comprising more than 30% of the tumour are amphicrine-like ACCs (Kim et al. 2026). The 6th edition requires morphologic neuroendocrine differentiation in ≥30% of neoplastic cells, confirmed by at least two neuroendocrine markers (Arends et al. 2026). The amphicrine-like subtype of pancreatic ACC behaves like pure ACC, intermediate between NET and ductal adenocarcinoma but closer to adenocarcinoma; the behavior of ALCs at other sites is not yet established (Arends et al. 2026). ALCs are staged with the carcinoma TNM system (Arends et al. 2026).
  • 5th-edition rule. Seven amphicrine-like ACCs in the Kim series had been diagnosed as MiNEN under the 5th edition (Kim et al. 2026). The CAP endocrine protocol, citing the 5th edition, lists mixed acinar-neuroendocrine carcinoma as a biphasic tumor with more than 30% acinar differentiation, reported with the exocrine carcinoma protocol (CAP 2024).
  • Molecular heterogeneity. Amphicrine-like ACCs comprised "true hybrid" tumors with MEN1 alterations beside APC, SMAD4 and CTNNB1 alterations, and "ACC-like" tumors with ACC-type alterations despite neuroendocrine differentiation (Kim et al. 2026).
  • Mixed acinar-ductal carcinoma is a separate histologic type in the CAP protocol (CAP 2025).
  • 5th-edition mixed carcinomas. Mixed acinar-ductal, acinar-neuroendocrine and acinar-neuroendocrine-ductal carcinomas required each component to form at least 30% of the tumor. Mixed acinar-neuroendocrine carcinomas formed about 20% of ACCs, most showed neuroendocrine differentiation only by immunohistochemistry, and their prognosis was similar to conventional ACC. Mixed acinar-ductal and acinar-neuroendocrine-ductal carcinomas usually had a poor prognosis (Luchini et al. 2020).

Pancreatoblastoma

  • Patients. Pancreatoblastoma accounts for less than 1% of pancreatic neoplasms and for 25% of those in the first decade, with a mean age of about 4 years (Omiyale 2021b). It affects mainly infants and young children. In one series, 9 patients were children (newborn to 4 years, mean 2.4) and 5 were adults (19–56 years) (Klimstra et al. 1995). In 11 adults with fine-needle aspirates, median age was 45 years, three had familial adenomatous polyposis (FAP) or FAP-related syndromes and four had metastasis at diagnosis (Reid et al. 2019). Of 69 adult tumors with site data, 52.1% involved the head and 30.4% the tail (Omiyale 2021b).
  • Histology. Tumors are very cellular, with uniform epithelial cells in sheets and nests and consistently present acinar structures. Squamoid corpuscles are circumscribed, whorled nests of plump spindle cells with a squamous appearance and occasional keratinization. The stroma is moderate to abundant and often cellular, especially in children (Klimstra et al. 1995).
  • Immunohistochemistry. Pancreatic enzymes were positive in 100%, endocrine markers in 82% and CEA in 85% (Klimstra et al. 1995). In adults, neuroendocrine markers were positive in all and acinar markers in 63%, and the median Ki-67 index was 21% (Reid et al. 2019). Tumors express trypsin, chymotrypsin, lipase and BCL10 (Omiyale 2021b). Nuclear β-catenin and LEF1 are centered around and within squamoid corpuscles (Singhi et al. 2014). Squamoid morules showed nuclear β-catenin in six of eight adult cases (Reid et al. 2019).
  • Gross and lobular architecture. Median age at diagnosis is 3–4 years. Tumors are large and solid with soft yellow lobules separated by fibrous bands, and some are cystic. Cells in squamoid nests may show nuclear clearing, and CD200 can be positive where β-catenin is nuclear (Luchini et al. 2020).
  • Alpha-fetoprotein. Serum AFP is frequently elevated in children, often above 1000 μg/L, but not consistently in adults. AFP can be shown immunohistochemically in tumors with raised serum AFP. Elevated AFP is not specific: ductal adenocarcinoma and ACC have been associated with it (Omiyale 2021b).
  • Staging. Pancreatoblastoma is staged with the TNM classification of exocrine pancreatic carcinoma (Omiyale 2021b).
  • Molecular pathology. Allelic loss on chromosome 11p was present in 86% and APC/β-catenin pathway alterations in 67%: five activating CTNNB1 mutations and biallelic APC inactivation in an FAP-associated tumor. No KRAS mutation or p53 alteration was found (Abraham et al. 2001).
  • Syndromes. Pancreatoblastoma occurs occasionally in Beckwith–Wiedemann syndrome and may be an extracolonic manifestation of FAP. Its genetics resemble those of hepatoblastoma (Abraham et al. 2001).
  • Behavior. Metastases developed in 36%, especially to the liver. Three of five adults died of tumor (mean survival 18 months), whereas five of six evaluable children were alive 22 months to 22 years after diagnosis and responded well to chemotherapy (Klimstra et al. 1995).
  • Cytologic mimicry. Original aspiration diagnoses in adults included neuroendocrine neoplasm, neuroendocrine carcinoma and ACC. Branching pseudopapillae and grooved nuclei raised the differential diagnosis of SPN (Reid et al. 2019).

Immunohistochemistry of solid cellular pancreatic neoplasms

Tumor Neuroendocrine markers Acinar markers β-catenin and LEF1 Other discriminating markers Source
PanNET Synaptophysin 96.4%, chromogranin 89.3% BCL10 confined to the acinar lineage and absent Nuclear β-catenin 0%; nuclear LEF1 0 of 44 Membranous E-cadherin 96.4%; membranous CD99 in 40 of 51; CD10 10.7%; keratin 46.4%; ISL1 82% and PAX8 88% of primaries (PAX8 antibody-dependent) Kim et al. 2008; La Rosa et al. 2009; Singhi et al. 2014; Guo et al. 2011; Koo et al. 2012; Liau et al. 2016
ACC Neuroendocrine differentiation common; >30% endocrine cells defined mixed acinar-neuroendocrine carcinoma BCL10 and trypsin most reliable; amylase and lipase unreliable Nuclear β-catenin and LEF1 negative in 9 of 9; APC/β-catenin pathway mutation in 23.5% CD99 negative in 6 of 6 La Rosa et al. 2012; Taskin and Adsay 2019; Singhi et al. 2014; Abraham et al. 2002b; Guo et al. 2011
SPN Synaptophysin 27.8%–46.8% and chromogranin 0%–11.3%, focal BCL10 confined to the acinar lineage and absent Nuclear β-catenin 94.4%–100%; diffuse nuclear LEF1 100% Paranuclear dot CD99 100%; extracellular-domain E-cadherin lost; CD10 83.3%–95%; PR 84.7%; AR 82.5%; keratin 5.6% Kim et al. 2008; Comut et al. 2026; Singhi et al. 2014; Guo et al. 2011; Chetty and Serra 2008; La Rosa et al. 2009
Pancreatoblastoma Endocrine markers 82% (children and adults), 100% in adult aspirates Pancreatic enzymes 100%; acinar markers 63% in adult aspirates Nuclear β-catenin and LEF1 centered in squamoid corpuscles; nuclear β-catenin in 7 of 9 tumors CEA 85% Klimstra et al. 1995; Reid et al. 2019; Singhi et al. 2014; Abraham et al. 2001
Ductal adenocarcinoma (comparator) Synaptophysin 0.7%; chromogranin 0% BCL10 confined to the acinar lineage and absent Nuclear β-catenin 0%; nuclear LEF1 0 of 25 Keratin 100%; E-cadherin 99.3%; CD10 9.9% Kim et al. 2008; Singhi et al. 2014; La Rosa et al. 2009
  • CD10 specificity. CD10 is positive in SPN, but ductal adenocarcinoma and PanNET can also express it (Kim et al. 2008).
  • Single most useful pair. Nuclear β-catenin and loss of E-cadherin establish SPN on small biopsies (Kim et al. 2008).

Histologic features separating acinar, pseudopapillary and neuroendocrine neoplasms

Tumor Prominent nucleoli Architecture Squamoid nests Necrosis Stroma Source
Acinar cell carcinoma Present Acinar, glandular, trabecular, solid Absent Frequent Scant, fibrous Luchini et al. 2020
Pancreatoblastoma Present Acinar, trabecular, solid Present Possible Fibrous, often hypercellular Luchini et al. 2020
PanNET Rare Nested, trabecular, glandular, solid Absent Very rare Highly vascular, hyalinized Luchini et al. 2020
Large cell NEC Frequent Nested or trabecular, occasional rosettes Absent Frequent Desmoplastic Luchini et al. 2020
Medullary carcinoma Present Solid, syncytial Absent Possible Lymphocyte-rich Luchini et al. 2020
Hepatoid carcinoma Present Trabecular, glandular, solid Absent Possible Scant, sometimes lymphocyte-rich Luchini et al. 2020
SPN Absent Solid and pseudopapillary Absent Possible (infarction common) Fibrovascular, hyalinized Luchini et al. 2020

Comparison of pancreatoblastoma, acinar cell carcinoma, SPN and PanNET

Feature Pancreatoblastoma Acinar cell carcinoma SPN PanNET
Patients and frequency Mainly young children; adults uncommon (Klimstra et al. 1995) Sixties (Taskin and Adsay 2019) Young women; 87.1% female (Comut et al. 2026) Wide age range; functioning or nonfunctioning; multifocal in MEN1 (CAP 2024)
Defining histology Acinar structures with squamoid corpuscles and cellular stroma (Klimstra et al. 1995) Acinar growth, single prominent nucleoli, chromophilia (Taskin and Adsay 2019) Discohesive polygonal cells, perivascular pseudopapillae, foamy histiocytes (Abraham et al. 2002a) Gyriform, solid or glandular patterns of monomorphic cells (CAP 2024)
Key genetics 11p loss 86%; APC/β-catenin 67% (Abraham et al. 2001) 11p loss 50%; BRAF fusions in acinar-type neoplasms 24%; HRD alterations 87.5% (Abraham et al. 2002b; Wang et al. 2018; Kim et al. 2026) CTNNB1 exon 3 mutation 90%–100% (Abraham et al. 2002a; Comut et al. 2026) MEN1, DAXX, ATRX, mTOR pathway (Rindi et al. 2018)
Behavior Metastases 36%; adults fare worse than children (Klimstra et al. 1995) Mean survival 18 months; stage is the independent prognostic factor (Abraham et al. 2002b; La Rosa et al. 2012) Metastases 10%–15%; long survival even with metastasis (Comut et al. 2026; Tang et al. 2005) Prognosis depends on function, completeness of resection, extent and grade (CAP 2024)

Metastases and secondary tumors of the pancreas

  • Frequency and sources. At autopsy, 81 of 190 pancreata involved by tumor had secondary tumors, most often from lung (34), the gastrointestinal tract (20), kidney (4) and breast (3). Among 973 surgical specimens, 38 contained secondary tumors: 11 lymphomas, 7 gastric, 6 renal and 2 lung carcinomas, and single liver, prostate, ovarian, uterine and Merkel cell carcinomas. Three malignant gastrointestinal stromal tumors and one retroperitoneal leiomyosarcoma also involved the pancreas, and two sarcomas were found at autopsy. Secondary tumors formed about 4% of pancreatic surgical specimens, and about one-third were clinically mistaken for primary pancreatic tumors, mainly hematopoietic, renal and gastric (Adsay et al. 2004).
  • Resected metastases. Renal cell carcinoma was the primary in 54.3% of 414 pancreatic metastasectomies. Patients with renal cell carcinoma survived longer than others, and a positive margin predicted worse outcome (Huang et al. 2019).
  • Renal cell carcinoma metastases. In 436 patients resected for metastatic renal cell carcinoma, metastases were metachronous in 94.7% with a median disease-free interval of 108 months (range 0–432). Median size was 3.0 cm, 61.7% were solitary, 6.8% had nodal involvement and 59.6% were asymptomatic. Five-year survival was 76.6% (Zhou et al. 2024).
  • Renal cell carcinoma versus serous cystadenoma. Both have glycogen-rich clear cells, distinct borders and rich vascularity. Metastatic clear cell renal cell carcinoma expressed PAX8 in 50%–90% of cells, whereas serous cystadenoma had PAX8 in no more than 2% of cells. The renal figures come from nine cytology specimens. CAIX and CD10 are expressed by both and do not separate them (Chi et al. 2023).
  • Renal cell carcinoma versus PanNET. PAX8 labeling of PanNETs depends on the antibody clone (Liau et al. 2016), as set out in Pancreatic Neuroendocrine Neoplasms: Neuroendocrine Tumors, Functioning Syndromes, Neuroendocrine Carcinoma, Hereditary Syndromes and Staging. Chromogranin and synaptophysin are strongly positive in most PanNETs (CAP 2024).
Secondary tumor Setting Pathologic clue Source
Clear cell renal cell carcinoma Most common resected metastasis; metachronous, median 108 months after nephrectomy; often solitary Clear cells with PAX8 in 50%–90% of cells; CAIX does not separate it from serous cystadenoma Huang et al. 2019; Zhou et al. 2024; Chi et al. 2023
Lung carcinoma Most common source at autopsy, in disseminated disease Adenocarcinoma: CK7, TTF-1 and napsin A positive; CK20 negative Adsay et al. 2004; Wang et al. 2024
Gastrointestinal and gastric carcinoma Second most common source at autopsy; gastric carcinoma the most common secondary carcinoma in surgical specimens (7 of 38) Often mistaken for a primary pancreatic tumor Adsay et al. 2004
Lymphoma Most common secondary tumor in surgical specimens (11 of 38) Often mistaken for a primary pancreatic tumor Adsay et al. 2004
Colorectal adenocarcinoma Part of the gastrointestinal group (20 of 81 at autopsy) CK20, CDX2 and SATB2 positive; CK7 negative Adsay et al. 2004; Wang et al. 2024
Breast carcinoma Three of 81 autopsy secondary tumors CK7, GATA3, TRPS1, mammaglobin, GCDFP-15, ER and PR positive Adsay et al. 2004; Wang et al. 2024
Melanoma Two of 81 autopsy secondary tumors SOX10, S100, Melan-A and HMB45 positive; cytokeratin negative Adsay et al. 2004; Wang et al. 2024

Related page: Large B-Cell Lymphomas, Burkitt Lymphoma, Immunodeficiency-Associated Lymphoproliferations, Hodgkin Lymphomas and Lymphoma Staging (histology of large B-cell lymphomas) Related page: Small B-Cell Lymphomas and Leukemias: CLL/SLL, Mantle Cell, Follicular, Marginal Zone, Splenic B-Cell and Lymphoplasmacytic Lymphomas and Hairy Cell Leukemia (histology of small B-cell lymphomas)

Pancreatic Neuroendocrine Neoplasms: Neuroendocrine Tumors, Functioning Syndromes, Neuroendocrine Carcinoma, Hereditary Syndromes and Staging

Definition and classification. Pancreatic neuroendocrine neoplasms (PanNENs) are well-differentiated pancreatic neuroendocrine tumors (PanNETs), graded G1 to G3, and poorly differentiated neuroendocrine carcinomas (PanNECs) of small cell or large cell type (Rindi et al. 2018). Mixed neuroendocrine–non-neuroendocrine neoplasm (MiNEN) and, from the WHO Classification of Digestive System Tumours, 6th edition (2026), amphicrine-like carcinoma (ALC) are the nonpure categories (Arends et al. 2026). PanNETs account for about 2% of pancreatic malignancies but about 10% of patients living with pancreatic tumors (Chauhan et al. 2024). The CAP Pancreas (Endocrine) protocol, version 5.0.1.0 (June 2024), applies to resected well-differentiated neuroendocrine tumors and uses AJCC Version 9. NEC, mixed ductal-neuroendocrine carcinoma and mixed acinar-neuroendocrine carcinoma are reported with the exocrine carcinoma protocol (CAP 2024).

Related page: Neuroendocrine, Mesenchymal and Lymphoid Tumors of the Esophagus, Stomach and Small Intestine (digestive NEN classification across sites, duodenal and ampullary NETs including gastrinoma and somatostatinoma, CoGNET, and Version 9 staging of gastric, duodenal-ampullary and jejunoileal NETs) Related page: Solid cellular neoplasms of the pancreas on cytology (PanNET on EUS-FNA, Ki-67 grading on cell blocks, the 6th-edition G2a/G2b subdivision and validated digital Ki-67 analysis) Related page: Normal pancreas, gastrointestinal contaminants and EUS-guided sampling (intrapancreatic accessory spleen as a PanNET mimic on EUS sampling) Related page: Solid Cellular Neoplasms of the Pancreas: Solid Pseudopapillary Neoplasm, Acinar Cell Carcinoma, Pancreatoblastoma and Metastases to the Pancreas (SPN, acinar cell carcinoma, pancreatoblastoma, the solid-tumor immunohistochemistry table and metastatic renal cell carcinoma) Related page: Cystic and Intraductal Neoplasms of the Pancreas: IPMN, IOPN, ITPN, Mucinous Cystic Neoplasm, Serous Neoplasms and Simple Mucinous Cyst (serous cystadenoma in von Hippel–Lindau disease) Related page: Pancreatoduodenectomy Specimens and the Staging and Reporting of Pancreatic and Ampullary Carcinoma (AJCC 8th edition exocrine staging used for PanNEC, MiNEN and ALC) Related page: Diabetes and Glycemic Markers: Glucose, HbA1c, Ketones and the Hypoglycemia Workup (insulinoma biochemistry: glucose, insulin, C-peptide and the fasting test) Related page: Endocrine Function Tests: Thyroid, Adrenal and Pituitary (MEN biochemical screening and gastrin testing) Related page: Renal Cell Carcinoma and Oncocytic Renal Tumors (renal cell carcinoma in von Hippel–Lindau disease)

WHO grading of pancreatic neuroendocrine neoplasms

Category Differentiation Mitoses per 2 mm² Ki-67 index 6th edition (2026) 5th edition (2019) rule Source
NET G1 Well differentiated <2 <3% Tumor necrosis recorded as present or absent beside the grade Same thresholds; necrosis not a grading parameter Arends et al. 2026; Nagtegaal et al. 2020; Rindi et al. 2018
NET G2 Well differentiated 2–20 3%–20% For PanNET, G2 may be subdivided into G2a (Ki-67 3% to <10%) and G2b (Ki-67 10% to ≤20%); grading parameters unchanged Single G2 category Arends et al. 2026; Nagtegaal et al. 2020
NET G3 Well differentiated >20 >20% Necrosis recorded beside the grade G3 NET introduced as well differentiated and genetically distinct from NEC Arends et al. 2026; Nagtegaal et al. 2020
NEC, small cell or large cell type Poorly differentiated >20 >20% Not graded; necrosis supports NEC but is neither definitive nor mandatory Not graded; high grade by definition Arends et al. 2026; Nagtegaal et al. 2020
  • Necrosis. Necrosis is recorded beside the grade, for example "G2 NET, tumour necrosis present", to gather evidence for its possible future inclusion in grading. The best evidence for necrosis in grading is for PanNETs. Only true tumor necrosis is considered significant, and infarct-like necrosis is excluded (Arends et al. 2026). Previous rule: necrosis was recognized as a potential adverse prognostic factor but was not a grading parameter (Rindi et al. 2018). CAP records tumor necrosis as an optional element. It separates nonischemic necrosis, which is punctate or geographic and associated with higher grade, from ischemic necrosis (CAP 2024).

Counting mitoses and Ki-67 in PanNETs

  • Mitoses. Mitoses are reported per 2 mm² after evaluating at least 10 mm² in the most mitotically active area. Only clearly identifiable mitoses are counted; hyperchromatic, karyorrhectic and apoptotic nuclei are excluded. The number of high-power fields equal to 10 mm² depends on field diameter: 42 fields at 0.55 mm and 50 at 0.50 mm (CAP 2024). The 5th edition expressed 10 mm² as 50 high-power fields of 0.2 mm² each (Nagtegaal et al. 2020).
  • Ki-67. Ki-67 is the percentage of positive tumor cells in the area of highest labeling (hot spot), with at least 500 tumor cells counted. A manual count on a printed image of the hot spot is recommended near grade cut-offs (CAP 2024; Nagtegaal et al. 2020).
  • Discordant indices. When mitotic count and Ki-67 give different grades, the higher grade is assigned, usually the Ki-67-based grade (Arends et al. 2026; CAP 2024).
  • UICC 9th edition grading. The UICC TNM 9th edition left the TNM categories of well-differentiated gastrointestinal NETs unchanged and proposed a grading scheme consistent with WHO: G1 <2 mitoses per 2 mm² and Ki-67 <3%, G2 2–20 and 3%–20%, G3 >20 and >20%, with Ki-67 counted in 500–2000 cells in areas of highest labeling and the final grade set by whichever index is higher. Poorly differentiated NECs are classified with the carcinoma criteria of each site (Brierley et al. 2026).
  • CAP reporting. The CAP grade element offers G1, G2, G3 and GX for well-differentiated NET. The mitotic rate is required only when Ki-67 is not reported, and Ki-67 only when the mitotic rate is not reported (CAP 2024).

Neuroendocrine differentiation and immunohistochemistry

  • 6th-edition rule. Neuroendocrine differentiation is confirmed by expression of at least two neuroendocrine markers, preferably including one of chromogranin A, synaptophysin and INSM1. CD56 is insufficiently specific to be used (Arends et al. 2026).
  • 5th-edition framework. General markers of neuroendocrine differentiation were chromogranin A, chromogranin B and synaptophysin (Rindi et al. 2018). The 2022 WHO endocrine classification lists INSM1, synaptophysin, chromogranins and somatostatin receptors as lineage markers, with transcription factors to assign the site of origin of a metastasis (Rindi et al. 2022).
  • PanNET staining. Most PanNETs are strongly positive for synaptophysin and chromogranin A (CAP 2024). In one series, synaptophysin and E-cadherin were positive in 96.4% of PanNETs, chromogranin in 89.3%, keratin in 46.4% and CD56 in 26.8% (Kim et al. 2008).
  • Lineage transcription factors. ARX and PDX1 expression reflects islet cell lineage in PanNETs. ARX-positive tumors resemble alpha cells in DNA methylation and frequently carry MEN1, DAXX or ATRX mutations. PDX1-positive tumors, typically insulinomas, resemble beta cells and usually lack these mutations (Kasajima et al. 2026). Serotonin-producing PanNETs form 1.4%–4% of PanNETs; PDX1 and PAX6 expression with absent substance P and VMAT1 helps separate them from pancreatic metastases of ileal NETs. CDX2 is positive in about 15% of PanNETs, usually weaker and patchier than in intestinal enterochromaffin-cell tumors, and TTF1 is negative (La Rosa et al. 2025).
  • Somatostatin receptor. SSTR2A expression is usual in PanNETs and only occasional in PanNECs (Rindi et al. 2018).
  • Pancreatic origin of a metastasis. Islet 1 and PAX8 were positive in 82% and 88% of primary PanNETs and in 68% and 54% of metastatic PanNETs. Ileal NETs were negative for both, but 86% of rectal NETs expressed Islet 1 and 79% expressed PAX8 (Koo et al. 2012). PAX8 labeling of NETs depends on the antibody: the polyclonal and MRQ50 antibodies cross-react with other PAX proteins, and C-terminal-specific monoclonal antibodies were negative in all NETs (Liau et al. 2016). ATRX or DAXX loss and alternative lengthening of telomeres (ALT) are highly specific for pancreatic origin among NET metastases of unknown primary (Hackeng et al. 2022).

Gross features, microadenoma and histologic patterns of PanNET

  • Microadenoma. A pancreatic neuroendocrine microadenoma is a nonfunctional neuroendocrine tumor smaller than 0.5 cm. A CAP case summary is not required for an incidental microadenoma in a specimen removed for another reason. "Adenomatosis" denotes multiple neuroendocrine tumors each less than 5 mm (CAP 2024).
  • Multifocality. PanNETs are multifocal in most patients with MEN1, in up to 30% of gastrinomas and in 13% of insulinomas. Resection specimens are sectioned at 3- to 5-mm intervals to detect small tumors (CAP 2024).
  • Size. A diameter of 3.0 cm or more correlates with aggressive behavior, cystic appearance on imaging and calcification. Tumors larger than 10 cm are highly likely to be metastatic (CAP 2024).
  • Growth patterns. Gyriform cords that resemble islets, solid or medullary sheets and glandular acini or pseudorosettes are typical, and sarcomatoid or anaplastic growth may occur. Most tumors consist of monomorphic cells with clear to eosinophilic cytoplasm. Growth pattern correlates with neither behavior nor functional type (CAP 2024). Cytoplasm is often oncocytic (eosinophilic, finely granular) (Monroe and El Naili 2025); fine lipid droplets mark the lipid-rich PanNET (Wang et al. 2024).
  • Less common patterns. Trabecular, insular, nested and alveolar architectures are typical, and glandular, paraganglioma-like and solid patterns also occur (La Rosa et al. 2025). Oncocytic PanNETs enter the differential diagnosis of oncocytic ductal adenocarcinoma, IOPN, oncocytic SPN and metastatic chromophobe renal cell carcinoma (La Rosa et al. 2025).
  • Cystic PanNET. Cystic PanNETs are mixed cystic and solid lesions with rim enhancement and no communication with the pancreatic ducts (Danti et al. 2026).

Molecular pathology of PanNET

  • Somatic drivers. Exome sequencing found somatic inactivating MEN1 mutations in 44% of PanNETs, DAXX or ATRX mutations in 43% and mTOR pathway mutations in 14% (Jiao et al. 2011). Recurrent somatic mutations also involve PTEN (Rindi et al. 2018).
  • Germline variants in apparently sporadic tumors. Sporadic PanNETs also carry germline variants in the DNA repair genes MUTYH, CHEK2 and BRCA2 (Rindi et al. 2018).
  • DAXX and ATRX protein loss. DAXX and ATRX expression was lost in 45% of PanNETs with intact p53 and Rb, and retained in NECs (Yachida et al. 2012).
  • Prognostic markers in AJCC Version 9. ALT status by in situ hybridization and loss of ATRX or DAXX by immunohistochemistry are reviewed as emerging prognostic markers. ALT is highly associated with ATRX or DAXX loss and, in pancreatic primaries, with adverse prognosis and metastasis. ARX (alpha-cell) and PDX1 (beta-cell) expression also appear prognostic, with ARX adverse, but routine use of these markers is not suggested (Chauhan et al. 2024).
  • Prognostic conflict. In the original exome study of 68 PanNETs (curative resections and metastatic disease), MEN1 and/or DAXX/ATRX mutations were associated with prolonged survival; all patients with metastatic tumors carrying both MEN1 and DAXX/ATRX mutations survived at least 10 years, whereas over 60% of those without these mutations died within 5 years (Jiao et al. 2011). In 561 resected primary nonfunctional PanNETs, ATRX/DAXX protein loss and ALT were associated with distant metastasis or recurrence: 5-year relapse-free survival was 40% (ATRX/DAXX loss) and 42% (ALT) against 85% and 86% for wild-type tumors, also in tumors ≤2.0 cm (65% versus 92% for ATRX/DAXX), and both were independent of size; ARX/PDX1 was not independently prognostic (Hackeng et al. 2022). The studies differ in design: gene mutation and overall survival in a selected mixed cohort, against protein loss and relapse-free survival after resection of nonfunctional primaries. AJCC Version 9 reviews ATRX/DAXX loss and ALT as emerging adverse prognostic markers (Chauhan et al. 2024).

Functioning pancreatic neuroendocrine tumors

A functioning PanNET is diagnosed from a clinical syndrome with biochemical evidence of inappropriate hormone secretion; the CAP functional-type element requires correlation with the syndrome and elevated serum hormone levels (Hofland et al. 2023; CAP 2024). Nonfunctioning tumors may secrete hormones such as pancreatic polypeptide that produce no syndrome (CAP 2024). Gastrinoma and insulinoma are the two most common functioning syndromes. Apart from insulinoma, most patients with functioning PanNENs have metastases at diagnosis (Magi et al. 2023).

Tumor Hormone and syndrome Site, frequency and behavior Source
Insulinoma Insulin; hypoglycemia with neuropsychiatric disturbance; Whipple triad; stromal amyloid of islet amyloid polypeptide, a nonspecific but characteristic feature Most common functioning PanNET; 90%–95% benign; multifocal in 13%; insulinoma in about 10% of MEN1 patients; small benign tumors (<1 cm) may be enucleated Magi et al. 2023; CAP 2024; Geurts 2020; Monroe and El Naili 2025
Gastrinoma Gastrin; Zollinger–Ellison syndrome with abdominal pain, ulcer disease, diarrhea and gastrointestinal bleeding; hypergastrinemia with gastric hyperchlorhydria 70% duodenal, 25% pancreatic and 5% in adjacent tissues; about 25% metastatic at diagnosis; multifocal in up to 30%; about 25% arise in MEN1; at surgery 70%–85% lie in the duodenal and pancreatic head area, the gastrinoma triangle Magi et al. 2023; CAP 2024; Jensen et al. 2012
Glucagonoma Glucagon; necrolytic migratory erythema in almost 90%, diabetes mellitus, weight loss, deep vein thrombosis, neuropsychiatric symptoms and stomatitis Rare; all pancreatic, mainly tail or body; over 50% metastatic at diagnosis Magi et al. 2023; CAP 2024
VIPoma (Verner–Morrison tumor) Vasoactive intestinal polypeptide; large-volume watery diarrhea, hypokalemia and achlorhydria Rare; usually solitary, >3 cm and in the tail (75%) Magi et al. 2023; CAP 2024
Somatostatinoma Somatostatin; diabetes (60%), cholelithiasis (70%), steatorrhea and achlorhydria Rare; duodenum or jejunum in 44% Magi et al. 2023; CAP 2024
ACTH-producing NET ACTH; Cushing syndrome Rare CAP 2024; Hofland et al. 2023
Serotonin-producing NET Serotonin; carcinoid syndrome with flushing and diarrhea Rarely primary in the pancreas CAP 2024
Other syndromes PTHrP, calcitonin and GHRH Rare Hofland et al. 2023
  • Behavior by function. Insulinomas behave indolently, probably because hypoglycemia leads to early discovery. Other functioning tumors, gastrinoma among them, are generally aggressive (CAP 2024; Rindi et al. 2018).

Pancreatic neuroendocrine carcinoma

  • Morphology. PanNECs are usually of large cell type and may contain components of adenocarcinoma, which are typically absent from NETs (Rindi et al. 2018). NEC is frequently associated with extensive necrosis and typically has a Ki-67 index above 55%. Small cell NEC resembles small cell lung carcinoma, and large cell NEC resembles a poorly differentiated carcinoma with neuroendocrine differentiation shown by immunohistochemistry (Chauhan et al. 2024).
  • Genetics. PanNECs commonly have TP53 and RB1 mutations and may share KRAS and SMAD4 mutations with ductal adenocarcinoma (Rindi et al. 2018). Abnormal p53 (95%) and Rb (74%) immunolabeling correlated with TP53 and RB1 mutations in small cell and large cell NECs, which were genetically similar. SMAD4, DAXX and ATRX were retained, and Bcl-2 was overexpressed in all small cell NECs (Yachida et al. 2012).
  • Behavior and treatment. PanNECs are rapidly lethal in most patients and respond best to platinum-based chemotherapy. PanNETs are treated with somatostatin analogs, mTOR inhibitors, alkylating agents or VEGF inhibitors (Rindi et al. 2018).

G3 PanNET versus PanNEC

Feature G3 PanNET PanNEC Source
Morphology Typical well-differentiated morphology; G1 or G2 areas or a prior well-differentiated tumor support the diagnosis Small cell or large cell carcinoma; may contain adenocarcinoma CAP 2024; Tang et al. 2016; Rindi et al. 2018
Proliferation Ki-67 >20%; mean 46% (range 30%–80%); the mitotic count is often lower than the Ki-67 grade (higher grade assigned) Ki-67 >20%; mean 72% (range 26%–93%); often >55% Tang et al. 2016; Chauhan et al. 2024; Arends et al. 2026
Immunohistochemical surrogates Loss of DAXX or ATRX Abnormal p53, Rb or SMAD4 Tang et al. 2016
Genes MEN1, DAXX, ATRX TP53, RB1; KRAS and SMAD4 in some Rindi et al. 2022; Rindi et al. 2018
Somatostatin receptor SSTR2A usually expressed SSTR2A occasional Rindi et al. 2018
Treatment response Less responsive to platinum than NEC Platinum-based chemotherapy CAP 2024; Rindi et al. 2018
Outcome Disease-specific survival 75 months; worse than G2 Disease-specific survival 11 months Tang et al. 2016; CAP 2024
  • Ki-67 overlap. Seven of 20 G3 NETs had Ki-67 >55% and 8 of 12 NECs had Ki-67 <55% (Tang et al. 2016).
  • Reproducibility. Three pathologists agreed on the morphologic class of only 33% of 33 G3 pancreatic NENs. DAXX or ATRX loss, abnormal p53, Rb or SMAD4, and review of other slides or prior diagnoses resolved all but one ambiguous case (Tang et al. 2016).
  • TP53 in G3 NET. Some pancreatic G3 NETs have TP53 mutations, although less often than NECs. Next-generation sequencing can resolve difficult cases (Chauhan et al. 2024).
  • NEC-like change after treatment (6th edition). NETs may acquire NEC-like features (diffuse growth, high-grade atypia, necrosis), particularly after treatment, and rarely RB1 and TP53 mutations. These changes carry adverse outcomes, and whether they are classified as "G3 NET with NEC-like morphology" or "NEC arising from NET" is unresolved (Arends et al. 2026). Previous view: progression from G1 or G2 to G3 NET occurs, and progression from G3 NET to NEC is very rare if it occurs at all (Rindi et al. 2018).

MiNEN and amphicrine-like carcinoma in the pancreas

  • MiNEN (6th edition). MiNEN has morphologically distinct zones or nodules of neuroendocrine and non-neuroendocrine differentiation (Arends et al. 2026). Each component constitutes at least 30% of the neoplasm, with clear neuroendocrine marker expression in the neuroendocrine component. A tumor whose non-neuroendocrine component is only a precursor or intramucosal lesion is not MiNEN (Chetty and Gill 2026). Necrosis is assessed in the neuroendocrine component only when it is a NET (Arends et al. 2026). In the 5th edition, each component was graded separately when feasible (Nagtegaal et al. 2020).
  • Amphicrine-like carcinoma (6th edition). In ALC, neuroendocrine and non-neuroendocrine cells are intimately intermixed or single cells show both lines of differentiation. ALC is a family named by its non-neuroendocrine line, for example amphicrine-like adenocarcinoma. Recognition requires morphologic neuroendocrine differentiation in at least 30% of neoplastic cells with immunohistochemical expression of at least two neuroendocrine markers. ALCs are staged as carcinomas, and necrosis assessment is not required (Arends et al. 2026).
  • 5th-edition rule. The CAP endocrine protocol, citing the 5th edition, classifies biphasic tumors with more than 30% ductal or acinar differentiation as mixed ductal-neuroendocrine or mixed acinar-neuroendocrine carcinoma, reported with the exocrine protocol (CAP 2024). Amphicrine-like acinar cell carcinomas in a 2026 series had been diagnosed as MiNEN under the 5th edition (Kim et al. 2026).
  • Clonality. Molecular data indicate that MiNEN and ALC components arise clonally from a common precursor (Chetty and Gill 2026).

Related page: Solid Cellular Neoplasms of the Pancreas: Solid Pseudopapillary Neoplasm, Acinar Cell Carcinoma, Pancreatoblastoma and Metastases to the Pancreas (acinar cell carcinoma and its amphicrine-like subtype)

Hereditary syndromes with pancreatic neuroendocrine tumors

About 10% of PanNETs arise in a hereditary syndrome, most commonly MEN1, and germline testing is considered in all patients. Carriers of germline variants do not necessarily show the full syndrome (Chauhan et al. 2024). Hallmarks of a hereditary endocrine neoplasia syndrome include multiple primary tumors, rare tumors, onset usually before age 40 and a characteristic personal or family pattern (Geurts 2020).

Related page: Parathyroid Pathology and Multiple Endocrine Neoplasia Syndromes (MEN1, MEN4 and the other multiple endocrine neoplasia syndromes)

Syndrome (gene) Pancreatic and duodenal manifestations Other features Source
MEN1 (MEN1, 11q13.1; autosomal dominant) Gastroenteropancreatic NETs in nearly 70%; gastrinoma in about 40% and insulinoma in about 10%; multifocal PanNETs in most; MEN1 present in 16%–38% of patients with gastrinoma Hyperparathyroidism, pituitary adenoma and other tumors (Parathyroid Pathology and Multiple Endocrine Neoplasia Syndromes) Geurts 2020; CAP 2024
MEN4 (CDKN1B) Gastroenteropancreatic NETs observed; natural history uncertain Primary hyperparathyroidism and pituitary tumors (Parathyroid Pathology and Multiple Endocrine Neoplasia Syndromes) Geurts 2020
Von Hippel–Lindau disease (VHL, 3p; autosomal dominant) PanNETs in 9%–17%, mostly nonfunctional and often numerous, with a better prognosis than sporadic PanNETs; metastasis risk with diameter >3 cm, doubling time <500 days and exon 3 or missense variants; serous cystadenoma; pancreatic cysts nearly always benign; up to 60% of VHL-associated PanNETs show clear cell or lipoid change Clear cell renal cell carcinoma, pheochromocytoma, hemangioblastomas, endolymphatic sac tumors Geurts 2020; Monroe and El Naili 2025
Neurofibromatosis type 1 (NF1, 17q) Gastroenteropancreatic NETs in up to 10%, mostly nonfunctioning duodenal somatostatinomas with glands and psammomatous calcifications Neurofibromas and cutaneous findings Geurts 2020
Tuberous sclerosis complex (TSC1, TSC2) Functional and nonfunctional PanNETs in about 1% Hamartomas in many organs, neurologic and dermatologic features Geurts 2020
Mahvash disease, glucagon cell hyperplasia and neoplasia (GCGR; autosomal recessive) Glucagonomas and microadenomas with α-cell hyperplasia Elevated serum glucagon without the glucagonoma syndrome Monroe and El Naili 2025
  • Microscopic tumors at MEN1 resection margins. Microscopic tumors not seen grossly may be present at the margins of MEN1 resections (CAP 2024).
  • Testing. MEN1 sequencing with deletion and duplication analysis identifies a pathogenic variant in about 90% of familial and 65% of apparently sporadic MEN1 (Geurts 2020).

AJCC Version 9 staging of pancreatic neuroendocrine tumors

Pancreatic NETs are staged with AJCC Version 9. Chauhan et al. report no change in the T, N and M categories from the 8th edition (Chauhan et al. 2024). The CAP Version 9 template (5.0.0.0 and 5.0.1.0) is worded differently from the 8th-edition template (4.1.0.0): pT1 is ≤2 cm (8th: less than 2 cm, with 2–4 cm as pT2), pT3 adds invasion of the ampulla of Vater, and pT4 names the superior mesenteric vein, splenic artery and vein, gastroduodenal artery and vein, and portal vein besides the celiac axis and superior mesenteric artery (CAP 2024; CAP 2023; CAP 2021). The template's footnote defining "limited to the pancreas" still names only the celiac axis and superior mesenteric artery (CAP 2024). PanNEC, MiNEN and ALC are staged with the exocrine carcinoma system (CAP 2024; Arends et al. 2026).

Category AJCC Version 9 (CAP 5.0.1.0) AJCC 8th edition wording (CAP 4.1.0.0) Source
pT1 Limited to the pancreas, ≤2 cm Limited to the pancreas, less than 2 cm CAP 2024; CAP 2021
pT2 Limited to the pancreas, >2 cm but ≤4 cm Limited to the pancreas, 2–4 cm CAP 2024; CAP 2021
pT3 Limited to the pancreas, >4 cm; or invading the duodenum, ampulla of Vater or common bile duct Limited to the pancreas, greater than 4 cm; or invading the duodenum or common bile duct CAP 2024; CAP 2021
pT4 Invading adjacent organs (stomach, spleen, colon, adrenal gland) or the wall of large vessels (celiac axis, superior mesenteric artery or vein, splenic artery or vein, gastroduodenal artery or vein, portal vein) Invading adjacent organs (stomach, spleen, colon, adrenal gland) or the wall of large vessels (celiac axis or superior mesenteric artery) CAP 2024; CAP 2021
pN0 / pN1 No regional nodal metastasis / regional nodal metastasis No regional nodal involvement / regional nodal involvement CAP 2024; CAP 2021
pM1a Metastasis confined to the liver Metastasis confined to the liver CAP 2024; CAP 2021
pM1b Metastasis in at least one extrahepatic site (lung, ovary, nonregional lymph node, peritoneum, bone) Metastasis in at least one extrahepatic site CAP 2024; CAP 2021
pM1c Both hepatic and extrahepatic metastases Both hepatic and extrahepatic metastases CAP 2024; CAP 2021
  • "Limited to the pancreas." This means no invasion of adjacent organs or the wall of large vessels. Extension into peripancreatic adipose tissue is not a basis for staging (CAP 2024).
  • Multiple tumors. The largest tumor (highest T) assigns the category, with the multiplicity indicated as pT3(m) or the number as pT3(4). The m suffix applies only to grossly recognizable synchronous primary tumors. A single gross tumor with separate microscopic foci does not receive it (CAP 2024).
  • Regional lymph nodes. For head and neck tumors, regional nodes lie along the common bile duct, common hepatic artery, portal vein, posterior and anterior pancreaticoduodenal arcades, superior mesenteric vein and right lateral wall of the superior mesenteric artery. For body and tail tumors, they lie along the common hepatic artery, celiac axis, splenic artery and splenic hilum. Peripancreatic nodal involvement is N1. The minimum number of nodes for staging PanNET has not been determined; 12 has been suggested for adenocarcinoma (CAP 2024).
  • Metastasis. The liver is the most common site, often without nodal metastasis (CAP 2024).
  • Stage groups (AJCC 8th edition). Stage I is T1 N0 M0; stage II, T2–T3 N0 M0; stage III, T4 N0 M0 or any T N1 M0; stage IV, any T any N M1 (You et al. 2019).
  • Survival (Version 9). Five-year overall survival by pathologic stage group is 92.98% for stage I, 91.86% for stage II, 85.18% for stage III and 53.59% for stage IV (Chauhan et al. 2024).
  • Serum chromogranin A. AJCC Version 9 does not recommend serum chromogranin A for diagnosis or monitoring of NETs (Chauhan et al. 2024).

CAP Pancreas (Endocrine) protocol 5.0.1.0: reporting elements and changes

Element Content Source
Scope Resections (pancreatectomy, Whipple) of well-differentiated NET; not required for biopsy, enucleation, recurrence or an incidental microadenoma ≤5 mm (CAP uses both <0.5 cm and ≤5 mm) CAP 2024
Clinical history and functional type (optional) MEN1, VHL, familial pancreatic cancer syndrome and syndromes; insulinoma, gastrinoma, VIPoma, glucagonoma, somatostatinoma, ACTH- and serotonin-producing NET CAP 2024
Tumor site, size and focality Head, uncinate process, body, tail; size of the largest tumor; number of tumors CAP 2024
Histologic type and grade G1, G2, G3 well-differentiated NET; mitotic rate or Ki-67 required to grade CAP 2024
Direct extension Pancreas, bile duct, ampulla, duodenum, stomach, spleen, colon, adrenal gland and named vessels CAP 2024
Lymphatic and/or vascular invasion; perineural invasion Required CAP 2024
Tumor necrosis (optional) Present, not identified, cannot be determined CAP 2024
Margins Parenchymal, uncinate (retroperitoneal or superior mesenteric artery), bile duct and enteric margins; distance to the closest margin optional CAP 2024
Nodes and pTNM Nodes examined and involved; AJCC Version 9 pT, pN, pM with m, y and r descriptors CAP 2024
Additional findings (optional) Atrophy, chronic inflammation, acute pancreatitis, adenomatosis CAP 2024
Change in 5.0.1.0 (June 2024) Ampulla of Vater, superior mesenteric vein, splenic artery and vein, gastroduodenal artery and vein and portal vein added to the direct-extension list CAP 2024; CAP 2023
Change in 5.0.0.0 (December 2023) Update to AJCC Version 9 pTNM; WHO 5th-edition content; "Lymphovascular Invasion" renamed "Lymphatic and / or Vascular Invasion" CAP 2023

Prognostic factors in resected PanNET

  • Main determinants. Prognosis depends mainly on functional subtype, completeness of resection, anatomic extent and grade (CAP 2024).
  • Grade. G2 PanNETs are more aggressive than G1, and G3 PanNETs somewhat more aggressive than G1 or G2 (Rindi et al. 2018).
  • Vascular invasion. Invasion of blood vessels, particularly veins in the tumor capsule, was seen in 90% of cases with distant metastases in some studies (CAP 2024).
  • Perineural invasion and necrosis. Perineural invasion has been associated with aggressive behavior and shorter survival, and tumor necrosis is generally regarded as an aggressive feature (CAP 2024).
  • Completeness of resection. Debulking can control endocrinopathies and may prolong survival (CAP 2024).

Differential diagnosis of pancreatic neuroendocrine tumor

Mimic Distinguishing findings Source
Solid pseudopapillary neoplasm Young women; nuclear β-catenin, nuclear LEF1, paranuclear dot CD99 and loss of membranous E-cadherin; synaptophysin focal and chromogranin usually negative Kim et al. 2008; Guo et al. 2011; Comut et al. 2026
Acinar cell carcinoma Single prominent nucleoli; BCL10 and trypsin; neuroendocrine differentiation common La Rosa et al. 2012; Taskin and Adsay 2019
Metastatic clear cell renal cell carcinoma Diffuse PAX8; PAX8 in PanNET depends on the antibody; lipid-rich PanNET mimics metastatic renal cell carcinoma and ectopic adrenal cortical tissue Chi et al. 2023; Liau et al. 2016; Wang et al. 2024
Pancreatic neuroendocrine carcinoma Poorly differentiated small or large cells; abnormal p53 and Rb; Ki-67 often >55%, with overlap Yachida et al. 2012; Chauhan et al. 2024; Tang et al. 2016
Pancreatoblastoma Mainly children; acinar structures with squamoid corpuscles; endocrine markers in 82% Klimstra et al. 1995
Ductal adenocarcinoma Synaptophysin in 0.7%; keratin and E-cadherin positive Kim et al. 2008
Paraganglioma Exceedingly rare in the pancreas; synaptophysin, chromogranin and GATA3 positive, with cytokeratin (CAM5.2, AE1/AE3) negative; paragangliomas are regarded as the cytokeratin-negative counterparts of NETs Storozuk and Vecchio 2026; Kasajima et al. 2026; La Rosa et al. 2025

pancreatic neuroendocrine tumor grade calculator

References

  1. Abraham SC, Klimstra DS, Wilentz RE, et al. Solid-pseudopapillary tumors of the pancreas are genetically distinct from pancreatic ductal adenocarcinomas and almost always harbor beta-catenin mutations. Am J Pathol. 2002;160(4):1361–1369. doi:10.1016/s0002-9440(10)62563-1. PMID 11943721 (cited as Abraham et al. 2002a)
  2. Abraham SC, Wu TT, Hruban RH, et al. Genetic and immunohistochemical analysis of pancreatic acinar cell carcinoma: frequent allelic loss on chromosome 11p and alterations in the APC/beta-catenin pathway. Am J Pathol. 2002;160(3):953–962. doi:10.1016/s0002-9440(10)64917-6. PMID 11891193 (cited as Abraham et al. 2002b)
  3. Abraham SC, Wu TT, Klimstra DS, et al. Distinctive molecular genetic alterations in sporadic and familial adenomatous polyposis-associated pancreatoblastomas: frequent alterations in the APC/beta-catenin pathway and chromosome 11p. Am J Pathol. 2001;159(5):1619–1627. doi:10.1016/s0002-9440(10)63008-8. PMID 11696422
  4. Adsay NV, Andea A, Basturk O, et al. Secondary tumors of the pancreas: an analysis of a surgical and autopsy database and review of the literature. Virchows Arch. 2004;444(6):527–535. doi:10.1007/s00428-004-0987-3. PMID 15057558
  5. Adsay NV, Basturk O, Klimstra DS, et al. Pancreatic pseudotumors: non-neoplastic solid lesions of the pancreas that clinically mimic pancreas cancer. Semin Diagn Pathol. 2004;21(4):260–267. doi:10.1053/j.semdp.2005.07.003. PMID 16273945
  6. Adsay NV, Basturk O, Saka B, et al. Whipple made simple for surgical pathologists: orientation, dissection, and sampling of pancreaticoduodenectomy specimens for a more practical and accurate evaluation of pancreatic, distal common bile duct, and ampullary tumors. Am J Surg Pathol. 2014;38(4):480–493. doi:10.1097/PAS.0000000000000165. PMID 24451278
  7. Adsay NV, Zamboni G. Paraduodenal pancreatitis: a clinico-pathologically distinct entity unifying "cystic dystrophy of heterotopic pancreas", "para-duodenal wall cyst", and "groove pancreatitis". Semin Diagn Pathol. 2004;21(4):247–254. doi:10.1053/j.semdp.2005.07.005. PMID 16273943
  8. Ang DC, Shia J, Tang LH, et al. The utility of immunohistochemistry in subtyping adenocarcinoma of the ampulla of Vater. Am J Surg Pathol. 2014;38(10):1371–1379. doi:10.1097/PAS.0000000000000230. PMID 24832159
  9. Arends MJ, Esposito I, Gill AJ, et al. Changes in the 6th edition of the World Health Organization classification of tumours of the digestive system. Histopathology. 2026;88(7):1295–1314. doi:10.1111/his.70116. PMID 41724188 (summarizes the WHO Classification of Tumours, Digestive System Tumours, 6th edition)
  10. Banks PA, Bollen TL, Dervenis C, et al. Classification of acute pancreatitis—2012: revision of the Atlanta classification and definitions by international consensus. Gut. 2013;62(1):102–111. doi:10.1136/gutjnl-2012-302779. PMID 23100216
  11. Basturk O, Adsay V, Askan G, et al. Intraductal tubulopapillary neoplasm of the pancreas: a clinicopathologic and immunohistochemical analysis of 33 cases. Am J Surg Pathol. 2017;41(3):313–325. doi:10.1097/PAS.0000000000000782. PMID 27984235
  12. Basturk O, Hong SM, Wood LD, et al. A revised classification system and recommendations from the Baltimore consensus meeting for neoplastic precursor lesions in the pancreas. Am J Surg Pathol. 2015;39(12):1730–1741. doi:10.1097/PAS.0000000000000533. PMID 26559377
  13. Bengtsson A, Andersson R, Ansari D. Histological variants of pancreatic ductal adenocarcinoma: a survival analysis. Langenbecks Arch Surg. 2024;409(1):312. doi:10.1007/s00423-024-03506-6. PMID 39425752
  14. Bonaroti JW, Doane S, McCue PA, et al. Intraoperative frozen section analysis of the pancreas: a case report and review of the literature. Case Rep Pancreat Cancer. 2016;2(1):71–74. doi:10.1089/crpc.2016.0014. PMID 30631821
  15. Borges MPF, Rebelo P, Vilas-Boas F, et al. Assessing the accuracy of the International Evidence-Based Kyoto Guidelines for detecting malignancy in intraductal papillary mucinous neoplasms of the pancreas. GE Port J Gastroenterol. 2025. doi:10.1159/000548886. PMID 41409549
  16. Brierley JD, Van Eycken LJ, Giuliani ME, et al. The 9th edition of the UICC TNM classification of malignant tumours: updates and rationale for change. Int J Cancer. 2026;159(7):1588–1601. doi:10.1002/ijc.70561. PMID 42261202
  17. Cancer Genome Atlas Research Network. Integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell. 2017;32(2):185–203.e13. doi:10.1016/j.ccell.2017.07.007. PMID 28810144
  18. Carnovale V, Tosco A, Castaldo A, et al. Clinical and genetic interplay between chronic pancreatitis, cystic fibrosis and CFTR-related disorders. Int J Mol Sci. 2026;27(19):8620. doi:10.3390/ijms27198620
  19. Carrara S, Cassano F, Terrin M, et al. Insights into acute pancreatitis: pathogenesis, diagnosis, and management. J Clin Med. 2026;15(8):2819. doi:10.3390/jcm15082819. PMID 42074619
  20. Chang MC, Liang PC, Jan IS, et al. Comparison and validation of International Consensus Diagnostic Criteria for diagnosis of autoimmune pancreatitis from pancreatic cancer in a Taiwanese cohort. BMJ Open. 2014;4(8):e005900. doi:10.1136/bmjopen-2014-005900. PMID 25138812
  21. Chauhan A, Chan K, Halfdanarson TR, et al. Critical updates in neuroendocrine tumors: Version 9 American Joint Committee on Cancer staging system for gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin. 2024;74(4):359–367. doi:10.3322/caac.21840. PMID 38685134
  22. Chetty R, Gill AJ. Mixed neuroendocrine-non-neuroendocrine neoplasms, amphicrine-like carcinoma and related lesions: a review of changes in classification and current concepts. Histopathology. 2026. doi:10.1111/his.70291. PMID 42815537
  23. Chetty R, Serra S. Membrane loss and aberrant nuclear localization of E-cadherin are consistent features of solid pseudopapillary tumour of the pancreas. Histopathology. 2008;52(3):325–330. doi:10.1111/j.1365-2559.2007.02949.x. PMID 18269583
  24. Chi Z, Xu J, Karamchandani DM, et al. Pax8 as a useful adjunct marker to differentiate pancreatic serous cystadenoma from clear cell renal cell carcinoma in both cytologic and surgical specimens. Diagn Pathol. 2023;18(1):54. doi:10.1186/s13000-023-01339-3. PMID 37098593
  25. Colino-Gallardo AM, Fernández-Aceñero MJ, de la Torre-Serrano M, et al. Prognostic validity of the eighth edition of the U.S. Joint Committee on Cancer TNM staging system for pancreatic adenocarcinomas: an analysis of 214 patients at a Spanish center. Cancers (Basel). 2025;17(11):1890. doi:10.3390/cancers17111890. PMID 40507371
  26. College of American Pathologists. Cancer protocols summary of changes, June 2025. https://www.cap.org/wp-content/uploads/documents/New-Cancer-Protocols-June-2025/2025-June-Cancer-Protocol-Summary-of-Changes.pdf (accessed 2026-11-17). Cited as CAP 2025c.
  27. College of American Pathologists. Protocol for the examination of specimens from patients with carcinoma of the pancreas, version 4.3.0.0. Posted June 2025. https://www.cap.org/protocols-and-guidelines/cancer-reporting-tools/cancer-protocol-templates (accessed 2026-11-17; the cap.org page labels this file v4.3.0.2, and the document itself states 4.3.0.0). Cited as CAP 2025.
  28. Comut E, Celik A, Uguz A, et al. Clinicopathological and molecular features of solid pseudopapillary neoplasms: a retrospective series including a small subset of aggressive cases. Pathol Oncol Res. 2026;32:1612367. doi:10.3389/pore.2026.1612367. PMID 41907195
  29. Contractor JB, Bharti L, Shah I, et al. Congenital hyperinsulinism in the era of precision medicine: genetically driven diagnosis and novel therapies. Children (Basel). 2026;13(10):1431. doi:10.3390/children13101431. PMID 42940750
  30. Crippa S, Salvia R, Warshaw AL, et al. Mucinous cystic neoplasm of the pancreas is not an aggressive entity: lessons from 163 resected patients. Ann Surg. 2008;247(4):571–579. doi:10.1097/SLA.0b013e31811f4449. PMID 18362619
  31. Danti G, Scalzone L, Mattolini L, et al. Pancreatic cystic lesions: from basic knowledge to recent guidelines. J Clin Med. 2026;15(2):585. doi:10.3390/jcm15020585. PMID 41598521
  32. Doi S, Yamada T, Kito Y, et al. Adult-onset focal nesidioblastosis with nodular formation mimicking insulinoma. J Endocr Soc. 2022;6(1):bvab185. doi:10.1210/jendso/bvab185. PMID 35024540
  33. Drachenberg CB, Buettner-Herold M, Aguiar PV, et al. Banff 2022 pancreas transplantation multidisciplinary report: refinement of guidelines for T cell-mediated rejection, antibody-mediated rejection and islet pathology. Assessment of duodenal cuff biopsies and noninvasive diagnostic methods. Am J Transplant. 2024;24(3):362–379. doi:10.1016/j.ajt.2023.10.011. PMID 37871799
  34. Drachenberg CB, Odorico J, Demetris AJ, et al. Banff schema for grading pancreas allograft rejection: working proposal by a multi-disciplinary international consensus panel. Am J Transplant. 2008;8(6):1237–1249. doi:10.1111/j.1600-6143.2008.02212.x. PMID 18444939
  35. Drachenberg CB, Seshan SV, Papadimitriou JC. Banff 2022 pancreas pathology update: how to make the right diagnosis and decrease inconclusive pathology results. Curr Opin Organ Transplant. 2025;30(4):258–265. doi:10.1097/MOT.0000000000001231. PMID 40395184
  36. Drachenberg CB, Torrealba JR, Nankivell BJ, et al. Guidelines for the diagnosis of antibody-mediated rejection in pancreas allografts—updated Banff grading schema. Am J Transplant. 2011;11(9):1792–1802. doi:10.1111/j.1600-6143.2011.03670.x. PMID 21812920
  37. Farhoud N, Al-Rajabi RMT, Baranda JC, et al. Pancreatic acinar cell carcinoma: a rare pancreatic malignancy with distinct biology and emerging therapeutic opportunities. Cancers (Basel). 2026;18(14):2315. doi:10.3390/cancers18142315. PMID 42512378
  38. Furukawa T, Klöppel G, Volkan Adsay N, et al. Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study. Virchows Arch. 2005;447(5):794–799. doi:10.1007/s00428-005-0039-7. PMID 16088402
  39. Geurts JL. Inherited syndromes involving pancreatic neuroendocrine tumors. J Gastrointest Oncol. 2020;11(3):559–566. doi:10.21037/jgo.2020.03.09. PMID 32655935
  40. Goggins M, Overbeek KA, Brand R, et al. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut. 2020;69(1):7–17. doi:10.1136/gutjnl-2019-319352. PMID 31672839
  41. Guo Y, Yuan F, Deng H, et al. Paranuclear dot-like immunostaining for CD99: a unique staining pattern for diagnosing solid-pseudopapillary neoplasm of the pancreas. Am J Surg Pathol. 2011;35(6):799–806. doi:10.1097/PAS.0b013e318219c036. PMID 21566515
  42. Hackeng WM, Brosens LAA, Kim JY, et al. Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size. Gut. 2022;71(5):961–973. doi:10.1136/gutjnl-2020-322595. PMID 33849943
  43. Haeberle L, Esposito I. Pathology of pancreatic cancer. Transl Gastroenterol Hepatol. 2019;4:50. doi:10.21037/tgh.2019.06.02. PMID 31304427
  44. Hofland J, Falconi M, Christ E, et al. European Neuroendocrine Tumor Society 2023 guidance paper for functioning pancreatic neuroendocrine tumour syndromes. J Neuroendocrinol. 2023;35(8):e13318. doi:10.1111/jne.13318. PMID 37578384
  45. Huang Q, Zhou H, Liu C, et al. Surgical resection for metastatic tumors in the pancreas: a single-center experience and systematic review. Ann Surg Oncol. 2019;26(6):1649–1656. doi:10.1245/s10434-019-07258-2. PMID 30924017
  46. Hyland C, Kheir SM, Kashlan MB. Frozen section diagnosis of pancreatic carcinoma: a prospective study of 64 biopsies. Am J Surg Pathol. 1981;5(2):179–191. doi:10.1097/00000478-198103000-00007. PMID 7223929
  47. Jais B, Rebours V, Malleo G, et al. Serous cystic neoplasm of the pancreas: a multinational study of 2622 patients under the auspices of the International Association of Pancreatology and European Pancreatic Club (European Study Group on Cystic Tumors of the Pancreas). Gut. 2016;65(2):305–312. doi:10.1136/gutjnl-2015-309638. PMID 26045140
  48. Jensen RT, Cadiot G, Brandi ML, et al. ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology. 2012;95(2):98–119. doi:10.1159/000335591. PMID 22261919
  49. Jiao Y, Shi C, Edil BH, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science. 2011;331(6021):1199–1203. doi:10.1126/science.1200609. PMID 21252315
  50. Kang JS, Park T, Han Y, et al. Clinical validation of the 2017 international consensus guidelines on intraductal papillary mucinous neoplasm of the pancreas. Ann Surg Treat Res. 2019;97(2):58–64. doi:10.4174/astr.2019.97.2.58. PMID 31388508
  51. Karoumpalis I, Christodoulou DK. Cystic lesions of the pancreas. Ann Gastroenterol. 2016;29(2):155–161. doi:10.20524/aog.2016.0007. PMID 27065727
  52. Kasajima A, Perren A, Klöppel G. Concept of neuroendocrine neoplasms of all organs with a focus on grading, subtyping. Virchows Arch. 2026;488(1):3–20. doi:10.1007/s00428-025-04296-y. PMID 41483302
  53. Khatua B, Yaron JR, El-Kurdi B, et al. Ringer's lactate prevents early organ failure by providing extracellular calcium. J Clin Med. 2020;9(1):263. doi:10.3390/jcm9010263. PMID 31963691
  54. Khristenko E, Garcia EE, Gaida MM, et al. Lymphoepithelial cyst of the pancreas: can common imaging features help to avoid resection? Langenbecks Arch Surg. 2023;408(1):82. doi:10.1007/s00423-023-02777-9. PMID 36773118
  55. Kim C, Yun HN, Kim D, et al. Molecular profiling of pancreatic acinar cell carcinoma and amphicrine-like carcinoma: high frequency of homologous recombination deficiency and molecular heterogeneity. Histopathology. 2026. doi:10.1111/his.70274. PMID 42697596
  56. Kim MJ, Jang SJ, Yu E. Loss of E-cadherin and cytoplasmic-nuclear expression of beta-catenin are the most useful immunoprofiles in the diagnosis of solid-pseudopapillary neoplasm of the pancreas. Hum Pathol. 2008;39(2):251–258. doi:10.1016/j.humpath.2007.06.014. PMID 17959228
  57. Klimstra DS, Wenig BM, Adair CF, et al. Pancreatoblastoma. A clinicopathologic study and review of the literature. Am J Surg Pathol. 1995;19(12):1371–1389. doi:10.1097/00000478-199512000-00005. PMID 7503360
  58. Koo J, Mertens RB, Mirocha JM, et al. Value of Islet 1 and PAX8 in identifying metastatic neuroendocrine tumors of pancreatic origin. Mod Pathol. 2012;25(6):893–901. doi:10.1038/modpathol.2012.34. PMID 22388755
  59. Krupa K, Fudalej M, Miski H, et al. KRAS-wild pancreatic cancer—more targets than treatment possibilities? Cancers (Basel). 2025;17(23):3769. doi:10.3390/cancers17233769. PMID 41374970
  60. La Rosa S, Adsay V, Albarello L, et al. Clinicopathologic study of 62 acinar cell carcinomas of the pancreas: insights into the morphology and immunophenotype and search for prognostic markers. Am J Surg Pathol. 2012;36(12):1782–1795. doi:10.1097/PAS.0b013e318263209d. PMID 23026929
  61. La Rosa S, Franzi F, Marchet S, et al. The monoclonal anti-BCL10 antibody (clone 331.1) is a sensitive and specific marker of pancreatic acinar cell carcinoma and pancreatic metaplasia. Virchows Arch. 2009;454(2):133–142. doi:10.1007/s00428-008-0710-x. PMID 19066953
  62. La Rosa S, Maragliano R, Marchiori D. Roadmap to challenges in limited cellularity specimens from pancreatic neuroendocrine neoplasms: diagnostic tools for the most appropriate management of limited material. Endocr Pathol. 2025;36(1):25. doi:10.1007/s12022-025-09870-3. PMID 40668487
  63. Lam MM, Swanson PE, Upton MP, et al. Ovarian-type stroma in hepatobiliary cystadenomas and pancreatic mucinous cystic neoplasms: an immunohistochemical study. Am J Clin Pathol. 2008;129(2):211–218. doi:10.1309/U2BBP4EMBAHCM6E6. PMID 18208800
  64. Larsen AR, Globa E, Andersen DC, et al. Germline and somatic mutations in histologically atypical congenital hyperinsulinism. Front Endocrinol (Lausanne). 2025;16:1692539. doi:10.3389/fendo.2025.1692539. PMID 41561050
  65. Li G, Zhang D. Research progress on the correlation between islet amyloid peptides and type 2 diabetes mellitus. Open Med (Wars). 2025;20(1):20241124. doi:10.1515/med-2024-1124. PMID 40109329
  66. Liau JY, Tsai JH, Jeng YM, et al. The diagnostic utility of PAX8 for neuroendocrine tumors: an immunohistochemical reappraisal. Appl Immunohistochem Mol Morphol. 2016;24(1):57–63. doi:10.1097/PAI.0000000000000149. PMID 25710581
  67. Lu X, Dai Y, Liu X, et al. Differences in the clinicopathologic and radiological characteristics of patients with microcystic and macrocystic serous cystadenoma of the pancreas. Pancreas. 2025;54(4):e317–e323. doi:10.1097/MPA.0000000000002436. PMID 39999293
  68. Lucà S, Salzillo C, Masola V, et al. MTAP in small biopsy samples of pancreatic lesions: a potential diagnostic biomarker. Immunohistochemical, fluorescence in situ hybridization and molecular analysis. Pathologica. 2025;117(5):486–495. doi:10.32074/1591-951X-1243. PMID 41454767
  69. Luchini C, Brosens LAA, Wood LD, et al. Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications. Gut. 2021;70(1):148–156. doi:10.1136/gutjnl-2020-320726. PMID 32350089
  70. Luchini C, Fassan M, Doglioni C, et al. Inflammatory and tumor-like lesions of the pancreas. Pathologica. 2020;112(3):197–209. doi:10.32074/1591-951X-168. PMID 33179622
  71. Luchini C, Grillo F, Fassan M, et al. Malignant epithelial/exocrine tumors of the pancreas. Pathologica. 2020;112(3):210–226. doi:10.32074/1591-951X-167. PMID 33179623 (cited as Luchini et al. 2020a)
  72. Magi L, Marasco M, Rinzivillo M, et al. Management of functional pancreatic neuroendocrine neoplasms. Curr Treat Options Oncol. 2023;24(7):725–741. doi:10.1007/s11864-023-01085-0. PMID 37103745
  73. Malik SS, Padmanabhan D, Hull-Meichle RL. Pancreas and islet morphology in cystic fibrosis: clues to the etiology of cystic fibrosis-related diabetes. Front Endocrinol (Lausanne). 2023;14:1269139. doi:10.3389/fendo.2023.1269139. PMID 38075070
  74. Maruyama M, Watanabe T, Kanai K, et al. International consensus diagnostic criteria for autoimmune pancreatitis and its Japanese amendment have improved diagnostic ability over existing criteria. Gastroenterol Res Pract. 2013;2013:456965. doi:10.1155/2013/456965. PMID 24348535
  75. Masugi Y, Takamatsu M, Tanaka M, et al. Post-operative mortality and recurrence patterns in pancreatic cancer according to KRAS mutation and CDKN2A, p53, and SMAD4 expression. J Pathol Clin Res. 2023;9(5):339–353. doi:10.1002/cjp2.323. PMID 37291757
  76. Matsuda Y, Ohkubo S, Nakano-Narusawa Y, et al. Objective assessment of tumor regression in post-neoadjuvant therapy resections for pancreatic ductal adenocarcinoma: comparison of multiple tumor regression grading systems. Sci Rep. 2020;10(1):18278. doi:10.1038/s41598-020-74067-z. PMID 33106543
  77. Mejia M, Alvarez Alvarado DA, Trujillo Gómez AM. A case of acute pancreatitis with fat saponification mimicking carcinomatosis in an adolescent: is it carcinomatosis or fat necrosis? Cureus. 2026;18(3):e105504. doi:10.7759/cureus.105504. PMID 42005207
  78. Mino-Kenudson M, Fernández-del Castillo C, Baba Y, et al. Prognosis of invasive intraductal papillary mucinous neoplasm depends on histological and precursor epithelial subtypes. Gut. 2011;60(12):1712–1720. doi:10.1136/gut.2010.232272. PMID 21508421
  79. Monroe HL, El Naili R. Educational case: pancreatic neuroendocrine neoplasms. Acad Pathol. 2025;12(1):100161. doi:10.1016/j.acpath.2025.100161. PMID 40034114
  80. Na GH, Seo C. Incremental prognostic information beyond nodal positivity: the AJCC 8th edition N1/N2 subdivision and the lymph node ratio in resected periampullary adenocarcinoma. Cancers (Basel). 2026;18(20):3321. doi:10.3390/cancers18203321. PMID 42938856
  81. Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76(2):182–188. doi:10.1111/his.13975. PMID 31433515 (summarizes the WHO Classification of Tumours, Digestive System Tumours, 5th edition)
  82. Nista EC, De Lucia SS, Manilla V, et al. Autoimmune pancreatitis: from pathogenesis to treatment. Int J Mol Sci. 2022;23(20):12667. doi:10.3390/ijms232012667. PMID 36293522
  83. Ohtsuka T, Fernandez-Del Castillo C, Furukawa T, et al. International evidence-based Kyoto guidelines for the management of intraductal papillary mucinous neoplasm of the pancreas. Pancreatology. 2024;24(2):255–270. doi:10.1016/j.pan.2023.12.009. PMID 38182527
  84. Okazaki K, Kawa S, Kamisawa T, et al. Amendment of the Japanese consensus guidelines for autoimmune pancreatitis, 2020. J Gastroenterol. 2022;57(4):225–245. doi:10.1007/s00535-022-01857-9. PMID 35192048
  85. Omiyale AO. Adult pancreatoblastoma: current concepts in pathology. World J Gastroenterol. 2021;27(26):4172–4181. doi:10.3748/wjg.v27.i26.4172. PMID 34326617 (cited as Omiyale 2021b)
  86. Omiyale AO. Solid pseudopapillary neoplasm of the pancreas. World J Hepatol. 2021;13(8):896–903. doi:10.4254/wjh.v13.i8.896. PMID 34552696 (cited as Omiyale 2021a)
  87. Paolino G, Basturk O, Esposito I, et al. Comprehensive characterization of intraductal oncocytic papillary neoplasm of the pancreas: a systematic and critical review. Mod Pathol. 2024;37(9):100554. doi:10.1016/j.modpat.2024.100554. PMID 38950698
  88. Park JI. Squamoid cyst of pancreatic ducts: a case report. Ann Hepatobiliary Pancreat Surg. 2021;25(2):293–298. doi:10.14701/ahbps.2021.25.2.293. PMID 34053935
  89. Park N, Cho IR, Lee SH, et al. Prognostic efficacy of lymph node parameters in resected ampullary adenocarcinoma based on long-term follow-up data after adjuvant treatment. World J Surg Oncol. 2024;22(1):308. doi:10.1186/s12957-024-03587-z. PMID 39574167
  90. Pateras IS, Igea A, Nikas IP, et al. Diagnostic challenges during inflammation and cancer: current biomarkers and future perspectives in navigating through the minefield of reactive versus dysplastic and cancerous lesions in the digestive system. Int J Mol Sci. 2024;25(2):1251. doi:10.3390/ijms25021251. PMID 38279253
  91. Pea A, Bevere M, Gkountakos A, et al. Mucinous cystic neoplasms and simple mucinous cysts are two distinct precursors of pancreatic cancer: clinicopathological, genomic, and transcriptomic characterization. J Pathol. 2025;266(4-5):421–434. doi:10.1002/path.6437. PMID 40371932
  92. Pitman MB, Centeno BA, Ali SZ, et al. Standardized terminology and nomenclature for pancreatobiliary cytology: the Papanicolaou Society of Cytopathology guidelines. Cytojournal. 2014;11(Suppl 1):3. doi:10.4103/1742-6413.133343. PMID 25191517
  93. Redfield RR, Kaufman DB, Odorico JS. Diagnosis and treatment of pancreas rejection. Curr Transplant Rep. 2015;2(2):169–175. doi:10.1007/s40472-015-0061-x. PMID 26000231
  94. Reid MD, Balci S, Ohike N, et al. Ampullary carcinoma is often of mixed or hybrid histologic type: an analysis of reproducibility and clinical relevance of classification as pancreatobiliary versus intestinal in 232 cases. Mod Pathol. 2016;29(12):1575–1585. doi:10.1038/modpathol.2016.124. PMID 27586202
  95. Reid MD, Bhattarai S, Graham RP, et al. Pancreatoblastoma: cytologic and histologic analysis of 12 adult cases reveals helpful criteria in their diagnosis and distinction from common mimics. Cancer Cytopathol. 2019;127(11):708–719. doi:10.1002/cncy.22187. PMID 31581358
  96. Rindi G, Klimstra DS, Abedi-Ardekani B, et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol. 2018;31(12):1770–1786. doi:10.1038/s41379-018-0110-y. PMID 30140036
  97. Rindi G, Mete O, Uccella S, et al. Overview of the 2022 WHO classification of neuroendocrine neoplasms. Endocr Pathol. 2022;33(1):115–154. doi:10.1007/s12022-022-09708-2. PMID 35294740 (summarizes the WHO Classification of Tumours, Endocrine and Neuroendocrine Tumours, 5th edition)
  98. Scheers I, Berardis S. Congenital etiologies of exocrine pancreatic insufficiency. Front Pediatr. 2022;10:909925. doi:10.3389/fped.2022.909925. PMID 35935370
  99. Sharma S, Sureka B, Yadav T, et al. The varieties of ignorance: imaging of congenital variants of pancreas and its ductal system—a pictorial review. Indian J Radiol Imaging. 2024;34(2):324–331. doi:10.1055/s-0043-1776414. PMID 38549890
  100. Shimosegawa T, Chari ST, Frulloni L, et al. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. Pancreas. 2011;40(3):352–358. doi:10.1097/MPA.0b013e3182142fd2. PMID 21412117
  101. Shin DW. [Treatment of ampullary adenocarcinoma]. Korean J Gastroenterol. 2023;82(4):159–170. doi:10.4166/kjg.2023.110. PMID 37876255
  102. Singhi AD, Lilo M, Hruban RH, et al. Overexpression of lymphoid enhancer-binding factor 1 (LEF1) in solid-pseudopapillary neoplasms of the pancreas. Mod Pathol. 2014;27(10):1355–1363. doi:10.1038/modpathol.2014.40. PMID 24658583
  103. Singhi AD, Pai RK, Kant JA, et al. The histopathology of PRSS1 hereditary pancreatitis. Am J Surg Pathol. 2014;38(3):346–353. doi:10.1097/PAS.0000000000000164. PMID 24525505
  104. Singhi AD, Wood LD, Parks E, et al. Recurrent rearrangements in PRKACA and PRKACB in intraductal oncocytic papillary neoplasms of the pancreas and bile duct. Gastroenterology. 2020;158(3):573–582.e2. doi:10.1053/j.gastro.2019.10.028. PMID 31678302
  105. Soer E, Brosens L, van de Vijver M, et al. Dilemmas for the pathologist in the oncologic assessment of pancreatoduodenectomy specimens: an overview of different grossing approaches and the relevance of the histopathological characteristics in the oncologic assessment of pancreatoduodenectomy specimens. Virchows Arch. 2018;472(4):533–543. doi:10.1007/s00428-018-2321-5. PMID 29589102
  106. Sperti C, Belluzzi A. International evidence-based Kyoto guidelines for the management of intraductal papillary mucinous neoplasm of the pancreas: what is the breaking news? Hepatobiliary Surg Nutr. 2025;14(1):155–158. doi:10.21037/hbsn-2024-662. PMID 39925910
  107. Stoffel EM, McKernin SE, Brand R, et al. Evaluating susceptibility to pancreatic cancer: ASCO provisional clinical opinion. J Clin Oncol. 2019;37(2):153–164. doi:10.1200/JCO.18.01489. PMID 30457921
  108. Storozuk T, Vecchio M. Case report: pancreatic paraganglioma mimicking a well-differentiated neuroendocrine tumor: the importance of cytokeratin immunohistochemistry. Diagn Cytopathol. 2026;54(10):E240–E243. doi:10.1002/dc.70171. PMID 42387308
  109. Tan C, Chen X, Ni SJ, et al. Risk stratification in locally invasive pancreatic serous cystic neoplasms: systematic review and two cases. J Clin Pathol. 2026;79(8):541–547. doi:10.1136/jcp-2025-210480. PMID 42150789
  110. Tanaka M, Fernández-Del Castillo C, Kamisawa T, et al. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology. 2017;17(5):738–753. doi:10.1016/j.pan.2017.07.007. PMID 28735806
  111. Tang LH, Aydin H, Brennan MF, et al. Clinically aggressive solid pseudopapillary tumors of the pancreas: a report of two cases with components of undifferentiated carcinoma and a comparative clinicopathologic analysis of 34 conventional cases. Am J Surg Pathol. 2005;29(4):512–519. doi:10.1097/01.pas.0000155159.28530.88. PMID 15767807
  112. Tang LH, Basturk O, Sue JJ, et al. A practical approach to the classification of WHO grade 3 (G3) well-differentiated neuroendocrine tumor (WD-NET) and poorly differentiated neuroendocrine carcinoma (PD-NEC) of the pancreas. Am J Surg Pathol. 2016;40(9):1192–1202. doi:10.1097/PAS.0000000000000662. PMID 27259015
  113. Taskin OC, Adsay V. Lipase hypersecretion syndrome: a distinct form of paraneoplastic syndrome specific to pancreatic acinar carcinomas. Semin Diagn Pathol. 2019;36(4):240–245. doi:10.1053/j.semdp.2019.07.001. PMID 31300257
  114. Ukegjini K, Steffen T, Tarantino I, et al. Systematic review on groove pancreatitis: management of a rare disease. BJS Open. 2023;7(5):zrad094. doi:10.1093/bjsopen/zrad094. PMID 37749756
  115. Urgesi R, Pagnini C, Di Paolo MC, et al. Intraductal papillary mucinous neoplasm (IPMN) of the pancreas: history, myths, and realities between past and future. Med Sci (Basel). 2026;14(3):405. doi:10.3390/medsci14030405. PMID 42506374
  116. US Food and Drug Administration. FDA grants accelerated approval to zenocutuzumab-zbco for non-small cell lung cancer and pancreatic adenocarcinoma. December 4, 2024. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-zenocutuzumab-zbco-non-small-cell-lung-cancer-and-pancreatic (accessed 2026-11-17).
  117. van der Heide V, McArdle S, Nelson MS, et al. Integrated histopathology of the human pancreas throughout stages of type 1 diabetes progression. Nat Commun. 2026;17(1). doi:10.1038/s41467-026-68610-1. PMID 41673026
  118. Verbeke CS, Gladhaug IP. Resection margin involvement and tumour origin in pancreatic head cancer. Br J Surg. 2012;99(8):1036–1049. doi:10.1002/bjs.8734. PMID 22517199
  119. Wallace ZS, Naden RP, Chari S, et al. The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease. Ann Rheum Dis. 2020;79(1):77–87. doi:10.1136/annrheumdis-2019-216561. PMID 31796497
  120. Wang L, Basturk O, Wang J, et al. A FISH assay efficiently screens for BRAF gene rearrangements in pancreatic acinar-type neoplasms. Mod Pathol. 2018;31(1):132–140. doi:10.1038/modpathol.2017.106. PMID 28884748
  121. Wang M, Lozano MD, Cai G. The World Health Organization System for Reporting Pancreaticobiliary Cytopathology: standardized categories and practical approaches to pancreatic lesions. J Clin Transl Pathol. 2024;4(3):122–135. doi:10.14218/jctp.2024.00034. PMID 40191142
  122. Wang T, Askan G, Adsay V, et al. Intraductal oncocytic papillary neoplasms: clinical-pathologic characterization of 24 cases, with an emphasis on associated invasive carcinomas. Am J Surg Pathol. 2019;43(5):656–661. doi:10.1097/PAS.0000000000001226. PMID 30986801
  123. Wilentz RE, Su GH, Dai JL, et al. Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas: a new marker of DPC4 inactivation. Am J Pathol. 2000;156(1):37–43. doi:10.1016/S0002-9440(10)64703-7. PMID 10623651
  124. Wu D, Radisic G, De Sousa SMC, et al. The epidemiology of PRSS1 hereditary pancreatitis and its clinical implications: a systematic review. Pancreas. 2026;55(8):e868–e878. doi:10.1097/MPA.0000000000002668. PMID 42132515
  125. Wu J, Jiao Y, Dal Molin M, et al. Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci U S A. 2011;108(52):21188–21193. doi:10.1073/pnas.1118046108. PMID 22158988 (cited as Wu et al. 2011b)
  126. Wu J, Matthaei H, Maitra A, et al. Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med. 2011;3(92):92ra66. doi:10.1126/scitranslmed.3002543. PMID 21775669 (cited as Wu et al. 2011a)
  127. Xue Y, Reid MD, Balci S, et al. Immunohistochemical classification of ampullary carcinomas: critical reappraisal fails to confirm prognostic relevance for recently proposed panels, and highlights MUC5AC as a strong prognosticator. Am J Surg Pathol. 2017;41(7):865–876. doi:10.1097/PAS.0000000000000863. PMID 28505002
  128. Yachida S, Vakiani E, White CM, et al. Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. Am J Surg Pathol. 2012;36(2):173–184. doi:10.1097/PAS.0b013e3182417d36. PMID 22251937
  129. You Y, Jang JY, Kim SC, et al. Validation of the 8th AJCC cancer staging system for pancreas neuroendocrine tumors using Korean nationwide surgery database. Cancer Res Treat. 2019;51(4):1639–1652. doi:10.4143/crt.2019.023. PMID 30999719
  130. Zen Y. Type 2 autoimmune pancreatitis: consensus and controversies. Gut Liver. 2022;16(3):357–365. doi:10.5009/gnl210241. PMID 34670874
  131. Zhang M, Tong K, Jing C, et al. Histopathological subtypes independently predict survival in ampullary carcinoma: a contemporary SEER nomogram study. J Gastrointest Oncol. 2026;17(4):226. doi:10.21037/jgo-2026-0544. PMID 42703401
  132. Zhong XY, Liang ZJ, Lan ML, et al. Acinar cystic transformation of the pancreas: a rare case report. World J Clin Cases. 2025;13(23):107096. doi:10.12998/wjcc.v13.i23.107096. PMID 40821410
  133. Zhou X, Li H, Yang X, et al. A case report of Shwachman-Diamond syndrome caused by heterozygous variants in the EFL1 gene and literature review. Mol Genet Genomic Med. 2026;14(6):e70249. doi:10.1002/mgg3.70249. PMID 42281160
  134. Zhou Y, Wang X, Chen S, et al. A pooled analysis of pancreatic resection for metastatic renal cell carcinoma. Front Oncol. 2024;14:1442256. doi:10.3389/fonc.2024.1442256. PMID 39619443
  135. Zou DM, Shu ZY, Cao X. Cystic ductal adenocarcinoma of pancreas complicated with neuroendocrine tumor: a case report and review of literature. World J Radiol. 2024;16(10):621–628. doi:10.4329/wjr.v16.i10.621. PMID 39494143